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Abstract 
Polarization is a term that is often excluded from almost all virtual screening. Polarizability 
helps explain interactions between nonpolar atoms and electrically charged species. When 
studying fragments in FBDD these minor interactions could have large effect in changing 
how well a ligand will bind to its target. After including the polarizability terms in docking a 
validation set of ligands (Favia et al., 2011) with GLIDE, it improved the results the amount 
good docked poses (< 2 Å RMSD) by up to 12%. However some ligands were bound in 
incorrect poses. Further investigation was carried out with MD to observe if given enough 
time ligands bound in an incorrect pose would return to the binding site. In the first stages 
of investigating MD we ascertained if we could use GPUs to simulate larger systems and 
faster. After some performing some MD simulations in GROMACs we found that GPUs were 
an improved option and thus continued the simulation work with ACEMD which allowed 
multiple GPUs in tandem. After running the MD simulations for 200ns with atomic charges 
generated from the polarization the results we found were quite interesting. Some ligands 
would be trapped in their binding site but would fluctuate quite readily such as 2GVV. Some 
ligands showed that despite low RMSD they would be ejected from the binding site. In some 
cases the ligands would then attempt to return to their binding site. Ligands such as in 2CIX 
would show binding based on the breathing movement of the protein. Some ligands such as 
1F5F or 1F8E bound tightly to their binding site during the MD, these ligands also enjoyed 
improved docking polarization with 0.1 – 1.0 Å improvement. These could be carried 
forward to become good candidates for experimental testing. Polarization is shown to have 
an overall positive effect improving binding data and if implemented with simple methods 
would have little opportunity cost to be added to modern FBDD methods.
Page | 1 
 
Chapter 1  
Introduction and applications of FBDD 
1.1 Introduction 
Over the past two decades with the advancement in technology, the use of 
simulations using computer programs simulations in the Bioinformatics field has 
been growing greatly as according to Perola et al. (2004) and Law et al. (2009). 
Computers have gained more processing speed and are able to accommodate larger 
and more complex calculations than ever before. One such field that has seen 
growth in computation is Fragment Based Drug Discovery (FBDD); this is a target 
based‐approach to drug design and discovery. The central theme to FBDD is to 
optimise each unique interaction along the way as the small fragments bind to the 
active site of the protein, as discussed by Hajduk and Greer (2007). Starting with a 
single small fragment with a high affinity, each interaction is maximised then more 
fragments or groups are added. Eventually, multiple suitable fragments are 
combined into a single lead compound with drug‐like properties, as described for 
example  by Lipinski's rule of 5, or preferably the rule of 3 for lead compounds as 
shown in Congreve et al. (2008). 
1.1.1 Aims 
Here we aim to improve computational docking of ligands by including polarization. 
Currently full polarization is lacking in almost all virtual screening in Fragment Based 
Drug Design experiments be they docking or QM/MM studies as noted by Jorgensen 
(2007). The calculations in chapter 2 seek to account for these missing polarization 
terms to improve the docking results that can be obtained by fragments. 
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1.2 Fragment based drug design 
1.2.1 Brief History 
The origins of FBDD started with work on binding energies, e.g. as performed by 
Jencks (1981). Jenks used empirical approaches to derive a Gibbs free energy term 
for the intrinsic binding energy for a ligand binding to a protein. These early works 
did not yet use the powers of computers but were instead establishing equations 
that could be used. A few years later, Goodford (1984) implemented these similar 
calculations into a computational environment. Goodford (1985) implemented a 
scheme for determining the interaction energy of very small fragments (atomic and 
molecular probes that represented functional groups) on a 3D grid around a protein. 
Within the GRID program, the interaction energies were plotted as contour maps 
and facilitated the discovery of favourable binding sites for discrete functional 
groups (and hence ligands) around the protein. 
Around the same time Abraham et al. (1984) were beginning to design, by molecular 
modelling, new compounds to bind active sites, which is the basis of FBDD. This was 
a follow on from Abraham et al. (1983) tests of testing potential antisickling agents 
using X‐ray studies.  In their tests on the Val‐6 beta mutation site of sickle cell 
haemoglobin they observed in approved drug libraries that an aromatic ring 
containing two halogens attached to a benzyloxy or phenoxyacetic acid were 
required to generate the desired effect. In this case it was an antigelling agent. 
However they used this data to perform tests on different molecules based on this 
common structure found amongst the approved drugs. Similarly in FBDD as seen 
later there are fragments that provide the necessary binding and Abraham et al. 
(1984) used these fragments to formulate a complete drug by fusing the fragments 
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together to target binding sites within proteins. In this paper Abraham et al. (1984) 
have thus have fabricated multiple lead targets based up the central benzene ring. 
This process of fusing fragments together to formulate a complete drug is called 
linking. However the programs that could perform these links came a few years 
later. This started with Lauri and Bartlett (1994) with the CAVEAT program and Eisen 
et al. (1994) with the HOOK program. Both programs had the same goal, namely 
making molecular skeletons from a database of ligands that suit the binding site. 
Both these programs were meant as assisting tools to a chemist as they were visual 
tools that allowed the user to make the molecular scaffold, albeit in a somewhat 
automated manner. Upon generating a structure these programs would calculate 
how favourable the binding of the ligand is to the active site. These were the 
preliminary steps to what has become a modern technique. There are still good uses 
for designing a ligand by hand but modern methods can help predict better 
structures that can then be adjusted by hand for an improved fit. 
Newer techniques began to surface in the 90s such as Mattos and Ringe (1996) use 
of X‐ray crystal structure to address the interaction of functional groups with 
proteins through the use of organic solvents. The technique they used is one called 
multiple solvent crystal structure or MSCS. Much of the previous work relies on the 
biological functions of the ligand to the protein such as the Gibbs free energy of 
binding to solve the binding. MSCS began to implement modelling techniques from 
processes such as GRID to develop a map of the entire binding surface of the 
protein. They repeatedly solved the crystal structure of their target protein in 
several different organic solvent to mimic different functional groups. This allows 
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them to map out all the binding sites in a protein as opposed to just the binding site 
of a known substrate. This method opened up new techniques to study the protein 
as a whole to design inhibitors and substrates for different sites that were mapped 
out in the protein. Combining this with previous techniques such as those found in 
CAVEAT or HOOK, it is possible to design drugs for different sites of a protein.  
Later these methods were targeted by big pharma to locate lead targets that failed 
high throughput screening (HTS), the common technique at the time to discover 
drug lead targets. This led to the rise of many small pharma companies in the 
industry, such as Astex (2015) in 1999, Vertex (2015) in 1989 and Plexxikon (2015) in 
2001 to commence focusing on the FBDD process. 
 
1.2.2 Modern FBDD 
FBDD in recent years has quickly become a suitable substitute to older methods of 
drug target screening due to favouring more structure‐based approaches as 
reported by Law et al. (2009). It has been recognised that fragments can quickly and 
efficiently be built into suitable lead compounds using FBDD. Computers have played 
an integral role in FBDD, as over the past 25 years computers have constantly 
expanded the capabilities of this field, as summarised by Martin et al. (2012). As 
stated by Congreve et al. (2008) and Orita et al. (2009), FBDD has two major ideas 
that set it apart from older methods such as High throughput screening (HTS). The 
first is using computational analysis of the chemical space near the active site. It is 
far more efficient to use small sized fragment sized ligands rather than the 
traditional libraries of large molecules (which also need to contain far more 
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molecules). The key idea behind this efficiency is that chemical space of fragment is 
far smaller at approximately 107 compounds for up to 12 non‐hydrogen atoms. In 
contrast, the chemical space of a drug‐like compound of up to 30 atoms is 
approximately 1060 compounds. Due to the difference in the sizes of the two sets of 
chemical space, screening in FBDD is eminently tractable as it is quite feasible to 
screen 106 – 107 compounds. However, screening 1060 compounds in a traditional 
screen of drug‐like compounds is impossible, requiring the need to design specific 
targeted libraries and the inherent risk of missing hits.   
The second idea is that due to the small nature of fragments when they bind to the 
protein they will bind with less affinity since they cannot make as many interactions 
as the larger drug‐like molecules; however the binding efficiency for each individual 
atom is potentially the same in both methods, meaning that the fragments, despite 
their low binding energy, can still make a number of high‐quality interactions. 
Fragment‐based Quantum Mechanical (QM) calculations on fragments are easier to 
carry out as shown in Hesterkamp and Whittaker (2008), due to their small size. In 
addition, at these low affinities it becomes difficult to screen and therefore 
screening can become more expensive as it requires sophisticated methods. This is 
where evolving computational techniques such as FBDD can help cut down the 
number of compounds that need to be screened experimentally, thus lowering the 
cost of the overall research, as reported by Pors (2011). It is possible to use these 
small fragments as building blocks to develop a drug‐like molecule by fusing them 
together with small linker fragment to maintain structural and conformational 
integrity. 
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This process is called Fragment based lead discovery, as reviewed by Erlanson 
(2006); the basic concept is also shown in Figure 1.1 below.  The process starts with 
an initial fragment hit from fragment based screening which is then optimised by 
evolution or by linking to another fragment. Growing a molecule is shown in Figure 
1.1. This starts with the initial hit, and then the molecule is expanded around that 
initial hit to fill up the space to form more interactions with the rest of the active 
site. In contrast, in linking, the initial hit is combined with another initial hit, by using 
a linker molecule specifically designed/chosen for the site in question. Although 
using linkers is on the increase, their use is inefficient. In some cases linking will 
generate needlessly large molecules that have lost some of their binding affinity to 
the site in the process. The two methods can be used individually or in conjunction 
with each other to optimise a final molecule that binds to the site. 
 
 
  
  
 
Erlanson (2006) lists some examples such as Wood et al. (2005) who used fragment 
based methods to discover and optimise protease inhibitors. Despite the examples 
shown, not all attempts of using FBDD increased the efficiency of the final molecule 
when compared to the initial hit. However, a significant portion still did increase the 
ligand efficiency by use of growing. Whereas using linking there was never a case 
Figure 1.1: Basic concept to fragment‐based lead discovery, adapted from Erlanson (2006). 
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where the final molecule had greater ligand efficiency when compared to both the 
initial hits used to form the final linked molecule. FBDD is in its infancy but it is 
starting to show promise within the pharmaceutical industry. FBDD should hopefully 
reach its potential to increase the speed of lead targets found but also improve the 
number of ligands that may tightly bind to their proteins drug target. 
 
1.2.3 Ligand Efficiency 
Ligand Efficiency (LE) is the measure of the free energy of binding of a ligand to its 
target protein per number of non‐hydrogen atoms. The binding free energy in the 
equations 1.1 and 1.2 is shown as  , often defined as   = ‐RTlnK. The Gibbs free 
energy change due to mutation of a structure can be used to characterize the 
stability of that structure. This Gibbs free energy change is defined as   . 
Equation 1.1 from Kuntz et al. (1999) used this term to look at the best ligands for 
macromolecular targets based on their stability. 
 
         =                 +              +       +                 (1.1) 
 
Hopkins et al. (2004) improved upon the initial equation 1.1 and calculations put 
forward by Kuntz et al. (1999) to make equation 1.2 given below to define Ligand 
Efficiency. Non‐hydrogen atoms are otherwise defined as heavy atoms. 
   =    = (  )  ⁄                                       (1.2) 
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Where LE is ligand efficiency,   (Delta small g) is the free energy per atom and N is 
the number of non‐hydrogen atoms (Abad‐Zapatero 2007). LE is a useful tool to any 
researcher designing drugs through the use of lead‐based design. Ligand efficiency is 
used at each step of the design, either growing or linking a ligand, to ensure that it 
remains with the target range, typically < 0.3. As shown in Congreve et al. (2008), 
this helps prevent the researcher being blindsided and only focusing on the potency 
(defined here as the binding affinity) of the drug and not neglect  its physiochemical 
properties of binding.  
Abad‐Zapatero (2007) reports that other terms similar to LE have been in 
development during recent years, which are based on the LE equation. The terms 
were designed due to the variation of molecular weight in a compound which can 
also change its potential size and surface area for interaction. Thus, the following 
indices were developed using molecular weight as measured in kDa: Percent 
Efficiency Index (PEI), Binding Efficiency Index (BEI) and Surface Efficiency Index 
(SEI). The PEI is an indication of inhibition brought about by the ligand, presented as 
a fraction. The BEI is a measure of the potency in relation to the molecular weight of 
the ligand. The SEI is a measure of potency gained that is related to the polar surface 
area (PSA) of the ligand. These three indicators can be used as a numerical reference 
for considerations when formulating a drug. These indicators show representations 
for important variables, potency, molecular weight and surface area. When used in 
tandem with older rules, such as Lipinski's rule of five and other drug indicators, a 
researcher can estimate the confines he has to work with when developing the drug 
from the initial hit. 
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The above indicators have been useful in a myriad of techniques used in FBDD to 
quantify how potentially useful compounds are for the drug design purposes. 
 
1.2.4 Fragment Libraries 
In FBDD, in order to begin study on a protein or other biomacromolecule a fragment 
library is required. This allows a base set of ligands from which to work. According to 
Congreve et al. (2008) there are a good number of considerations that constitute a 
good or useful fragment library. The range of physiochemical properties for the 
fragments included, quality control, assessment of molecular diversity, chemical 
tractability of the fragments, which chemical functionalities are allowed, 
druglikeness of the fragments with precedence set by studies in oral drugs and 
natural products and sampling sets of privileged medical scaffolds. 
Also to take into consideration is the complexity of a ligand (Hann et al., 2001), and 
if there is an optimal level of complexity that a library should consider.  As shown in 
Fattori (2004) if there is too much complexity in a library then overall the there will 
be fewer hits from which to create a lead. This of course reinforces the idea that 
fragments need to be small and when designing a drug, it should be built it up either 
from several fragments or by growing it out as shown earlier in section 1.2. 
However, at the same time a ligand can’t be too small, as a ligand must be large 
enough to act as a molecular anchor. This is to say that it has enough interactions 
(electrostatic, H‐bonds etc) so that it binds with enough affinity, thus taking into 
account the ligand efficiency which was discussed in section 2.1. With regards to an 
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optimal size Congreve et al. (2008) believes that fragments should be between 100‐
250 Da, which lowers the chance of steric clashes while maintaining a high ligand 
efficiency.  
 
1.2.5 Deconstructing leads into Fragments 
One other method in FBDD to find a fragment is to reverse engineer one from lead 
compounds. Reverse engineering can derive a fragment from the larger lead like 
structure where it’s possible to take parts of the lead target apart and by use of 
these pieces to discover structural information for the binding site, as shown in 
Hajduk (2006). In 2006, Hajduk (2006) deconstructed several inhibitors and found 
that the fragments all had a similar ligand efficiency. However, in experimental tests 
this might not always be true despite Hajduk’s similar ligand efficiency. Babaoglu 
and Shoichet (2006) deconstructed a β‐lactamase inhibitor into four fragments. Only 
one of their fragments bound in the same way as the inhibitor would. According to 
Congreve et al. (2008) this has caused much debate in the FBDD community in how 
much weight binding mode would have for optimisation and subsequent growth of a 
fragment.  
One example of deconstructing being a benefit is the work by Liu et al. (2001). In 
their study they found a series of p-arylthio cinnamides that could act as antagonists 
to a reaction between leukocyte function‐associated antigen‐1 (LFA‐1) and 
intracellular adhesion molecule‐1 (ICAM‐1). They used one of the ligands that bound 
to an allosteric site, a known diaryl sulphide. They deconstructed it, splitting it at its 
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sulphide bond.  They found that this fragment could still bind well and used NMR 
screening with the fragment present to find an alternative fragment that could be 
linked on to the structure they had to improve binding. They found two different 
compounds which they appended to the main fragment. One of the new drug 
targets only improved the binding affinity of the drug marginally form 0.044 µM to 
0.040 µM. The other structure improved the binding to 0.020 µM. More importantly 
the presence of the sulphide portion of the molecule caused the drug target to have 
no oral bioavailability as shown in Liu et al. (2001) but the new molecule that had 
stronger binding affinity had an oral half‐life of 4.7hrs. This means they could make a 
drug that could be ingested out of this new molecule. So by using known ligands as a 
scaffold it is possible to change parts of the ligand by deconstructing them to try to 
give the target more favourable properties. 
 
1.2.6 Interactions of ligands with proteins and the importance of structure 
According to Murray et al. (2012), small molecules i.e. fragments, need to pass a 
large entropic barrier in order to bind. This barrier is actually larger proportionally 
for the fragment than it is for a complete drug as shown in Murray and Verdonk 
(2002). This means that high quality bonds are required to bind fragments. This can 
be seen by inspecting fragments visually when in a binding pocket. Many of them 
have strong hydrogen bonds or powerful electrostatic interactions. This arises from 
the complementary structure of the fragment to its binding site. Not having key 
components in a ligand for a particular binding site will cause a lot lower binding 
affinity. For example a carboxylate group has the potential to form strong hydrogen 
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bonds with a protonated amino acid such as arginine. If the binding site has an 
arginine nestled in its structure then a carboxylate group on a fragment can serve as 
an anchor. Subsequently this anchor could be used to grow out the proceeding drug.  
Congreve et al. (2008) performed a review of several binding sites and fragments 
attached to them to better show how a complementary fragment forming multiple 
hydrogen bonds to the binding site is important for a ligand. In figure 1.2 we can see 
one of the ligands from Favia et al. (2011) used in section 2.9.  
    
 
Figure 1.2: Ligand‐receptor interactions within a binding pocket. In the centre of the figure 
is a fragment. The coil structures are the alpha helices of the receptor protein. The green 
dotted lines represent the Van der Waal and electrostatic interactions between the ligand 
and receptor. 
 
The ligand in figure 1.2 has a strong anchor point. This can be seen by the many 
interactions with the binding pocket shown by the green dotted lines. These can be 
electrostatic, hydrophobic or hydrogen bonds. These interactions are important to 
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the overall structure of the ligand as the more interactions present the tighter the 
ligand will bind. In the case of the ligand in figure 1.2 the bottom half of the ligand 
acts as the anchor which will fluctuate infrequently, whereas the top half has 
relatively few interactions so it will fluctuate rapidly. This means the top half is a 
candidate to grow the ligand using FBDD.   
 
1.2.7 Thermodynamic equilibrium 
As explained by Kuriyan et al. (2012), the equilibrium of a ligand binding to a protein 
is expressed as shown in equation 1.1. 
[ ] + [ ] [  ]     (1.3) 
Where [P] is concentration of the protein, [L] is the concentration of the ligand and 
[PL] is the concentration of the ligand‐protein complex. Equation 1.1 is where at the 
point where the concentrations of reaction do not change, there is an equilibrium 
between the rate of formation of the complex (products) and the formation protein 
and ligand (reactants). 
The equilibrium of this reaction can be expressed as a constant as shown in equation 
1.4. 
  =  
[  ]
[ ] [ ]
       (1.4) 
Since this is a reaction of the ligand binding to the protein, this is a binding constant. 
The free energy of binding for a reaction is expressed in section 1.2.3. In binding 
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studies it is more common place to measure the dissocation of a ligand, which is 
simply the inverse of the association constant as shown in equation 1.5. 
   =  
[ ] [ ]
[  ]
        (1.5) 
Where Ki is the equilibrium dissociation constant of inhibition. As shown in Neubig et 
al. (2003), the Ki is usually determined by using a radioligand binding study to 
measure the inhibition of binding against the binding of a reference ligand in 
equilibrium conditions. Another binding term often used is IC50 which is an assay 
term that denotes an inhibitor concentration needed to reduce a protein or enzyme 
activity to 50% of its capacity. This however can be affected by concentrations of 
substrate, inhibitor and protein.  
 
1.2.8 Other experimental and computational approaches  
There are other approaches to FBDD than just HTS. One such method experimentally 
is High‐Content Screening (HCS) as reported by Abraham et al. (2004).  
HCS. Unlike HTS, HCS uses cell‐based system in the screening process instead of just 
the target proteins. The screening technology is based around automated digital 
microscopy and flow cytometry, in combination with computer systems to quickly 
analyse and store the data. HCS exposes cells to a potential drug and changes in the 
cell morphology and protein production are measured using the aforementioned 
microscopy and flow cytometry to determine the impact of that drug. 
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FEP. Another method that has been in use for many years is the Free Energy 
Perturbation (FEP) method. This method can be summarized as measuring the free 
energy difference between the initial state and final state of a system to their 
average energy difference. This was developed by Zwanzig (1954) and is often 
expressed as shown in equation 1.6.  
 (  →  ) =         =         exp (  
     
   
 )     (1.6) 
Where F is the free energy, kb is the Boltzmann constant, T is the temperature of the 
system and E is the energy of the initial or reference state. This free energy 
difference can be used to measure the binding strength of a ligand as seen in 
Jorgensen and Thomas (2008). However, this measure free energy differences 
between say two ligands, and in order for the average to converge to the correct 
free energy, it is important that the ligands are not too different and that they bind 
in a similar mode. These restrictions limit the use of this method in practical drug 
design. 
MMPBSA. Another method used that involves MD simulation is the Molecular 
Mechanics‐Poisson‐Boltzmann Surface Area (MMPBSA) method as developed by 
Kollman et al. (2000). According to Zoete et al. (2010) this method uses the free 
energy of binding (      ) written as a sum of its gas phase contribution (      
   
), 
desolvation free energy (        ) of the system upon binding and its entropic 
contribution (     ), this is shown in equation 1.7. 
 
      =       
   
+                 (1.7) 
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To find each term the method runs a single trajectory but evaluating the energy for 
each portion separately. As seen in Zoete et al. (2010) evaluting the energy of  the 
complex, solely the protein and solely the ligand.          s the difference between 
the solvation free energy of the complex and its isolated parts, so this is calculated 
from the energy difference from the trajectory.      
   
 contains difference in energy 
between the interactions of the complex and the isolated parts. This includes the 
van der Waal, electrostatic and intramolecular forces. Lastly, the       term is 
caclculated using standard equations of statical mechanics. The accuracy of this 
method is like most MD methods dependent on the accuracy of sampling. The 
MMPBSA also largely depends upon the Surface Area terms used as seen in Miller III 
et al. (2012).  
 
 
1.3 Conclusion 
FBDD, while still a budding field has progressed in leaps and bounds, in both 
experimental aspects and also the associated computational aspects. Many of the 
calculations that previously might have taken weeks now only take hours with 
modern computers. This will allow the field to branch out into new techniques, by 
allowing larger systems and full proteins to be modelled and studied. Virtual 
screening has come a long way in 30 years but is continuing to show that it can be 
used as an alternative and as an adjustment to high throughput screening. Many of 
the techniques used by modern FBDD can be performed efficiently and with finesse 
in ligand construction, providing new drug candidates each year.  However with any 
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growing field there are portions of it that still need expanding. In this thesis we will 
investigate the pressing quest of lack of polarization in FBDD virtual screening. We 
will examine how it can be used in both docking and in molecular dynamics to attain 
more accurate binding and to examine how it can give us insight into the behaviour 
of ligands. 
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Chapter 2 
Exploring the use of polarization in docking 
 
2.1 Introduction 
Docking attempts to determine the ideal pose or orientation of a molecule, usually a 
small molecule ligand, as it is bound to another molecule, which is usually a protein. 
In this part of the project we look at how ligands, or fragments, bind to large 
biomacromolecules that are proteins. Docking is useful for predicting binding 
affinities of ligands to the protein. Docking is also useful for beginning the process of 
fragment‐based drug discovery. Here, the rationale is that to begin either linking or 
growing a fragment hit into a lead compound, it is helpful to know the docked pose 
of the ligand that is being used as a base for the lead optimization. With regards to 
hits once you know a ligand docks it might help decide which kind of ligands to 
screen next based on the binding pocket and the chemical properties of the ligands. 
There are a number of widely used approaches to docking, as implemented in a 
number of well‐used programs, e.g. AUTODOCK (Trott and Olson, 2010), GLIDE 
(Eldridge et al., 1997), GOLD (Jones et al., 1997), FLEXX (Schellhammer and Rarey, 
2004), FRED (McGann, 2011), SURFLEX (Jain, 2003) and QXP (McMartin and 
Bohacek, 1997). All of these programs perform reasonably well, though the 
performance of the program tends to be system‐specific as seen in Warren et al. 
(2006) . Our hypothesis is that polarization will improve docking, and this limits the 
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choice of program that can be used to test this hypothesis. For example, GOLD does 
not use electrostatics and so cannot be used here. AUTODOCK does use 
electrostatics, but the implementation is complex and it is difficult to modify the 
electrostatics as seen in Illingworth et al. (2008). Consequently, the docking in this 
chapter utilizes the program GLIDE (Eldridge et al., 1997), (Friesner et al., 2004), 
(Halgren et al., 2004), (Friesner et al., 2006), partly because it is relatively straight 
forward to modify the atomic charges and partly because GLIDE performs well on a 
number of different systems as seen in Repasky et al. (2007) and its implementation 
within the Maestro GUI facilitates comparison against other methods e.g. QM/MM. 
GLIDE or Grid‐based ligand docking with energetics is a relatively new docking 
methodology found in software such as FirstDiscovery (Schrödinger, 2015) or 
Maestro, as reported by Halgren et al. (2004); grid‐based docking was also used by 
ligandfit (Venkatachalam et al., 2003). GLIDE itself has the advantage of both being 
able to maintain a sufficient processing speed scanning large libraries while 
performing an exhaustive search of all the conformational positions for the ligand in 
the space provided within its receptor docking grid.  
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2.2 Docking using GLIDE 
The main method that GLIDE uses to perform docking is through the use of a set of 
hierarchical filters. It performs four major steps, a site‐point search, a series of 
refinements, grid minimization + Monte Carlo methods then moves to the final 
scoring function as shown in Figure 2.1, taken from Halgren et al. (2004).   
 
 
Figure 2.1. Glide docking hierarchy 
 
A receptor based grid is first generated that maps out the region of the receptor 
where the ligand is likely to bind. A grid involves the pre‐calculations of part of the 
Coulombic and Lennard‐Jones, energies on the grid, due to the target receptor, 
similar to the methods shown in Goodford (1985). A grid helps to speed up 
calculations for finding correct conformations because of the pre‐computed values 
when it is set up. In the majority of cases the target receptor is a protein. Each point 
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within the grid that is either too close to the receptor or touching it is flagged as a 
point for the conformations to avoid.  Afterwards a set of initial ligand 
conformations are generated, as reported by Halgren et al. (2004). This part focuses 
on the ligand torsion‐angle space and takes a set of the best scored poses based on 
the energetic minima for these conformations. Then the poses that have been 
selected are energetically minimised within the receptor grid according to an energy 
function set by the user in tandem with using a distance‐dependent dielectric 
model. In most cases, of this project this energy function is one of the OPLS force 
fields, generally the OPLS 2015 force field, as seen in Robertson et al. (2015). A 
scoring function is an approximation used in many methods to predict the strength 
of the binding affinity for a ligand to the binding site as reported by Jain (2006) The 
lowest energy poses after this step are subject to a Monte Carlo procedure to 
examine the torsional minima. In the cases where GLIDE is calculating a redocking 
based upon an original crystal structure as opposed to using a compound library at 
this point, the program will calculate the Root mean square deviation (RMSD) value 
based upon the original position of the ligand in the crystal structure; the smaller 
this number the less the ligand has been displaced from its original positions. The 
RMSD has helped determine the accuracy of the program compared to similar 
docking programs, as GLIDE consistently attains RMSD results of 2 Å or lower as 
shown in Kontoylanni et al. (2004). The RMSD script in GLIDE can give erroneously 
high values by equivalent atoms or shapes swapping places for example in 
symmetric molecules. However we use an in‐house script that can be found in the 
appendix 2.1 that does away with this issue.  
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2.2.1 Scoring Function 
As stated previously, scoring functions are used by many Ligand docking programs as 
an approximation of how to rank ligand poses as they are generated. Generally a 
search algorithm will produce far too many results to be useful. Approximately 109 
poses could be generated according to Halperin et al. (2002). Thus scoring functions 
are utilised to discriminate to find the plausibly right answer, which is usually a pose 
with a lower RMSD, though that might not always be the case. Dependent on the 
algorithm and scoring function used, the results for a search can vary widely as 
scoring algorithms that can produce false positives. This means that the ligand 
docked with a high RMSD is given a low rank. This can be a problem as there isn't 
currently a reliable way to discern the difference between false positives and the 
correct docked posed for a given receptor. If the binding site and ligand is known 
from a source, such as the X‐ray crystal structure, it is possible to notice that the 
ligand has been docked incorrectly forming this false positive. However if the 
binding site is unknown then the problems of false positives becomes a major 
hindrance. There is no way to discern the difference between the false positive and 
the right answer as stated before. Thus when the ligand is docked to an unknown 
receptor there is no way of confirming if the poses generated are correct. The way 
forward therefore is to seek to improve the scoring function, hence our interest in 
including polarization of both the ligand and the protein. 
GLIDE's scoring functions is based upon the ChemScore function of Eldridge et al. 
(1997), as shown in equation 2.1. 
  =    +       ∑  (   ) +        ∑  (  ) (  ) +        ∑  (   ) +            (2.1) 
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Where C0 is a constant, according to the review presented by (Friesner et al., 2004), 
the sum in the second term (Clipo) refers to the interaction between ligand‐atom and 
receptor‐atom pairs that are defined as lipopholic, this is a hydrophobic effect and is 
an entropy term, GLIDE uses this term without changing it The third term's (Chbond) 
sum takes into account all ligand‐receptor hydrogen‐bonding interactions, GLIDE 
expands this term weighting the components that depend on whether the donor or 
acceptor are both neutral or if one or both are charged. The fourth term’s (Cmetal) 
takes into account all metal‐ligand bonding interactions, GLIDE changes this term to 
consider only the anionic accepter atoms, it counts the single best interaction when 
two or more metals are found and GLIDE assess thenet charge on the metal ion in 
the unligated protein. If it is a positive value the metal ligand is incorporated into 
scoring if it is negative it is suppressed. The fifth term (Crotb and Hrotb) is a penalty 
scored for freezing rotatable bonds (which is an entropy term), this term is used by 
GLIDE unchanged from the Chemscore. The terms f, g and h will all denote either a 
full score (1.00) or a partial score (0.00 ‐ 1.00). The full score is given to a pose that 
has distances or angles that lie within nominal limits whereas the partial score is 
given to those that lie outside those boundaries but have not passed a threshold 
limit. The term (r) being the distance or angles in those cases. To include solvation 
effects GLIDE docks explicit waters into the binding site for each ligand pose and 
uses an empirical scoring term that measures the exposure of various functional 
groups to the explicit waters. 
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GLIDE has two main forms of Glidescore that alter and extend the ChemScore 
function. They are defined as two docking modes of Standard‐Precision (SP) and 
Extra‐Precision (XP), the majority of tests performed in this project are under the SP 
docking procedure. The SP scoring function is more forgiving in its parameters than 
that of the XP function and is thus a soft scoring function, as presented in Friesner et 
al. (2004). The advantage of using this scoring function over the XP version is that it 
is more proficient at identifying ligands that have decent susceptibility to bind to the 
receptor. This allows for some flexibility in the glide pose and takes into account a 
possibly lower resolution receptor or ligand. Thus, it is far superior at general 
screening. XP scoring functions place some additional penalties into the function 
which forces only poses or ligands that have a favourable conformation to score. 
This has its advantages: mostly it has the potential to reduce the potential of false 
positives. However it is best used with a small subset of compounds that are under 
study for lead‐optimisation and other methods. Due to the harsh parameters set for 
XP the ligand and receptor need to be of a very high resolution. This was the case for 
some of the complexes used (e.g. 1S5N, 1PWM and 1UWC (Favia et al., 2011)), but 
not all, so for consistency Glide SP was used. 
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2.2.2 OPLS-AA Force fields  
GLIDE utilises force fields as a standard during refinement for scoring. During the 
grid minimisation step (step 3, figure 2.1) GLIDE performs a torsionally flexible 
energy optimisation on an OPLS‐AA grid for the last few poses left after initial 
refinement (Friesner et al., 2004). OPLS force fields, in short, are a set of parameters 
that mimic experimental thermodynamic and structural data of atoms in fluid as 
seen in Jorgensen and Tirado‐Rives (1988). An OPLS force field packages a 
description or set of values for the potential interactions that an organic liquid 
would yield. These potential interactions cover bond angles and stretches as well as 
intermolecular and intramolecular forces; the equation is similar to that of the 
AMBER and CHARMM force fields – see chapter 4.2. 
OPLS force fields continue to change and include more parameters and 
conformations as the field evolves. In the works of Damm et al. (1997), the force 
fields were expanded to include carbohydrates. As techniques become more refined 
so too does OPLS. Kaminski et al. (2001) re‐evaluated the OPLS force field for 
peptides. 
The computational efficiency and accuracy of the OPLS force field has made it 
popular for simulating biomolecules. To keep it up with the times, scientists 
continue to update the parameters for each new challenge. Recently Siu et al. (2012) 
started optimising OPLS parameters for use with long hydrocarbon chains. The OPLS 
parameters were originally grounded in using short alkanes thus were not good for 
long chains. However Siu et al. (2012) have used gas‐phase ab initio energy profiles 
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as an addition to OPLS. By having this as an additional parameter, the OPLS yields 
improved hydrocarbon diffusion coefficients.  
 
2.2.3 The docking problem 
One of the biggest hindrances in Ligand docking has been around since the very 
beginning that of rigidity of the docking process. Originally, both the ligand and the 
receptor were both frozen rigidly for the process, as stated by Lorber and Shoichet 
(1998). This created the problem where the ligand would often not dock in the 
correct conformation or in the binding site, as the ligands could not flex around the 
binding site, although this problem only affected flexible ligands. However, since the 
early days, programs like GLIDE have overcome the rigid ligand problem. These 
programs use the strength of computer speeds so it has become less of a problem to 
calculate all the conformations a ligand might have as it is relatively small and thus 
has a manageable number of poses.  However the problem still remains that there is 
a rigid receptor in place. For rigid receptors it must be assumed that the ligand 
conformations must be tested near to the experimentally observed conformations 
or the test will not function. Thus, this is a problem that has yet to be fully 
addressed. However, as reported by Verdonk et al. (2005), some programs are 
starting to accommodate this problem, at least modestly. GOLD, like GLIDE, includes 
full ligand flexibility but it also allows rotational flexibility for hydrogen atoms based 
around the receptor; this was also a feature of ligandfit. Another problem with 
docking is the use of the scoring function. As the scoring function in docking 
programs tends towards neglecting solvation effects, including them in some implicit 
way, or using solvent models as a snap shot (i.e. including a small number of explicit 
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water molecules from the X‐ray structure). A snap shot is where a structure is 
generated in vacuo with solvent molecules in place and it is then ranked with a 
scoring function.  The consequence of this is that the docked ligand will be funnelled 
onto the correct place by the water molecules.  
However, there have been studies to sidestep the receptor rigidity problem. 
Techniques such as soft docking and partial side‐chain flexibility are amongst those 
used today according to Cavasotto et al. (2005). Using multiple receptor 
conformations (MRCs) is one of the best choices to reduce the problem currently, as 
presented by (Carlson, 2002). The advantage to this method over others is that the 
structural space of the binding pocket can be represented even in the case of loop 
displacements. This works by making an ensemble of multiple conformations, hence 
the name, of different discrete conformations of separate structures sharing the 
same backbone trace. Alternatively, for example, multiple snapshots from MD 
simulations can be used (Carlson, 2002). However, this introduces additional 
variables into the docking assessment and so this was not used here. 
 
2.2.4 The presence of water molecules in Ligand docking 
Despite the relative accuracy of GLIDE, there are still problems within the field of Ligand 
docking, as shown in Verdonk et al. (2005). One of these major problems is the prediction of 
the effect of water molecules on ligand to protein interactions. Either water molecules can 
have no effect on the docking and thus do not need to be present as this only causes spatial 
and conformational problems and the water is normally displaced, or in some cases water 
molecules near the active site will form hydrogen bonds with the ligand thus helping to 
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mediate the docking process. Therefore in some cases, the presence of water is important 
to the docking process, such as in the HIV‐1 protease system (Lam et al., 1994). However, 
another problem arising from having water molecules present for the docking process is the 
fact that a rigid crystal structure is used in all calculations; this includes the water molecules 
present. Amongst the other problems the rigid paradigm causes, this can develop a slight 
problem where when the receptor grid is generated there is an empty binding pocket where 
the ligand would normally be situated. This in nature is usually filled with water that will be 
displaced by the ligand, however now we have an energetically favourable location for the 
ligand to bind too with a slight bias towards it as there is more space for the ligand within 
the structure. In essence it would not generate false positives but it is not be an accurate 
test of docking as it would be artificially biased. 
Verdonk et al. (2005) discuss that a key missing concept to current approaches is that in 
nature when a ligand displaces a water molecule to bind to the receptor site it gains rigid‐
body translational and rotational entropy. This is currently not factored into scoring 
functions and should be used possibly as a term that would reward a ligand for performing 
this displacement. This can help the scoring function have a higher chance of generating the 
correct answer when water is present. 
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2.2.5 Series of test molecules 
The SERAPhiC benchmark set, as presented in Favia et al. (2011) was chosen for this 
study;  these proteins were chosen as they were part of a validation set. In this case, 
a majority of the proteins have a good RMSD associated with the docking tests in the 
paper, as a rule of thumb this is about 2.0 Å. Each entry in the SEARPhiC set needed 
to: have a resolution of ≤ 2.5 Å, date of disposition ≥ year 2000, presence of an 
article describing the crystal structure, a macromolecule of ≥ 200 amino acids and 
have at least one ligand of between 78 and 300 daltons with at least 6 heavy atoms. 
Each protein was prepared using Maestro's protein preparation package following 
the standard procedure, except all the waters were removed from around the 
structure.  
Each of the fragments in the docking set forms non‐covalent bonds with their 
respective proteins. The fragments in the SERAPhiC set all modulate protein activity 
by either being an inhibitor or a substrate.  
In the SERAPhiC set Favia et al. (2011) performed docking similar to the methods 
presented in this chapter. The docking program adopted by Favia et al. (2011) was 
Molsoft using Internal Coordinate Mechanics  (ICM) forcefields. Molsoft for the 
SERAPhiC set used a Biased Probability Monte Carlo Method, as shown in Totrov and 
Abagyan (2001). Each ligand was considered with and without water molecules. There were 
3 grid sizes generated for each fragment; 3.5 Å, 5 Å and 7 Å. The analysis performed was to 
determine if the docking used with the ICM engine could find the native pose of the 
fragment in the top 10 hits and if the best docking score attained was the native pose. Favia 
et al. (2011) referred to this as the soft and hard successes respectively. Using their methods 
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soft success was approximately 90% of all structures and hard success was approximately 
60% of all structures.  
The SERAPhiC set was also analysed using BINANA which is an algorithm developed by 
Durrant and McCammon (2011). This algorithm summarises the interactions between a 
fragment and protein within their complexes. The data for this can be found in the paper by 
Favia et al. (2011). The resolution of each model can be found in appendix 2.2. 
 
2.2.6 Molecule preparation 
The standard procedure in Maestro’s protein preparation wizard is as follows: assign 
bond orders, add hydrogens, create zero‐order bonds to metals, create disulfide 
bonds, convert selenomethionines to methionines, Cap N and C termini with ACE 
and NH3 (small fragments were not capped). We had no selenomethionines in the 
protein but the setting was left on as default.  
Each protein was then minimized. The waters were removed by setting the 
maximum distance that waters were kept to 0 Å. Once the protein has been 
prepared then a docking receptor grid is generated using the original position of the 
ligand from the crystal structure as the centre of the grid. The ligand is removed 
from the grid to create an open pocket. The size of the docking grids was set to be 
larger than normal, to 36 Å  36 Å  36 Å. This was to reduce bias to the binding site 
so that the ligand might dock in other pockets within the grid and not just to the 
centre. GLIDE has a slight inbuilt bias towards the centre of the grid; making the box 
larger offsets this bias. The ligand is then docked into this new docking receptor grid 
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and the best 15 ligand poses were generated for each protein. The criteria for the 
best poses was set by glidescore, as detailed in Friesner et al. (2004). This often 
coincides with the lowest RMSD though this was not always the case. In the cases 
where there was more than one identical chain, a docking run was performed with 
only one chain present, usually chain A, with their respective ligand, but all active 
site from the chain were left empty as per the other runs.  
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2.3 QM/MM 
The concept behind the QM/MM method is to take into account QM calculations 
such as the processes behind bond‐breaking/forming, charge transfer and electronic 
excitation of atoms while also including a MM force field that is based on small inter 
and intra molecular forces, such as Van der Waal  and electrostatic interactions as 
presented by Lin and Truhlar (2007). The QM/MM method aims to include the 
environment around the active site of the protein. 
The QM portion of the method takes the localised region around the active site and 
calculates the QM forces in this region. The QM region will also include its 
surroundings, the protein environment also known as the secondary subsystem (SS) 
at the MM level. The key amino acids in the active site and its neighbours are 
defined as the primary system (PS); here the PS was the ligand. QM/MM methods 
can be treated in two different ways by changing how the electrostatic interactions 
take place between PS and SS, either by mechanical or electrostatic embedding. 
According to Bakowies and Thiel (1996), mechanical embedding handles the 
interaction between the PS and SS only at the MM level, which is a simpler 
approach. The electrostatic embedding calculates the QM calculations for the PS in 
presence of the SS. One electron operators are included to describe the electrostatic 
interactions between the two systems; these operators enter the QM Hamiltonian. 
This is the sum of all kinetic energies for the atoms in the system and the potential 
energy for any atoms currently associated with the system; this is the approach 
taken here. 
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Methods have been suggested by Illingworth et al. (2008) that takes the QM/MM 
approach and combines it with the polarization of both the ligand and its target. As 
often polarisation is a key term that isn't present for most molecular mechanics 
studies, it is an area of interest. This project hopes to expand on this research and 
assess new techniques using the hybrid QM/MM and polarization to attain more 
accurate results for blind docking. 
 
2.3.1 QM/MM using Jaguar 
For a given docking run, each of the 15 ligand poses were then merged with the rest 
of the protein structure, creating a separate file for each. These merged files were a 
separate input files for each pose that included the posed ligand and the protein. A 
Qsite input file was generated for each of the 15 combined structures. Each test was 
performed as a single point QM/MM calculation with the ligand as QM and the 
protein as MM, for the purposes of calculating the QM potential derived charges. 
Each test also had 1000 cycles set for MM optimization. This was performed for 
general geometric minimization of the structure.  At this point, instead of using Qsite 
normally with the above settings, in‐house polarisation scripts to polarise the ligand 
and the surrounding binding pocket were used instead. The in‐house scripts can be 
found in the appendix 2.3. This generated the polarized charges for the ligand and 
for the protein, which could be used in the re‐docking (see below). 
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2.3.2 Methods for modelling Polarization 
Polarizability helps explain interactions between nonpolar atoms and electrically 
charged species, such as ions or polar molecules. These charged species will have 
dipole moments. When a neutral nonpolar atom is subjected to an electric field, its 
electron cloud can be distorted. Usually nonpolar atoms have roughly symmetric 
arrangement of electron clouds. The ease of this distortion is polarizability as 
according to Cornah (2013). There are several ways for modelling polarization, as 
described in sections 2.2.3.1 – 2.2.4.  
 
2.3.3.1 Quantum mechanics 
During the SCF procedure, the atomic charge distribution that emerges can be 
viewed as a consequence of the optimized linear combination of atomic orbitals 
(LCAO) coefficients. When the wavefunction is perturbed during a QM/MM 
calculation, these coefficients must be re‐optimized. Ligand polarization is therefore 
automatically included in QM/MM calculations (Feynman and Hibbs, 1965). 
 
2.3.3.2 Induced dipole method 
This model uses fixed atomic partial charges, as found in non‐polarziable force fields, 
then adds a set of inducible point dipoles as shown in Friedrich and Herschbach 
(1999). Each induced dipole, i, at site i, is then determined by the electric field, Ei, 
at that site according to equation 2.2, where i is the isotropic polarizability of site i. 
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Electrostatic interactions cannot be fully calculated via Coulomb potential in the 
region of the dipole as the Coulomb potential evaluates charge‐charge interactions. 
New terms must be added to take into consideration the dipole‐charge or dipole‐
dipole interactions as shown in Maple et al. (2005), and these considerably increase 
the complexity and cost of the calculations.  
)2.2(iii E   
2.3.3.3 Drude oscillator 
In the Drude oscillator model, the polarizability is modelled by adding massless 
charged particles attached to the polarizable atoms. The massless charged particles 
are Drude particles. In current models the polarizable atoms do not include 
hydrogens. These charged particles are attached via a harmonic spring. The 
polarizable atom then has its charged spread across its core and the massless Drude 
particle (Lopes et al., 2009). 
 
2.3.3.4 Charge equilibration 
The Charge equilibration model predicts charges of large molecules by using their 
geometry and experimental charge properties as shown in Rappe and Goddard III 
(1991). The formalism of this model assumes that the chemical potential of a 
molecule is equilibrated via the redistribution of charge density over the molecule. 
This approach allows the charges to respond to changes in environment. Due to the 
changing charges this is also referred to as the fluctuating charge method, as shown 
in Baker (2015). To determine the polarizabilities, the partial charge of each atom is 
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placed at the atomic nucleus. The electrostatic interactions are calculated using the 
normal Coloumb potential. To achieve the effect of changing charges according to 
the environment, this method assigns fictitious masses to each of the charges, 
therefore each of the nuclei, and treats them as new degrees of freedom when 
calculating the equations of motion, as shown in Rappe and Goddard III (1991).  The 
charges continually flow between the atoms until their electronegativities are 
equalized. However this method cannot represent polarization that is not in the 
direction of the bonds. This makes it difficult to polarize benzene against a species 
perpendicular to it, as stated in Baker and Grant (2006) and Winn et al. (1997).  
 
 
 
 
 
 
 
 
 
 
Page | 39  
 
2.3.4 The induced charge method 
2.3.4.1 Theoretical basis of the induced charge method 
 In the induced charge method, an induced dipole is approximated by the charges on 
neighbouring atoms and the central atom itself. This can be shown in Fig. 2.2. 
 
 
Figure. 2.2. Key descriptors relevant to the induced charge method of approximating 
polarization. 
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     (2.3) 
All equations in this section are from Ferenczy and Reynolds (2001). Here,    is the 
induced dipole in equation 2.3, this is expanded by using the equations 2.4 and 2.5, 
where    is the vector of the distances between the neighbouring atoms (B) and the 
central atom (A) shown in equation 2.4.  
    (2.4) 
In equation 2.5,    A(Bx) is the partial induced charges of each of the respective 
neighbouring atoms.  
      (2.5) 
Using equation 2.2 from the induced dipole method, we can modify it to generate 
equation 2.6.  
     (2.6) 
Then using Taylor expansion for electrostatic potential we can write it as equation 
2.7.where φ is defined as the electrostatic potential. 
     (2.7) 
Truncating equation 2.7 we can write equation 2.8.   
     (2.8) 
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Where Δ(  )  is the difference vector of electrostatic potential so we can write out a 
final formula of equation 2.9  
         (2.9) 
Thus, calculation of the MM induced charges required the QM calculation of the 
electrostatic potential at the MM atoms (using Jaguar); the electrostatic field was 
not required. The sum of induced charges on a given atom can be written as qIND(A). 
This is the sum of negative partial induced charges of atom A in the above diagram 
and the partial induced charges of the neighbouring atoms which can be 
summarized as: 
  (2.10) 
The total atomic polarized charge is a sum of the permanent and induced charges 
which can be written as:  
      (2.11) 
The Electrostatic energy can be then calculated using Coulomb following: 
    (2.12) 
Where: 
       (2.13) 
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2.3.4.2 Application of the induced charge method to GLIDE docking 
For the docking, we wish to be able to polarize just the ligand or the ligand and the 
enzyme target. Ideally, the ligand would be polarized in its correct pose, but in an 
actual docking investigation as part of a drug design programme, the correct pose 
would not be known prior. For this reason, we have made the assumption that the 
best docked pose is a sufficiently good approximation to the correct pose. 
Consequently, we have polarized the ligand and enzyme according to the geometry 
of the best pose and then re‐docked the ligand to the original crystal structure. Then 
their RMSDs of these new poses were compared to the original docked poses. 
Using the method within the in‐house scripts, a set of output files were generated 
with the new polarized charges for the QM region, which was set as the ligand; the 
MM region of the QM/MM system was the rest of the system, i.e. protein. The basis 
set used for the QM region was 6‐31G*. The method used was B3LYP. This in house 
script changed the polarisation charges for all the atoms in the region, both from the 
ligand and protein. The ligand charges were derived from the perturbed 
wavefunction of the ligand within the protein, as potential derived charges, while 
determination of the QM potential at the MM atoms enabled the calculation of the 
induced charges for the enzyme (via equation 2.9). The total enzyme charges are the 
induced charges added to the base charges. Once the charges were extracted from 
the file they were reinserted into the original structure, replacing the atomic charges 
of the atoms for the ligand and the protein. A set of atomic charges were generated 
for each of the 15 ligand poses of each complex for the ligand and protein. Chart 2.1 
 A flowchart indicating the steps required in protein and ligand preparation and the 
subsequent polarized docking, as described in sections 2.2.6 and 2.3.4.2.
 
Chart 2.1: Summary of protein preparation, docking and 
charges through the QM/MM method.
 
2.3.4.3 Generating new docking grids based upon new atomic charges from ligands
With the new atomic charges in place, each of the 15 different ligand poses was re
imported into Maestro; each ligand
derived from the top docked pose
top pose of each structure
the beginning of this method
repeated, but with the new 
were generated from the grid based upon the new charges from the QM/MM. These 
poses were then compared to the original set to observe if do
with the inclusion of the polarisation charges. This was 
generating polarization 
 
 has the same set of charges, namely the set 
. A receptor grid was once again generated for 
 using the ligands in place as the centre of the grid as per 
 (section 2.3.4.2). The GLIDE docking procedure is 
polarized charges. For each structure, 15 new poses 
cking had improved 
performed by comparing the 
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RMSD against the crystal structure for each of the original docked posed versus the 
RMSD of each of the polarized poses against the crystal structure. The in‐house 
scripts used to implement the induced charge method in GLIDE docking are shown in 
Appendix 2.2. 
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2.4 Results 
 
2.4.1 Initial Docking 
 
 
Table 2.1 shows the RMSD for each docked ligand before and after generating a 
QM/MM region around the binding site and running a QM/MM optimization with 
ligand and protein polarization. Thus, the basic Glide docking results are given in the 
‘before’ column, while the polarized docking results are given in the ‘after’ column. 
This is a condensed table of actual results as there are 15 QM/MM possible regions 
generated based on the 15 initial docking poses for each ligand. The QM/MM 
regions here are those generated from the first pose of each initial dock.  
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Table 2.1: Table of RMSD values of GLIDE docking before standard docking and after polarized docking using QM/MM polarisation taking the top docked posed according 
to Glidescore as starting geometry. Lowest RMSD for each column is shown in bold italics.  For some proteins, fewer than 15 poses were generated. The brackets next to a 
name denotes chain. 
PDB 
1MLW 
 
1Y2K 
IC50 = 
21 nM 
1FSG 
(C) 
IC50= 
9.5μM 
1FSG 
(A) 
IC50= 
9.5μM 
1TKU 
(A)  
1TKU 
(B)  1S5N 
 
Pose 
No. 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
1 3.331 3.360 2.336 3.803 0.142 0.155 0.146 0.085 3.336 3.354 3.132 1.911 2.857 2.877 
2 3.179 3.575 2.480 5.077 3.384 3.385 3.385 3.379 2.526 3.178 3.022 2.044 2.253 2.626 
3 3.572 2.863 2.328 2.468 7.376 6.812 5.770 5.146 3.331 2.528 2.583 2.969 2.105 2.641 
4 2.857 2.580 2.333 6.967 5.970 6.062 6.510 5.728 3.325 3.076 3.203 2.081 3.053 2.711 
5 1.633 2.070 2.746 7.063 6.677 6.096 7.540 6.70 3.229 3.256 3.209 1.896 2.507 2.995 
6 1.964 3.004 6.931 7.218 5.597 5.154 5.100 5.811 3.049 3.315 2.964 0.731 4.332 1.890 
7 2.050 2.679 7.043 6.988 6.679 7.237 5.721 7.568 2.787 3.342 3.316 0.454 2.926 3.122 
8 3.064 1.832 7.002 6.977 5.174 6.994 6.058 6.479 3.277 3.096 3.028 0.563 2.668 4.534 
9 1.715 2.150 7.010 3.498 6.977 7.471 4.950 6.703 3.248 3.055 2.888 1.096 3.373 2.531 
10 2.214 2.217 7.258 7.178 7.798 7.344 7.516 8.209 2.965 3.094 2.856 1.893 2.379 2.153 
11 2.275 2.578 7.220 7.277 7.735 6.231 4.974 7.732 2.984 3.132 2.855 1.573 2.566 1.595 
12 2.02 2.298 3.530 4.979 7.091 7.807 7.594 6.034 2.934 2.929 2.9 1.279 2.046 1.867 
13 1.621 2.764 7.511 4.957 6.022 5.299 5.682 7.833 3.184 3.052 2.989 1.791 2.289 3.329 
14 2.285 2.377 3.531  7.034 5.694 6.962 7.064 2.917 3.022 2.915 1.455 2.236 2.507 
15 2.598 2.767 3.601  5.115 4.857 5.375 5.443 2.981 2.861 3.003 1.458 1.572 2.454 
 
1MLW: tryptophan 5‐monooxygenase (Wang et al., 2002). 1Y2K: camp‐specific‐3’,5’‐cyclic phosphodiesterase (Card et al., 2005) 1FSG: hypoxantine‐guanine 
phosphoribosyltransferase (Héroux et al., 2000) 1TKU: 3,4‐dihydroxy‐2‐butanone 4‐phosphate synthase (Echt et al., 2004) 1S5N: xylose isomerase (Fenn et al., 2004) 
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PDB 1R5Y 
K i= 
0.35μM 1F8E 
K i= 
15μM 1PWM 
IC50= 
 935 nM 1SQN 
K d= 0.4 
nM 1UWC 
 2BRT  1F5F 
IC50= 
3.8 nM 
Pose 
No. 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
1 0.112 0.162 1.034 0.173 0.328 0.222 0.125 0.152 0.276 0.377 0.489 0.787 0.167 0.051 
2 0.148 2.715 1.023 0.715 4.542 4.570 0.957 0.511 5.102 1.253 6.727 1.816 6.284 6.296 
3 2.897 4.268 0.488 1.208 4.564 4.640 2.255 1.415 2.594 2.607 1.834 5.239 6.338 6.342 
4 4.244 4.383 0.488 1.349 4.66 4.738 2.585 2.348 1.150 0.592 1.94 2.172 6.634 6.651 
5 4.926 4.914 1.147 1.328 4.518 4.476 6.591 6.489 0.629 5.090 6.708 6.634 2.439 2.737 
6 2.927 3.005 1.189 1.443 4.427 4.417 6.525 6.600 1.006 2.357 2.205 6.672 2.655 2.639 
7 4.928 4.341 1.44 0.933 4.749 5.372 6.547 2.591 2.234 2.358 6.718 3.031 2.809 2.810 
8 4.459 4.675 1.287 0.868 4.473 6.679 2.907 6.535 5.978 4.775 1.953 6.770 6.503 2.551 
9 4.31 4.277 1.504 4.538 6.678 5.346 6.433 6.444 0.867 0.898 2.007 3.283 6.667 6.498 
10 4.12 4.093 0.674 1.347 6.906 4.886 2.645 2.282 2.574 6.065 6.544 3.627 2.886 2.530 
11 4.718 7.903 4.341 4.576 6.983 4.889 6.648 6.719 2.607 5.055 1.134 0.936 6.572 2.889 
12 4.872 8.458 4.562 4.054 7.499 4.239 6.475 6.526 2.427 2.698 0.883 6.467 6.420 6.682 
13 8.022  2.488  5.862 5.875   5.134  6.12 6.769 3.473 3.513 
14 6.968  4.405  4.97 4.222   5.598  4.55 4.550 2.728 6.428 
15 7.563  4.318  4.349      4.55 6.823   
 
1R5Y: queine trna‐ribosyltransferase (Brenk et al., 2004) 1F8E: neuramidase (Smith et al., 2001) 1PWM: aldose reductase (El‐Kabbani et al., 2004) 1SQN: progesterone 
receptor (Madauss et al., 2004) 1UWC: feruloyl esterase (McAuley et al., 2004) 2BRT: leucoanthocyanidin dioxygenase (Welford et al., 2005) 1F5F: sex‐hormone binding 
globulin (Avvakumov et al., 2000) 
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PDB 
1UI0 
(B) 
K i= 88 
nM 
1UI0 
(A) 
K i= 88 
nM 1YNH  2B0M 
K i= 
2.8μM 2BL9 
K i = 
0.16 nM 2CIX 
K d= 33 
mM 2CIX redock 
Pose 
No. 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
1 2.810 2.041 0.259 0.336 0.480 0.164 0.332 0.306 0.133 0.187 9.278 9.236 2.135 2.929 
2 8.568 7.716 2.86 2.877 0.444 0.566 1.436 1.002 0.642 0.660 7.915 9.347 1.748 1.609 
3 2.987 3.169 2.468 3.138 0.766 1.085 3.087 0.660 2.738 1.033 2.064 2.777 0.257 2.129 
4 8.344 2.292 3.056 2.399 0.459 1.165 3.14 1.242 2.432 2.647 2.774 1.336 2.409 1.902 
5 3.176 0.440 2.967 6.016 0.575 0.567 0.716 0.840 3.341 2.590 1.458 2.100 1.997 2.548 
6 2.837 2.456 6.074 2.583 0.834 0.670 1.692 3.088 5.609 2.916 1.349 1.791 0.852 0.511 
7 0.170 1.765 2.601 2.602 0.625 0.921 3.221 3.143 3.843 2.430 1.906 1.905 1.899 1.817 
8 2.216 2.235 3.064 3.102 1.022 0.544 2.769 3.231 3.745 5.634 1.637 8.562 2.839 2.222 
9 1.117 3.086 1.143 2.743 1.092 0.823 3.730 3.545 6.269 5.616 1.822 1.823 7.032 7.142 
10 3.220 2.447 5.178 5.842   2.251 2.254 4.897 3.689 7.641 1.901 6.944 8.135 
11 2.863 2.893 5.877 2.308   2.339 2.341 5.989 3.466 3.329 7.707 6.828 6.853 
12 2.615 2.839 2.922 5.182     5.145 6.051   5.824 7.297 
13 2.268 2.999 5.573 5.396     6.173 6.128     
14 2.509 3.257 4.037 3.793     6.662      
15 2.674 2.731 8.002 3.083           
 
1UI0: uracil‐dna glycosylase  (Marcyjaniak et al., 2004) 1YNH: succynilarginine dihydrolase (Tocilj et al., 2005) 2B0M: dihydroortate dehydrogenase (Hurt et al., 2006) 2BL9: 
dihydrofolate reductase‐thymidylate synthase (Kongsaeree et al., 2005) 2CIX: chloroperoxidase (Kühnel et al., 2006) 
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PDB 1W1A  2FDV 
K i= 
0.8μM 1M3U  2AIE 
IC50= 
2.2 2BKX  1M2X 
K i= 70 
100μM 1YKI  
Pose 
No. 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
1 0.149 0.643 1.168 1.621 0.217 6.342 1.608 1.597 1.964 1.485 2.607 0.182 8.773 1.870 
2 0.645 0.135 1.179 1.198 0.855 6.333 1.528 1.509 1.506 2.519 0.439 0.681 10.400 2.845 
3 2.72 2.648 1.189 1.175 1.600 7.044 1.477 1.458 1.880 2.346 1.562 1.928 10.113 2.558 
4 4.875 1.587 0.276 0.832 1.635 6.426 0.902 1.040 2.167 2.468 1.578 6.349 14.332 5.201 
5 2.578 1.723 0.835 0.261 1.612 5.987 1.339 0.898 1.715 2.322 7.499 2.684 11.929 4.046 
6 2.607 1.743 1.254 1.225 0.749 6.296 1.525 3.025 2.030 2.545 4.430 6.067 9.358 3.728 
7 5.541 2.524 1.255 0.796 1.842 7.012 2.264 1.521 0.811 2.756 7.548 2.356 6.470 0.481 
8 1.656 2.711 1.561 0.937 0.795 6.554 1.442 1.645 2.163 2.155 0.986 5.703 12.457 10.162 
9 5.41 1.761 0.968 1.535 2.116 7.181 2.223 2.129 2.854 2.484 7.577 5.036 9.840 2.728 
10 5.728 4.868 0.922 1.499 1.799 8.348 0.372 2.782 2.191 2.146 7.555 5.326 7.092 6.323 
11 5.298 4.919 1.812 1.347 0.894 8.511 2.243 2.32 2.166 2.138   12.328 6.853 
12 5.381 5.488 2.492 1.704 1.792 9.919 1.901 1.988 1.598 2.435     
13 5.512 5.487  1.698 7.087 2.442 2.848 1.003 1.795     
14 5.509 5.675  2.321 8.107 2.696  1.667 2.614     
15    2.224  1.894 2.105     
 
1W1A: polysaccharide deacetylase  (Blair and van Aalten, 2004) 2FDV: cytochrome p450 (Yano et al., 2006) 1M3U: ketopantoate transferase (von Delft et al., 2003) 2AIE: 
peptide deformylase (Smith et al., 2003) 2BKX: glucosamine‐6‐phosphate deaminase (Vincent et al., 2005) 1M2X: metallo‐beta‐lactamase (García‐Sáez et al., 2003)  1YKI: 
oxygen insensitive nad(p)h nitroreductase (Race et al., 2005) 
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PDB 2UY5 
K i= 
3.2μM 2RDR  2J5S  2Q6M 
K d= 
510 nM 2I5X  1OFZ 
K d= 
24.1μM 1WOG  
Pose 
No. 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
1 0.151 0.172 0.449 0.161 1.169 1.042 1.902 0.566 1.267 1.292 0.270 0.163 4.567 0.649 
2 0.939 0.940 4.339 4.451 0.258 2.338 1.928 2.040 1.314 1.267 0.866 0.865 4.181 0.861 
3 1.143 6.838 1.374 1.429 0.756 0.274 1.896 1.995 1.308 1.305 0.871 2.887 4.42 4.721 
4 2.497 6.894 4.606 1.071 0.708 2.254 0.607 1.452 1.052 1.077 3.054 4.053 4.722 1.366 
5 6.931 2.531 1.253 4.471 2.308 2.055 0.321 2.251 1.255 1.253 2.792 3.426 5.343 1.184 
6 6.972 5.459 4.554 4.301 2.021 0.883 1.988 0.689 1.241 1.193 4.074 3.459 4.479 4.324 
7 5.516 5.914 1.303 0.683 0.996 0.897 2.330 1.349 1.159 1.448 3.623 2.869 5.263 1.398 
8 5.535 5.193 0.728 0.839 2.244 0.700 1.520 5.652 0.697 1.697 3.337 2.411 4.794 2.784 
9 6.190 5.861 4.411 4.440 2.049 1.849 5.522 6.009 0.345 0.694 3.418 4.096 4.763 1.112 
10 5.785 6.065 4.555 1.723 1.968 2.249 6.020 5.895 1.387 0.342 3.367 2.895 4.868 0.709 
11 5.090 5.912 4.431 2.065 1.791 2.908 5.891 5.524   1.706 3.285 4.750 0.893 
12 5.058 4.767 4.468 4.304   5.517 3.511   2.009  5.066 1.219 
13 3.850 5.933 4.425 7.340   3.540 3.506   2.392  5.366 1.784 
14     5.525 3.314   3.997  5.114  
15         4.087    
 
2UY5: endochitinase (Hurtado‐Guerrero and van Aalten, 2007) 2RDR: 1‐deoxypentalenic acid 11‐beta hydroxylase fe(ii)/alpha‐ketoglutarate dependent hydroxylase (You et 
al., 2007) 2J5S: beta‐diketone hydrolase (hydrolase) (Bennett et al., 2007) 2Q6M: cholix toxin (Jørgensen et al., 2008)  2I5X: receptor‐type tyrosine‐protein phosphatase 
beta (Evdokimov et al., 2006)  1OFZ: fucose specific lectin (Wimmerova et al., 2003) 1WOG: agmatinase (Ahn et al., 2004) 
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PDB 2GG7 
IC50= 
1.75μM 2GVV 
K i= 
125μM 2ZVJ 
IC50= 
1.8μM 1YV5 
IC50 = 
5.7 0 3DSX 
K d= 
1.4 mM 
2FF2 K i = 
6.2 nM 
Pose 
No. 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
Before 
QM/MM 
After 
QM/MM 
1 0.303 0.278 0.570 0.812 4.024 0.101 1.255 0.609 2.695 2.849 2.017 0.230 
2 0.894 1.903 0.894 0.653 4.021 0.646 0.381 1.486 2.760 2.475 1.021 3.092 
3 1.428 0.739 0.879 0.271 0.805 4.163 1.439 1.304 5.799 6.080 0.902 3.231 
4 2.387 2.118 0.861 1.113 0.176 1.018 4.793 1.657 2.503 2.399 2.052 2.021 
5 4.363 3.237 1.269 1.014 3.521 4.069  1.010 7.584 5.126 2.462 2.379 
6 6.525 2.189 0.988 1.090 3.581 4.465  1.212 5.773 3.673 2.449 2.150 
7 6.594 2.393 0.935 1.233 4.336 1.591  1.081 5.544 4.826 3.118 3.170 
8 6.937 2.494 0.835 0.960 1.449 1.684  1.473 5.769 7.347 3.122 2.151 
9 7.056 3.097 0.526 0.795 2.698 3.337  1.007 4.985 5.830 2.762 3.149 
10 6.653 2.617 1.116 1.142 2.321 4.674  4.822 5.220 2.997 2.678 3.503 
11 6.971 4.791 1.008  2.426 3.396  4.709 9.745 4.223 2.015  
12 6.858 3.282 1.215     4.908 5.961 2.853 2.652  
13 7.183       2.863 5.848 2.284  
14 7.622       4.528 6.409 2.560  
15        9.522   
 
2GG7: methionine aminopeptidase (Evdokimov et al., 2007) 2GVV: phosphotriesterase (Blum et al., 2006)  2ZVJ: catecholo‐methyltransferase (Tsuji et al., 2009) 1YV5: 
farnesyl pyrophosphate synthetase (Kavanagh et al., 2006) 3DSX: geranylgeranyl transferase type‐2 subunit alpha (Guo et al., 2008) 2FF2: iag‐nucleoside hydrolase 
(Versées et al., 2006)
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The overall results of the docking are summarized in Table 2.2. Standard glide has a 
39% error rate, as it failed to dock top ranked pose for 16 out of 41 molecules to 
within 2 Å, while the polarized docking reduced the error by 39% down to 27%. An 
even more significant reduction in the error was observed if the criterion was to 
dock any of the poses to with 2 Å; the reduction was from 23% to 13%. In polarized 
docking, the top pose was more likely to be the best pose: the top pose was the best 
pose in 21 case for polarized docking and only 19 cases for standard Glide. In only 
one case did the standard Glide give a correct top pose while polarized docking 
failed. In contrast, polarized docking gave a correct pose in 6 cases where standard 
Glide failed. In only 2 of these 7 cases was there a failure to find a good pose with an 
RMSD of less than 2 Å, some if the aim is to find a correct pose of any rank, then 
there are certainly grounds for supplementing standard Glide with polarized 
docking. 
Table 2.2 Summary of Table 2.1.  
 Before (no 
polarization) 
# incorrect After (polarized 
docking) 
 # incorrect 
Na 41   41   
# < 2 A (top pose) 25 16 30  11 
# < 2 A (all poses) 33 9 36 5 
Top pose lowest 18 23 25 16 
Top pose lowest and < 2 
Å 
18 23 25 16 
best (all poses) 19 22 21 20 
Best (top pose) 19 22 21 20 
Only before correct (top 
pose < 2 Å ) 
1    
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Only after correct (top 
pose < 2 Å) 
  6 6 
After and Before 
incorrect (top pose) / all 
poses 
7 / 2 
  
     
After or before incorrect 
(top pose) / all poses 
6/4    
a including the 2CIX redock 
Thus, results such as 1WOG and 2ZVJ have improved over those obtained from 
standard Glide. For example, there is a significant improvement of the RMSD for 
1WOG from 4.57 to 0.65.  There is still one result where the regular glide dock is 
better than after the QM/MM calculations. The RMSD for 1M3U was 0.22 for 
standard Glide and 6.34 after polarized docking. 
The industry standard for a decent dock is an RMSD under 2 Å; thus for comparison 
of methods a good result for either method should have an RMSD of under 2 Å. 
2CIX first gave us some problems with docking to get a good RMSD. It was later re‐
docked several times by varying the size of the GRID before moving on to polarized 
docking to see if we could get an improvement. The best we could get is shown in 
table 2.1 as the last column. 
 
2.4.2 Polarized docking (re-docking) 
Table 2.3 presents the results of polarized docking in which both the ligand and the 
protein are mutually polarized according to the top ranked pose from the initial 
docking given in Table 2.1. Table 2.3 shows the glide score ranks of the first results 
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under 2 Å for the proteins that had better or worse RMSDs with polarized docking. It 
shows that in some cases such as 1TKU chain B, 1F8E or 1UI0 chain B that when 
taking the best glide score even when there is better RMSD results in the lower 
rankings we can still obtain a good result following re‐docking as an additional step 
after the QM/MM calculations.  
 
13 of the proteins tested have a markedly better RMSD. 1 is worse and 24 have not 
changed significantly. 1S5N fails on both methods. This is where the top glidescore 
poses were not below the 2 Å industry standard. 1S5N’s RMSD for both methods 
was above 2 Å. 
 
As stated in section 2.3.1, of the 38 results, 25 gave an RMSD below 2 Å and 24 gave 
an RMSD below 1.5 Å for the basic docking.  
After the QM/MM results, these figures were 31 and 29 respectively. In 24 of these 
cases the RMSD improved after QM/MM method. In 25 cases, the lowest RMS (over 
all poses) was for the QM/MM results. In 6 cases, the QM/MM method brought the 
results into the desired range of RMSD < 2 Å, while in one case, the good docking 
results were spoiled by the QM/MM method. 
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Table 2.2: Table of ranks of 1st results of initial docks or re‐docks under 2 Å. Where 
there is a difference in rank, the best result is in bold. 
Re-dock after 
QM/MM better 
Rank of 1
st
 significant 
result on initial dock (< 2 Å) 
Rank of 1
st
 significant 
result on re‐ dock (< 2 Å) 
1FSG chain A 1 1 
1TKU chain A 2 3 
1TKU chain B 3 1 
1F8E 1 1 
1PWM 1 1 
1UI0 chain A 1 1 
1UI0 chain B 7 5 
1F5F 1 1 
1M2X 2 1 
1YKI 11 1 
1YNH 1 1 
2B0M 1 1 
2RDR 1 1 
2Q6M 1 1 
 2BL9 1 1 
2AIE 1 1 
2BKX 1 1 
1M2X 2 1 
2J5S 1 1 
1OFZ 1 1 
1WOG 16+ 1 
2GG7 1 1 
2ZVJ 3 1 
1YV5 1 1 
2FF2 2 1 
Both Fail   
1S5N 15 5 
1Y2K 16+ 16+ 
2CIX 5 4 
Initial Glide 
Better 
  
1M3U 1 15+ 
1MLW 5 8 
1FSG chain C 1 1 
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1R5Y 1 1 
1SQN 1 1 
1UWC 1 1 
2BRT  1 1 
1W1A 1 1 
2FDV 1 1 
2UY5 1 1 
2I5X 1 1 
2GVV 1 1 
2CIX (redock) 2 2 
3DSX 4 2 
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Table 2.3: Table of atomic charges before and after polarization with associated atom for ligands in 1W0G, 1YV5 and 2GG7.  
Protein 
Before 
polarization 
After 
Polarization Atom Protein 
Before 
polarization 
After 
Polarization Atom Protein 
Before 
polarization 
After 
Polarization Atom 
1W0G ‐0.90000 ‐0.73233 N 1YV5 ‐1.11997 ‐0.72225 O 2GG7 ‐0.80000 0.71130 O 
 
0.06000 0.50270 C 
 
1.55780 0.41361 P 
 
0.71500 0.71215 C 
 
‐0.12000 ‐0.41183 C 
 
‐1.11997 ‐1.14608 O 
 
‐0.80000 ‐0.80497 O 
 
‐0.12000 0.28799 C 
 
‐1.11997 ‐0.81983 O 
 
‐0.11500 ‐0.03869 C 
 
‐0.12000 ‐0.19768 C 
 
‐0.13080 1.62935 C 
 
‐0.11500 ‐0.32094 C 
 
‐0.08000 ‐0.01248 C 
 
‐0.68300 ‐1.12335 O 
 
‐0.11500 ‐0.02051 C 
 
0.31340 0.25927 N 
 
1.55780 0.49767 P 
 
‐0.11500 ‐0.44919 C 
 
‐0.67240 ‐1.00933 H 
 
‐1.11997 ‐0.63453 O 
 
‐0.11500 ‐0.15878 C 
 
0.36000 0.52811 H 
 
‐1.11997 ‐1.01376 O 
 
0.03800 0.35427 C 
 
0.36000 0.46137 H 
 
‐1.11997 ‐0.89681 O 
 
‐0.03800 ‐0.29951 N 
 
0.06000 0.08927 H 
 
0.04300 ‐0.71285 C 
 
‐0.03800 ‐0.24570 N 
 
0.06000 ‐0.05856 H 
 
‐0.45500 0.23031 C 
 
‐0.13920 0.11339 C 
 
0.06000 0.05183 H 
 
0.22700 ‐0.01071 C 
 
0.71000 0.20783 C 
 
0.06000 0.15589 H 
 
‐0.44700 ‐0.48043 C 
 
‐0.92000 ‐0.76951 N 
 
0.06000 ‐0.16328 H 
 
0.47300 0.33497 C 
 
‐0.14900 ‐0.12707 N 
 
0.06000 ‐0.01769 H 
 
‐0.67800 ‐0.82029 N 
 
0.53800 0.43588 C 
 
0.06000 ‐0.00763 H 
 
0.47300 0.37390 C 
 
‐0.53100 ‐0.16269 N 
 
0.06000 ‐0.06436 H 
 
0.41800 0.63845 H 
 
‐0.92000 ‐1.12764 N 
 
0.06000 0.02397 H 
 
0.06000 0.11252 H 
 
0.11500 0.05601 H 
 
0.06000 0.13861 H 
 
0.06000 0.07571 H 
 
0.11500 0.04615 H 
 
0.40200 ‐0.10243 H 
 
0.06500 0.17730 H 
 
0.11500 0.12101 H 
 
0.28270 0.27860 H 
 
0.15500 0.05251 H 
 
0.11500 0.03814 H 
     
0.01200 ‐0.12935 H 
 
0.36000 0.48859 H 
     
0.01200 ‐0.02606 H 
 
0.36000 0.26504 H 
         
0.34100 0.49600 H 
         
0.36000 0.50829 H 
         
0.36000 0.39378 H 
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Table 2.3 shows a sample of three of the ligands from the SERAPhiC set before and 
after polarization with the atom associated with it next to the values. After the 
polarization for the ligand in 1W0G six of the hydrogen atoms gain a negative charge 
about as strong as the positive charge they had before. Two of the carbons have 
larger negative charges than before, ‐0.1200 increased to ‐0.41183 and ‐0.1200 
increased ‐0.19768.  
1YV5 and 2GG7 have several large changes in their carbon charges. 1YV5 has a 
carbon changing from ‐0.13080 to 1.62935 gaining a much larger positive charge. 
2GG7 has a carbon changing from 0.71000 to 0.20783 losing a lot of its positive 
charge. Several atoms involved in hydrogen bonding also gain a larger negative 
charge from ‐0.67800 to ‐0.82029 in a nitrogen from 1YV5 and ‐0.92000 to ‐1.12764 
in a nitrogen from 2GG7. The largest changes across the ligands is the change in 
their polar atoms such as 1.55780 to 0.49767 in P for 1YV5. Across all three the rest 
of the ligand goes through small subtle charge changes. 
 
2.5 Discussion 
GLIDE is a good docking program and is great for docking ligand libraries very 
quickly. Many reviews highly rate the program such as Warren et al. (2006), Perola 
et al. (2004), Cross et al. (2009) and Abagyan and Totrov (2001). Making marked 
improvements to the docking algorithms can be difficult. Despite this, we were able 
to attain some good improvements using our induced charge polarization. However 
our basic Glide docks were not perfect. In some cases the Favia et al. (2011) were 
able to get better results than us for the top docking poses and sometimes we 
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attained better results than them. This could be due to the differences in set up 
between our methods compared to theirs, especially when it comes to the grid size 
and protonation sites on histidine. However all these results come from crystal 
structure so each ligand should ideally bind to the binding site. The negative results 
show that even this simple experiment of docking a ligand back into its own crystal 
structure is not trivial. Consequently, we looked for other techniques that could 
improve the results.  
The QM/MM results can show more defined energy interactions of the binding. 
Since QM energy is potentially better in the sense that the QM energy is well 
defined by our method and basis set. The MM energy is also well defined as the 
OPLS force field is well defined for proteins from the literature (Damm et al., 1997).  
The methods follow the trend where the docking process tends to improve if a 
QM/MM region with polarization is generated. However in some cases like 2CIX the 
RMSD change was 9.28 to 9.24, and so this result is equally wrong by both methods. 
However in the case of 2CIX we re‐did the initial dock several times attaining 
variable results each time. The last column of table 2.1 shows the best results we 
attained. Even then however it was still not a remarkable improvement. 2CIX 
possibly requires something else to help it bind to its site. We left out water from 
our method so that might be what is causing the issue. Some water is tightly bound 
in some of the binding sites from the crystal models. These waters that are found 
there might be help facilitate binding of the ligand (Smith, 2015). We don’t usually 
want to explicitly add these water molecules into docking as the ligand would 
displace the water; however there are methods for predicting water molecules in 
Page | 60  
 
binding sites and for predicting which one as ‘happy’, and so unlikely to be displaced 
and which ones are ‘unhappy’ so are likely to be displaced. (Goodford, 1985), 
(Mason et al., 2013), (Wang et al., 2011).  
There are some results with quite a substantial difference in RMSD from the initial 
dock such as 1M2X with a change of 2.5 Å or 2Q6M with a change of 1.4 Å. This is 
quite a significant difference; in both cases these represented improvements.  
There were several proteins such as 2CIX and 1M2X that were investigated further 
using MD methods to investigate why there was either a great difference in their 
RMSD or why it didn’t improve as much as expected.  
There were some ligands such as in 1MLW where after polarization it found a new 
binding site. All the new poses were bound near the same region as evidenced by 
the graphics of the poses and the RMSDs. During sampling 1MLW could have found 
a new energy well where it can bind. This could suggest that there is a different 
position that 1MLW can bind when polarization is present that it wouldn’t have 
found before.  
Further works that could be planned other than what is described in sections 3.8 and 
4.2 is to potentially performing tests with actively bound water in a few of the 
ligands that showed higher RMSDs. In some cases, as stated before, there is water 
tightly bound in an active site of a protein that facilitates the binding of the ligand or 
forces the ligand to take the correct binding site. All the tests in this section were 
performed with no water present. The benefit to this is that the ligand can dock to 
other binding sites so we can analyze if the binding site in the crystal is one of the 
better sites. However this also eschews the fact that water is in the binding site in 
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some cases and that this could explain the abnormal RMSDs in some of the proteins 
such as 1M3U.  
The avenue we followed to help deal with some of the problems we found was to 
initiate MD simulations on our polarized ligands. Some of the problems might have 
been coming from the absence of water as stated before. However, when docking, if 
the crystal waters are left in there is a hole left behind by the missing ligand. When 
the dock is then performed with a large grid, as here, it will funnel the results into 
the open space left by the waters as the waters are frozen in place for the 
calculation. In molecular dynamics however the water when explicit moves around 
and can either displace the ligand or be displaced. This can help more visibly show 
the binding of the ligands. Molecular dynamics can also show if our well docked 
poses hold up in a fully moving water environment. The water has enough energy to 
be able to push the ligand. Thus, if the ligand is bound as well as the results show it 
should stay in place. However, we may possibly see that some of the ligands might 
be pushed away, thus showing that the binding strength is not as strong as we first 
thought. MD might also show if ligands bound in incorrect poses can find their 
binding site if they given enough time. 
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Chapter 3  
Investigating GPUs in Molecular Dynamics Simulation 
3.1 Introduction 
Molecular Dynamics (MD) is a useful tool for understanding the physical bases of 
structures and their function. Molecular dynamics at its core is a computer 
simulation of a system to represent the physical movement of atoms over time 
within given dimensions and according to Newton’s laws. MD can be used to 
calculate the interactions between these particles in motion; the trajectories of 
these atoms are determined by numerically solving Newton’s equations of motion. 
There are multiple programs that use various algorithms to  solve the equations, 
such as ACEMD (Harvey et al., 2009), AMBER (Case et al., 2015), CHARMM (Karplus, 
1983),  GROMACS (Berendsen et al., 1995), NAMD (Phillips et al., 2005), and Tinker 
(Ponder, 2004). 
At the initial stage of the project we utilised GROMACS as it was open‐
source. GROMACS’ main advantage was the speed of calculation, and in recent years 
has had added modules that utilise GPUs. This was the most cost effective, source 
code was available and also it did not need a proprietary (i.e. commercially 
purchased) GUI to run. Therefore any issues could be solved by altering the code in 
house. Moreover, GROMACS has a community through which newly added code is 
constantly added to a database providing new functions and modules to the 
program. Due to this community, many guides and help are available to users.  
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3.1.1 Boltzmann sampling in MD 
MD in modern usage concerns large macromolecules, due to their size there 
is a considerable amount of degrees of freedom in any statistical simulation. There 
needs to be a compact description of the thermodynamic properties of a system. In 
the context of Boltzmann sampling of phase space a simulation might lodged on one 
side of a high energy gradient. Even if a simulation was run for several ms the 
simulation could remain on one side of an energy gradient and be unable to sample 
the other side, this is one of the shortcomings of MD. There have been methods to 
adapt for this issue such as blue‐moon sampling where part of the system is 
constrained. The part of the system is changed for each run, essentially 
decomposing the free energy gradients into separate components to test and later 
averaging out the sampling. 
 
3.2 Molecular Mechanics (MM) and the MM force field 
Classical mechanics is used to model molecular systems in molecular mechanics‐
based approaches. The main aim in molecular mechanics is to define the energy 
within a molecule. It is possible to use this information to adjust the energy by 
changing the bond lengths and angles to minimise a structure.  
Each atom in MM is defined as a single particle with an assigned net charge, radius 
and polarizability. As shown in Hehre (2003), bonded interactions are considered as 
a set of springs, as the interactions include the stretching and compressing of bonds 
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in motion. Conventionally in MM this is called the steric energy. This is based upon 
the equation 3.1, taken from Hehre (2003). 
Esteric energy = Estr + Ebend + Estr‐bend + Eoop + Etor + EVdW + Eqq    (3.1) 
This includes the stretching (Estr) and bending of bonds past their equilibrium (Ebend). 
It also includes the bonds out of plane movement (Eoop), torsion interactions (Etor), 
Van der Waals (EVdW) and electrostatic interactions (Eqq). Figure 3.1, shows the 
direction of each of the interactions. 
 
 
 
 
 
 
 
The bonding portions of the equation are based on Hooke’s Law for a spring. The 
non‐bonded interactions are the VdW (EVdW) and electrostatic interactions (Eqq). 
Non‐bonded interactions are between atoms that are more than two bonds apart as 
shown in Figure 3.1. The 1‐4 interactions usually take the same form as those shown 
in Figure 3.2, but may have different scaling factors in from of the terms; these 1‐4 
interactions contribute to the torsional energy. 
  =       ∑ ∑
    
   
  + 
   
   
            +          ∑ ∑
      
         
          (3.2) 
Torsion 
Bond stretching 
Non‐bonded interactions 
Angle bending 
VdW term Electrostatic term 
Figure 3.1. Anatomy of MM force field interactions 
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Equation 3.2 shows the expanded VdW term and the Electrostatic term taken from 
Eliav (2008). VdW attraction occurs when the atoms are close, if they are more than 
a few Angstroms apart this force rapidly diminishes. The VdW forces are expressed 
as a Lennard‐Jones potential. The term rij refers to the distance between the two 
nuclei. A and B are constant values based upon the atom identity. The A and B 
parameters can be calculated by QM and can also be obtained from atomic 
polarizabilities or by fitting to experimental data, e.g. crystallographic data. When 
expressed on a plot, the energy, E, can be varies with distance as shown in Figure 
3.2. The first two terms in equation 3.2 can also be expressed as shown in equation 
3.3, giving a relationship between the A and B parameters: 
E = 4 [(/r)12 – (/r)6]    (3.3) 
where  = r at E = 0 and  is the depth of the energy minima. 
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Figure 3.2. Plot of Lennerd‐Jones potential between two carbons 
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Summarized, figure 3.2 shows that when the atoms are close together they repel 
each other with a large force, as shown in the top left section. Once they are an 
optimum distance apart the energy is lower and in an ideal state shown by the 
trough in the middle of the figure. As the atoms move further away, the less 
attractive force there is between them.  
The electrostatic interactions are based on Coloumbic potential, shown in equation 
3.1. This is a function of the charge based on their distance, once again defined as rij 
and each atom’s partial charge defined as qi. εr is the relative dielectric constant, this 
is usually set to 1 in the gas phase or if all particles are present. The partial charges 
can be calculated by high level quantum mechanical calculations on small molecules 
or peptide fragments, as shown in Shattuck (2008) and Shirts et al. (2003). Some 
programs will assign charges using rules or templates based on previous literature, 
especially for macromolecules.  
The steric energy of each bond pair is the function of a force field. All the constants 
in the previous equations 3.1, 3.2 and 3.3 can be calculated by QM. However in 
practice it is necessary to derive them empirically. Usually this takes the form of all‐
atom models where the force field terms for all atoms are parameterized. This 
allows for the calculation of the energy function of more complex molecules such as 
proteins.  
Non‐bonded interactions are typically as shown in figure 3.1. These are longer range 
interactions than the bonding interactions and take up the majority of the 
computational time. The number of non‐bonded interactions increases the larger 
the molecule. To compensate for this increase in computational cost, many 
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programs use cut‐offs, as shown in Plimpton (1995). This is where when calculating 
the force field energy terms, a program will cease to calculate non‐bonding 
interactions beyond a given cut‐off point. For example the typical cut‐off length for 
VdW forces is about 10 Å.  
 
3.3 Equations of motion in Molecular Dynamics 
The classical MD simulations require numerical integration of Newton’s equations of 
motions for the particles in a system. According to Rapaport (1995), the forces are 
determined from derivatives of the  potential functions. The potential energy is a 
function of the atomic positions of all atoms in a system according to Stote et al. 
(1999); however these must be solved numerically as there is no analytical solution 
to the equations of motion.  
Molecular dynamics uses different algorithms to integrate the equations of motions 
into molecular dynamics. When considering an algorithm the following criteria 
should be adhered to; the algorithm should conserve energy and momentum, 
compute efficiently and should permit a long time step for integration. Computing 
efficiently is one of the most important parts of any algorithm as evaluation of these 
forces in motion is the most time consuming component of any MD calculation, as 
shown in Stote et al. (1999). 
Some common algorithms include the leap‐frog and Verlet methods which are low 
order methods. These are easier to implement and are more stable than predictor‐
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corrector methods and take far less memory requirements on computers to be used 
as shown in Rapaport (1995) and Berendsen and Van Gunsteren (1984).  
All integration algorithms assume the positions, velocities and accelerations by a 
Taylor series expansion according to Stote et al. (1999). This can be shown as in 
equation 3.4 also shown in Stote et al. (1999). 
   (3.4) 
Where r is the position of a particle, v is the velocity, a is the acceleration, b is the 
second derivative of v(t) with respect to t. Each of the low order methods is derived 
from the expansions shown in equation 3.4. 
 
3.3.1 Verlet 
The Verlet algorithm uses positions and accelerations at a point in time t and the 
new positions at time t-δt to calculate the new positions of the particles at time 
t+δt. This is derived from the equation expansion in 3.4.  
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    (3.5) 
When combining equations 3.5, the resulting equation is 3.6. 
    (3.6) 
Verlet according to Stote et al. (1999), Rapaport (1995) and Verlet (1980) retain the 
advantages of being low order but only offer moderate precision.  
3.3.2 Leap-frog  
Leap‐frog algorithm according to Stote et al. (1999) has the velocities first calculated 
at time t+1/2δt. The velocities are then used to calculate the positions at the time 
t+δt. In this way the algorithm leaps the velocities over the position, then the 
position leaps over the velocity hence giving the name leap‐frog. The velocities are 
explicitly calculated in this method however because of the leaping nature of the 
equation it does not calculate this at the same time as the positions.  This is shown 
in the equation 3.7. 
    (3.7) 
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3.3.3 ‘Velocity’ Verlet 
The ‘Velocity’ Verlet algorithm is algebraically equivalent to the leap‐frog method 
according to Rapaport (1995). However it yields positions, velocity and accelerations 
at a point in time. This method doesn’t compromise precision. The method uses the 
same equation shown in 3.5 but rearranges it so it is a function of velocity hence the 
name Velocity Verlet. This is shown in the equation 3.8.  
   (3.8) 
 
3.4 Periodic boundary conditions 
As seen in Rapaport (1995), de Leeuw et al. (1980) and (Makov and Payne, 1995), 
when calculating the behaviour of a system, finite systems behave very differently to 
functionally infinite systems, i.e. a massive system such as cell. Regardless of how big 
a simulated system is, it is considered to be a lot smaller than a macroscopic system. 
A simulated system is relatively small within the walls of the system, the computed 
edges of the box, within which the calculations are taking place. In such a small box 
the proportion of particles that are near the edge of the system is a lot greater than 
in an infinite system. This would mean that within the box of the system, the 
majority of the behaviour would be dominated by surface effects. Electrostatic 
effects are long‐range and so these also require periodic boundary conditions. 
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To overcome these issues of size and surface effects, MD simulations use periodic 
boundary conditions. This is where the system that is enclosed in the box is 
functionally replicated to infinity in all 3 Cartesian directions, filling in the space. If a 
particle would leave the edge of the boundary conditions instead of rebounding as if 
within a non‐periodic box it will re‐enter the box from the opposite edge; an 
example of this in effect is shown in figure 3.3. This diminishes the surface effects 
and makes it so the position of the box plays no role in the calculation of the 
trajectory. 
 
 
Figure 3.3. An example of water passing through the periodic boundary 
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3.5 Trajectories 
In summation, MD simulations take place using atomic motions governed by 
classical mechanics. The force fields define the molecular surfaces and the steric 
bond interactions. This culminates in a trajectory where the process can calculate 
the dynamics of a system over the course of a relatively long time. The trajectory is a 
summation of the dynamics for a multi‐bodied system, while taking into account full 
dimensionality of the molecules within.  
The trajectories in MD however useMolecular Mechanics in classical mechanics, as 
shown in equations 3.6, 3.7 and 3.8. However MM as a whole has some well 
documented problems, shown in Moskowitz et al. (1988), Hu et al. (2003) Allinger et 
al. (1989), and Rappé et al. (1992). The limitation of these trajectories comes where 
the quantum mechanical behaviours are largely ignored and there is a singular 
potential governing the motion. Many methods are attempting to incorporate 
different quantum mechanical effects to attain more accurate results, such as 
processes in condensed matter as seen in Webster et al. (1991), treatment of multi‐
electronic states by Amarouche et al. (1989) and heavy ion collisions shown in 
(Aichelin, 1991). Quantum mechanical effects such as electronic transitions apply to 
biological processes such as carrier recombination and photochemistry, as seen in 
Tully (1990) and Weller et al. (1986). 
Within a trajectory, the algorithms can be run in parallel as seen in (Hess et al., 
2008) and Hess (2008). This is to improve the speed of calculation. When a 
computer uses more than one core or node it runs multiple algorithms in parallel. 
Some calculations such as updating particle position can be parallelized without any 
Page | 78  
 
communication; however most calculations, such as those shown in equation 3.1 for 
the force fields, require parallel algorithms. In addition, there are parallel constraint 
algorithms such as P‐LINCs by Hess (2008) which is used by GROMACs to remove the 
fastest degrees of freedom in the equation. This speeds up the calculation by 2 to 4 
times, allowing an increase in the timestep.  
The timestep’s size is usually constrained by the vibrational motion of atoms in a 
solid or liquid (Plimpton (1995)). This limits the time scale traditionally to fs, so 
between each calculation there are a few fs; this is what defines the timestep, e.g. t 
in equation 3.8.  
MD programs can use rectangular periodic boundary conditions as seen in section 
3.4 with a sliding scale of different pressures and temperatures to impose on the 
system. Molecular interactions can be handled in a number of ways, namely; 
Coulomb and Lennard‐Jones or Buckingham potentials. Using this we can make NVT 
and NPT ensembles. As shown in McDonald (1972), Wood (1968) and Rushbrooke et 
al. (1968), NVT ensembles are isothermal and constant volume, so the periodic 
boundary will not change during a trajectory with this ensemble but as per Boyle’s 
law, pressure has to change so MD programs will change the pressure to 
compensate. NPT ensembles on the other hand are isobaric and isothermal so 
during a trajectory the periodic boundary will change in size to compensate for the 
constant pressure.  
 
 
Page | 79  
 
3.6 Simulating the Water Bath  
GROMACS has two major settings to simulate the water bath surrounding a 
macromolecule, either implicit or explicit water. 
 
3.6.1 Implicit Solvent Methods 
Sometimes known as continuum solvation, this is where a water bath is represented 
as a continuous medium as opposed to individual molecules of water as in explicit 
solvation methods. Other methods include coarse‐graining, where water is 
represented as large subcomponents of force fields.  
The potential of mean force of the implicit solvent is an approximation of the 
average behaviour and movement of a large body of liquid; in the case of our 
docking problems, this is water. In GROMACS, the implicit solvent methods use the 
Generalized Born model augmented with hydrophobic accessible surface area, 
abbreviated as GBSA. In the GBSA method the total solvation free energy, Gsolv, is 
given as a sum of a solvent‐solvent cavity, Gcav, a solute‐solvent Van der Waals term, 
GVdW, and a solute‐solvent electrostatics polarisation term Gpol, as in equation (3.9) 
shown in P.Koehl and M.Levitt (2002) and Karplus and McCammon (2002). 
      =       +      +                                   (3.9) 
When performing a simulation using implicit solvent method, the macromolecules 
should ideally be reparameterised appropriately for GBSA force fields; compatible 
parameters must also be applied to the ligand. However these GBSA parameters 
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found in the implicit parameters file are OPLS force fields that are close to the 
structure of the ligand though are not the same; as shown in Bjelkmar et al. (2010), 
they are substitutes based on work by Qiu et al. (1997). Many of the ideal OPLS force 
fields are not compatible with implicit methods; we took a large amount of time to 
sift through the available parameterization to find force fields compatible with the 
chosen end groups of the protein and the ligand. In terms of speed however, the 
minutiae of parameterizing each ligand and then running the simulation was faster 
than running an explicit solvent simulation. 
The major advantage of this method is that the simulation does not have to 
calculate the movement of each individual explicit water molecule; this results in 
considerable savings on computational time. 
 
3.6.2 Explicit Solvent Methods 
Explicit solvent relies on using discrete solvent molecules and describing their 
interactions fully. A water bath for a GROMACs simulation is usually composed of 
thousands of water molecules.  The MD simulation then treats each of these as a 
separate body and calculates their interactions individually. This increases the 
computational time considerably (see Chapter 4). For this work, the TIP4P water 
molecule by Abascal and Vega (2005) was usually used. 
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3.7 GROMACS 
GROMACS stand for GROningen MAchine for Chemical Simulation; it is a parallel 
message‐passing implementation for Molecular Dynamics (MD) for macromolecules 
in aqueous environments. The program is also able to assign special forces to groups 
of particles which  are of particular interest. As stated in previous chapters, we have 
an interest in polarisation. We are thus attempting to utilise GROMACS to add in 
polarisation to a MD environment. GROMACs doesn’t handle explicit polarisation as 
it uses classical force fields such as CHARMM or OPLS as shown in Van Der Spoel et 
al. (2005) and Yu and van Gunsteren (2005). In our method in section 2.3.4.3 we 
generated new atomic charges based on the polarization. We will be utilising these 
atomic charges with the OPLS force field for molecular dynamics.  
GROMACS can do these MD simulations through the use of parallelization. 
Parallelization is the use of multiple computers or cores working in tandem upon the 
same system to gain a higher throughput for the calculations. GROMACS is using 
sequential code and multithreading it between each of the cores to use all of them 
simultaneously. This can greatly increase the throughput of the process by utilising 
multiple cores to complete the simulation. GROMACS is specialised in the use of CPU 
architecture and in recent years the developers have created GPU modules; we will 
touch on this later.  
GROMACS was utilized to investigate whether polarized charges facilitated the 
correct binding of the ligand to the target binding site. Since the binding pocket and 
ligand were polarized, the positions with the lowest RMSD or top glide score should 
in theory be bound relatively tightly by the stronger electrostatic forces present 
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during a molecular simulation. As discussed in section 2.2.1 due to how Glidescore 
calculates poses it can give a better rank to poses with a high RMSD, the top Glide 
score and lowest RMSD are not always the same. Thus, the aim was to perform 
dynamic simulations for both of these results for each molecule to see if a correctly 
polarized ligand is more likely to remain in a true binding site rather than one 
erroneously selected by GLIDE. 
 
3.8 MD simulations of the protein-ligand complex  
For each protein in the polarization set (described in chapter 2.3), both the lowest 
RMSD and top glide score poses were exported from Maestro and converted into 
pdb format. Before exporting the structures, the ACE and NME caps on the proteins 
from chapter 2.3 should be removed and hydrogens added in their place. The 
ligands bound to each protein were exported in separate files. This is due to 
GROMACS’ inability to convert ligands into OPLS format topology automatically. 
Instead the ligands were converted to OPLS format topology by using the PRODRG 
server.  
PRODRG is an online service provided by SchuÈttelkopf and Van Aalten (2004). This 
service can take a description of a small molecule based on its pdb coordinates and 
generate topologies for use with MD or other programs. In our case, this is 
GROMACs. However it can be used for other programs such as Autodock (Goodsell 
et al., 1996), HEX (Ritchie, 2003) or REFMAC (Murshudov et al., 2011). 
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The proteins were then converted to OPLS format topology by using the pdb2gmx 
GROMACS utility program which outputs a structure file and a topology file for each 
protein. OPLS forcefields were chosen for the topology to stay consistent with the 
Maestro‐based portion of the method. TIP4P water (Abascal and Vega, 2005) was 
used in the box as this water type functions better with OPLS forcefields as shown in 
Bjelkmar et al. (2010) and van der Spoel and Lindahl (2003) since OPLS‐AA force 
fields were developed almost completely using TIP4P.  After this, the ligand 
structure file was appended to the protein structure file. Several settings in the 
topology file were manually changed to include the newly appended ligand. 
Using genbox, a virtual box containing the protein‐ligand complex and a TIP4P water 
box was generated. Genbox is a GROMACS utility program that randomly inserts 
water molecules into a set box size until the box is filled. This structured was then 
minimized. The GROMACS simulation was then performed on the minimized 
structure.  
The typical protocol for each complex had a time step of 2 fs, cut‐off of 1.5 Å for 
VdW forces, the temperature was set to 300 K, pressure was set to the default of 
1.01325 bar and each production run was 10 ns. The pH of each simulation was 7 
and all the crystal structures resolutions were 2.5 Å or better. A typical input file is 
shown in appendix 3.1.  
All the frames generated from the simulation were then imported into VMD where 
they were superimposed on top of each other. This was done as the protein could 
potentially move around the box due to translation of the whole system during the 
simulation. Consequently, to calculate the RMSD, the structure was required to be 
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relatively stationary. An RMSD analysis tool was then used to calculate the RMSD of 
the ligand. Root mean square deviation (RMSD) is used as a measurement to 
structural similarities between two structures, as shown in  Maiorov and Crippen 
(1994). RMSD is a measure of the distance between each atom of two superimposed 
proteins. For the methods shown here, the RMSD is calculated using two different 
positions of the protein. The RMSD shows the distance between the atoms of the 
protein for each frame of the simulation against the crystal structure or the first 
frame of the simulation. 
 
3.8.1 Problems arising with pdb to maestro format conversion 
At the initial stages of the methods shown in 2.3.4.2‐2.3.4.3 all the pdb files of 
proteins were converted into the maestro format (.mae) so that maestro would 
natively interpret the files for the completion of the method. Simple problems arose 
through the different use of nomenclature of amino acids between the standard 
format and maestro. This is especially true for protein caps as each programwe used 
had a different name for the same cap. However the formatting issues were 
remedied through use of text editors, where each file was examined and the 
corresponding amino acids were altered to the maestro format. Without these 
changes maestro would have excluded those particular amino acid groups from the 
protein. The lack of a correct structure could cause issues in the docking 
calculations. 
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As we altered the amino acid format for maestro, we caused issues in later methods. 
The files were exported from maestro but they would not be converted accurately 
back into .pdb format. The files converted from .mae to .pdb files no longer 
contained their formal charge column that was native to the maestro format. This 
was remedied by either duplicating each atom in the file, giving it a separate ANISOU 
row to store the charge data for GROMACS or have a separate charge file, denoted 
as .chg, that could map the formal charges for ACEMD. 
 
3.8.2 Nomenclature problems and the order of hydrogens or carbons. 
The files of the protein‐ligand complexes that were extracted from stage 2.3.4.2 of 
the methods had all the formal charges after polarisation so these were the files that 
we needed to bring forward to the rest of the methods. As previously stated, there 
was some nomenclature problem converting from .pdb to .mae. This also happened 
in reverse for a different reason. Maestro has different labels for the carbons in 
amino acids, usually the order in which the carbons appear or the letter code would 
be different. For example Maestro might label a string of carbons as CH1, CH2 and 
CH3 whereas the pdb standard for the same set of carbons is C2, C3 and C4. We 
once again used text editors to change the nomenclature so that GROMACS and 
AMBER would be able to read the files. Caution was exercised, as taking the previous 
example we could not change C4 into C1. Instead we had to inspect each amino acid 
and either shift the numbers along (e.g changing C2, C3, C4 to C1, C2, C3) or change 
the letter code depending on the issue. Another problem that arose was that when 
converting back to pdb the protonation state of histidine would be lost. However 
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this was a simple, albeit tedious, matter of checking each histidine missing a 
protonation state against the literature and labelling it correctly. Fortunately, as 
maestro used a conversion algorithm each instance of a nomenclature problem was 
fairly consistent, so it became easier to correct with each subsequent protein. 
 A similar issue arose due to how maestro labels hydrogens. It is difficult to 
identify what name it gave to which hydrogen and how they differ for each instance. 
The work would be fairly laborious to change each one in turn. However, both MD 
packages we used could generate missing hydrogens and label them appropriately 
for the program. This problem was thus remedied by deleting hydrogens that were 
mislabelled; each program would then replace the missing hydrogens. 
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3.9 A first investigation into the use of GPUs for protein-ligand 
simulations 
Recent versions of GROMACS have allowed the use of parallel processing using GPU 
cores instead of CPUs. This is more advantageous for speed as GPUs have far more 
cores than CPUs. Typical configuration of our system was a pair of SLI linked GeForce 
560Ti cards which have 960 cores as seen on Nvidia (2015) which is more than the 
intel 8core CPUs in our typical configuration. A GPU is usually contained on a 
graphics card. As opposed to a CPU it is possible to link  multiple GPUs set up in 
tandem on a workstation. We bought a pair of the previously mentioned GPUs and 
installed them. Then we set up GROMACs to work off these cards with MPI. We 
decided to test whether we would get similar results for each of the methods: 
implicit solvent on CPUs, explicit solvent on CPUs, implicit solvent on GPUs and 
explicit on GPUs. We measured how long they would take in comparison to each 
other. We took a small subset of the SeraPHic collections of molecules (Favia et al., 
2011) to compare the effective speeds of a MD simulation on a GPU compared to a 
CPU. Each simulation was using the same method as described in section 3.8. We 
compared the speeds of both implicit and explicit methods. The CPU was a 4 core 
Intel Pentium chip 2600k running at 4.0Ghz (8 cores with hyperthreading) and used 
8Gb of RAM. The GPUs were a pair of GeForce 560Ti, using the same 8Gb of RAM. 
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3.10 Results – GROMACS 
3.10.1 GPU comparisons to CPU speeds 
Early on when learning to use GROMACs we attempted to use GPUs as a proof of 
concept as stated earlier in section 3.9. GROMACs introduced several modules to 
accommodate specific graphics cards. We started by  assessing the speeds (ns/day) 
to see if we could obtain faster results with the simulations performed on GPUs. The 
timing results for 5 proteins tested are given in Figure 3.4. 
 
Figure 3.4. Plot of comparisons of speed between GPUs and CPUs tested with either GPUs or CPUs. 
 
Figure 3.4 shows the timing results a small subset of ligands for both Implicit and 
explicit solvent methods with the speed of calculation for each. Implicit solvent does 
not need to calculate sets of all‐atom water such as TIP3P over every step. This 
explains the 4‐fold increase in speed regardless of whether CPUs or GPUs are 
processing the data.  These speed tests were performed before the main 
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experiments in section 3.8. This was to decide if the speed was worth the 
considerable effort to setup calculations on the GPUs, as additional preparatory 
work was required to accommodate the graphics cards. Most programs will run on 
CPUs regardless of the code, whereas CUDA requires a specific setup on the 
different iterations of graphics card, shown in Nvidia (2008). As shown in Figure 3.4 
the speed of the GPUs is almost double of the CPUs, despite the computer that was 
used only had a single graphics card. From this modest result, it was concluded that 
the additional efforts required to set up the GPU simulations were worthwhile, 
particularly given the prospect of more powerful GPUs in the future. The remaining 
simulations described in this chapter were therefore run on GPUs to explore 
whether they were capable of generating results relevant to FBDD. 
 
3.10.2 MD simulation results with RMSD based on crystal pose 
Figure 3.5a‐r, show a nanosecond by nanosecond RMSD analysis of the results of the 
GROMACs simulations of 18 different ligands binding to their protein targets. The 
simulation is of the top ranked pose; the RMSD is relative to the corresponding X‐ray 
crystal structure. Table 3.1 shows the original RMSDs from the polarization docking 
methods. In addition, some of the figures (3.6a, 3.6b and 3.6c) also show the results 
of simulation of the docked pose with the lowest RMSD. The lowest RMSD is shown 
as a red line and the legend shows which pose number had the lowest RMSD, as 
given by Glide. 
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Unlike the docking results seen in 2.4 we can observe that it is difficult to maintain a 
RMSD of 2Å across the MD simulation. In some cases such as 1MLW 13 in figure 3.6a 
the binding can stay around that low value. However, the majority of RMSDs over 
the MD simulations rest at about 4‐6Å. This is caused by the fluctuations of 
movement that the ligand is experiencing as it rests in the binding pocket. Since 
these ligands are all fragments they are being pushed around by water molecules as 
they move in and out of the binding site. This is different to docking where the 
ligand is static and we get specific poses. The MD data can show the ligands finding 
these poses for several ps, typically between 4‐5 ps, but then move back out again. 
This is the nature of the results for MD so overall we would not expect as low RMSD 
numbers. 
The first thing that is apparent from the simulation is that the very low RMSDs 
obtained in docking (See Table 2.1) are not replicated in the simulations with the 
same frequency. Neuramidase (1F8E) is an exception to this as the RMSD stays at 
about 1 Å throughout the simulation, while agmatinase (1W0G) shows more typical 
results with the RMSD hovering around 2‐4 Å. However, not all ligands can be 
considered to remain bound throughout the simulation. 
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Table 3.1 The RMSDs of the top ranked pose for the docking of the ligand to its protein target; the 
system is denoted by its PDB code. Where a lower RMSD but lower ranked pose is available, the 
lower RMSD is also given along with the pose number in parentheses. 
 
PDB RMSD / Å 
Lowest RMSD (and 
pose number) 
1FSF 0.17 ‐ 
1F8E 0.17 ‐ 
1M2X 0.18 ‐ 
1M3Ua 6.34 6.333 (2) 
1MLW 3.36 1.83 (13) 
1OFZ 0.57 ‐ 
1PWMa 0.22 ‐ 
1TKU_A 0.54 ‐ 
1UWCa 0.38 ‐ 
1W1A 0.72 ‐ 
1WOG 2.02 1.25 (2) 
1YV5 0.6 ‐ 
1Y2Ka  3.8 2.4 (3) 
2AIE 1.60 0.90 (4) 
2BRT 0.79 ‐ 
2BL9 0.19 ‐ 
2CIXb 2.9 ‐ 
2FF2   
2GG7 0.95 ‐ 
2GVV 0.75 ‐ 
2RDR 1.29 ‐ 
2J5S 1.04 ‐ 
2Q6M 0.57 ‐ 
2ZVJ 0.89 ‐ 
3DSXa 2.85 2.47 (2) 
a 
These protein complexes were used in simulations only in chapter 4. 
b 
This protein was tested using the redock data from chapter 2. 
 
 
The figures generally contain 3 shapes of graphs, as typified by 1YV5, 1F5F and 2J5S 
(figures 3.5i, 3.5a and 3.5r). Figure 3.5i 1YV5 shows that in the first few frames, the 
RMSD jumps to 4‐6 Å then the RMSD fluctuates between these values. This first type 
of shape indicates a relatively stable ligand that stays close to the binding site and 
just moves about in the binding site possible rolling or shifting slightly as these are 
fragments, only part of the fragment is likely to bind. This means that there is some 
movement that arises because there are only one or two strong interactions instead 
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of more, which would be expected if the whole structure of a lead‐like compound 
was locked in place. 
In the second type of shape, as typified by Figure 3.5a (1F5F), the RMSD steadily 
increases; sometimes the increase is very sharp like the one seen in protein 
chloroperoxidase (2CIX) where the RMSD continues to climb to 10‐15 Å (figure 3.5l).  
For the third type of shape, the RMSD goes up then down. There is just one example 
of this as in beta‐diketone hydrolase (2J5S, figure 3.5r). This signifies the ligand 
leaving the binding site then returning to a very similar binding pose. 
The hypothesis to this part of the work was that the results with low RMSD, if 
correctly docked, would yield graphs similar to the first shape (or 3rd) and those with 
a high RMSD would yield the second shape. This wasn’t always the case:  1M2X and 
1TKU had the ligand leave the binding site steadily, despite their low RMSD values in 
the docking. 1M2X and 1TKU were also the top‐scoring glide poses. However the 
other low RMSD poses such as 1OFZ (figure 3.5g) and 2FF2 (figure 3.5m) yielded 
results like the first shape (figure 3.5i c.f. 1YV5). Interestingly though, if we look at 
1MLW the top glide score pose stayed within the binding site whereas the 13th was 
bound much tighter and fluctuated less despite the lower Glidescore (highest score 
is best). 1WOG and 2AIE show that both the top scoring and the lowest RMSD stay in 
the binding site. However, for 2AIE the lowest RMSD showed better results, as 
would be expected.  
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Figure 3.5a-r. RMSD (in Å) of the GROMACs data set against the crystal structure. In the text 
lines are referred to as 3.4: a: 1F5F, b: 1F8E, c: 1M2X, d: 1MLW, e: 1W1A, f: 1TKU, g: 1OFZ, 
h: 1WOG, i: 1YV5, j: 2AIE, k: 2BL9, l: 2CIX, m: 2FF2, n: 2GVV, o: 2Q6M, p: 2RDR, q: 2ZVJ, r: 
2J5S 
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Figure 3.6a-c. RMSD (in Å) of simulation for top pose and pose with the lowest RMSD (in 
red) for a: 1MLW, b: 2AIE, c: 1WOG 
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In some cases such as 1F5F and 2CIX the ligand was ejected after sometime. 1F5F 
has a fairly strong binding affinity with an IC50 = 3.8 nM as in table 2.1. This could 
explain why there is little fluctuation despite binding in the wrong position, in that if 
it can form strong bonds to its binding site it could form strong bonds elsewhere.  
Conversely 2CIX has a much lower binding affinity with a Kd of 33 mM as in table 2.1. 
This weaker binding could explain how water can dislodge the ligand from its 
binding pocket: Fig 3.5l shows that the RMSD starts low and gradually increases. If 
we look at some of the more successful simulations such as 2Q6M and 2BL9 where 
the RMSD stays within the 1‐2Å region the binding affinity is stronger. Their affinities 
values are Kd = 510 nM for 2Q6M and Ki = 0.16 nM for 2BL9 as in table 2.1. So, some 
of the MD data reinforces strong affinity with low fluctuations. Even if, as shown for 
1OFZ, it obtains the wrong position, the binding may still remain strong. 
 
3.10.3 MD simulation results with RMSD based on starting frame  
Another way we can look at the results is instead of comparing the RMSD to the 
crystal structure we can instead take the first frame of movement for the ligand and 
calculate the RMSD from that position. This first frame is where the ligands were 
docked in section 2.3.4.2. In figure 3.7a‐r we can see a nanosecond by nanosecond 
analysis of the same data in figure 3.5a‐r except based on the first frame of the MD 
simulation. For correctly docked ligands, the analysis in figure 3.5a‐r and figure 3.7a‐
r will be similar, but for an incorrectly docked ligand these could be quite different. 
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This can help paint a clearer picture as to whether a ligand was ejected or not. For 
example for beta‐diketone hydrolase  (2J5S, Figure 3.7r) we see a near constant 
value of 8 Å, this means it quickly left its starting position – even before the RMSD 
for a pose close to the starting point could be determined. Even when it came back 
following the type of behaviour as shown in figure 3.5r it has moved far away from 
where it was initially docked. Most of the ligands follow a similar shape, staying 
within 1‐2 Å of fluctuations, showing that even if they initially moved from where 
they initially docked, they nevertheless tend to settle in a neighbouring pocket. In 
some cases such as 2CIX it does not stay settled and moves away, 1TKU exhibits 
similar behaviour. 2ZVJ exhibit similar RMSD however rotates a lot changing 
positions within the pocket. 
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Figure 3.7a-r. RMSD (in Å) of the GROMACs data set against the initial frame. In the text lines are 
referred to as 3.4: a: 1F5F, b: 1F8E, c: 1M2X, d: 1MLW, e: 1W1A, f: 1TKU, g: 1OFZ, h: 1WOG, i: 1YV5, j: 
2AIE, k: 2BL9, l: 2CIX, m: 2FF2, n: 2GVV, o: 2Q6M, p: 2RDR, q: 2ZVJ, r: 2J5S 
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3.10.4 Examining further 
There are several of the protein‐ligand complexes that exhibited unexpected 
behaviour. In figure 3.9a‐f we examine the RMSD of these ligands based on their 
average position. For 2J5S the average is calculated without the first 2 ns as its 
movement began with a large shift away from its initial position so that its RMSD 
rose to ~ 8 Å; this movement occurred during the 2 ns of equilibration.  
2J5S fluctuates surprisingly little compared to its average position; this means it kept 
within a close region from its binding site despite the erratic movement shown in 
figure 3.5r, which shows the RMSD relative to the X‐ray position. Figures 3.8a‐b 
shows the movement of 2J5S. 3.8a is its initial position and figure 3.8b is its final 
position. The ligand leaves the initial section of the binding site which is the pose 
closer to the X‐ray structure and continues to rotate in a gap near the binding site; 
this constant movement and likely lower binding affinity is preventing it from 
moving back into position. It latches onto the other side of the binding site shown in 
figure 3.8b 
   
 
Figures: 3.8a-b. A graphical representation of binding site of 2J5S; a on the left is the initial pose, b is 
the final pose. The ligand is in red. 
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Figure 3.9a-f: RMSD (in Å) of MD simulation based on the average RMSD, a: 25JS, b: 1OFZ, c: 1TKU, d: 
2AIE, e: 2CIX, f: 2ZVJ
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For 2AIE, as with 2J5S, there is not a significant fluctuation compared to its average 
pose. It moves into a slightly different point in the pocket as shown in 3.10b. The 
hydrophobic properties of this pocket appear to be similar to where the crystal 
structure is bound, so this could be a different configuration. This pose is slowly 
pushed a little bit away from the pocket and is shown in figure 3.10b to be relatively 
stable but not as tightly bound as in 3.10a. 
 
  
Figure 3.10a-b. A graphical representation of binding site of 2AIE; a on the left is the initial pose, b is 
the final pose. The ligand is in red. 
 
 
For Chloroperoxidase (2CIX), the ligand is ejected completely and the average data 
shows this. This behaviour is unfortunately not that interesting 10 ns into the run. 
The average position is far away from the correct position compared to the crystal 
structure and hasn’t found a suitable alternative binding site either. 
Catecholo‐methyltransferase (2ZVJ), like 2CIX, shows some erratic movement, as 
shown in figure 3.11 the ligand has not been completely ejected. The IC50 of the 
ligand is 1.8 µM according to Tsuji et al. (2009). Figure 3.11 shows that the ligand is 
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not tightly binding to anywhere in its pocket but is being thrown around inside. The 
original pose is found in blue whereas the majority of the simulation it is at the 
position in red. The fragment is big enough that it stays interacting with the pocket 
as it moves away and still manages to stay on the other end of the binding site. The 
original pose is closer to the conformation in the X‐ray structure. 
 
Figure 3.11. A graphical representation of the binding site of 2ZVJ. The original pose is in blue and 
the average position of the ligand over the course of the simulation is in red. 
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Figure 3.12a-b. A graphical representation of the binding site of 1TKU; a on the left is the initial 
pose, b is the final pose. The ligand is in red. 
 
1TKU, according to figure 3.12, shows similar behaviour to 2J5S in that the ligand 
fluctuates in the binding site. However in the case of 1TKU it leaves the initial 
binding position which is the pose that is closer to the X ray structure immediately 
then finds a new position at the other side of the pocket where it spends most of the 
simulation trying to find a resting position within that pocket.  
 
3.11 Discussion 
The use of even modest GPUs on simple workstations has indicated that GPU based 
simulations offer the potential of faster simulations than traditional CPUs, and hence 
raises the prospect of using such simulations in FBDD. Until recently, the use of GPUs 
would have involved considerable obstacles, not least because of the need to port 
the code. However, the implementation of suitable code into programs such as 
GROMACS, AMBER and ACEMD has transformed this situation, enabling us to 
explore various protein‐fragment complexes using explicit atomistic molecular 
dynamics simulations.  
The hypothesis was that for an incorrectly docked ligand, e.g. 1MLW and 2CIX in 
Table 3.1 where the RMSD of the top docked GLIDE pose was 3.36 Å and 2.9 Å, the 
ligand would not be stable, and would leave the binding site, which would be shown 
by an increasing RMSD to the docked pose. This is not fully the case, as 1MLW 
maintains an RMSD of ~ 1 Å, suggesting it is correctly docked. 2CIX on the other 
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hand presents an oscillating RMSD, which does suggest that the incorrect docking 
has yielded an unstable pose. 
A number of correctly docked ligands do show the expected behaviour, and 
maintain a relatively low RMSD (< 4 Å) to both the initial pose and to the X‐ray pose, 
which may not necessarily be known in a de novo drug design program. Examples of 
this behaviour include 1F5F, 1F8E, 1M2X, 1W1A, 1WOG, 1OFZ, 2AIE, 2BLS, 2FF2, 
2GVV and possibly 1YV5. However, whereas in Table 2.1 the RMSDs are generally 
below 2 Å, the RMSDs obtained from the simulations are higher, partly because 
these are dynamic systems and so it is inevitable that the breaking and reforming of 
hydrogen bonds will yield a higher RMSD. This is particularly true for compounds 
with a low experimental binding affinity such as 1TKU where the RMSD to the X‐ray 
pose was ~ 15 Å, despite a correctly docked pose, but compounds with a nanomolar 
binding affinity such as 2Q6M and 2BL9 showed low fluctuations within the correct 
binding site. Thus, it is possible that the hypothesis is more valid for tightly binding 
fragments. 
1MLW is the compound that most strongly challenges the hypothesis as it is docked 
incorrectly, but nevertheless has a low RMSD of 1 Å to the initial MD structure. 
Analysis of the graphics has shown that this has docked to an alternative nearby 
binding site.  The implications of this are that molecular dynamics could be used to 
find alternative binding sites, or alternative binding modes within the main binding 
site. Such second sites could be useful in a linking strategy of FBDD. The ability to 
identify alternative binding sites is important as there is currently much effort within 
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the pharmaceutical industry to utilize alternative binding sites so as to modify rather 
than to totally block the natural enzyme or receptor activity. 
Taking the example of 1OFZ we can perhaps find something interesting about the 
ligand using MD. On some initial trials which failed to run to completion (results not 
shown) it would move to another nearby binding site. 1OFZ has many  alternative 
sites as seen in Wimmerova et al. (2003). As reported by Hardy and Wells (2004), 
many drugs are designed to target these alternative sites. By targeting these sites it 
is possible to make a drug‐like target that isn’t directly competing with the active 
site or the inhibitors. In some circumstances, this could lead to a much more 
successful drug with fewer side effects.  
 
Figure 3.13. A graphical of the bound ligand for 1OFZ shown in blue and an alternative site 
shown in red. 
 
1OFZ as shown in Fig 3.13  The bound position it found during one of the initial runs 
is shown in blue and the position it was in for most of the simulation is shown in red. 
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As stated before (Section 3.10), it managed to bind quite tightly to this binding site 
as much as its normal one, showing that despite where it was initially placed by the 
docking it is able to find a new site and bind there. 
The results support the hypothesis to some extent, but as will be shown in the next 
chapter, the 2CIX results are somewhat limited by the short 10 ns simulations. This 
limited time can show different results when compared to the longer simulations 
performed with ACEMD later.  
One downside to using the charges as we have in this method is that as the ligand 
moves to a different environment the polarization may not be valid, and that 
perhaps improvements could have been made by re‐evaluating this every time there 
was a significant change in RMSD however the methods we have used in this 
chapter and chapter 4 do not account for a change in charge during a simulation. 
All of the preceding results were thus generated using the GPU methods encoded in 
GROMACs. After obtaining the data for these relatively short explicit simulations we 
were able to expand the work by using more new powerful equipment. This 
prompted our move to ACEMD and using more than one graphics card in tandem to 
process not only bigger systems but also to run the simulations over a longer period 
of time; this will be discussed in the next chapter. 
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Chapter 4 
Protein-fragment complex simulations using ACEMD 
4.1 An introduction to ACEMD 
ACEMD is a high performance MD code designed specifically for NVIDIA GPUs 
(Harvey et al., 2009). It has similarities to all the main MD codes such as GROMACs 
as it uses parallelisation. Due to the high performance of GPUs, ACEMD can reach 
over 40 ns/day in calculations with over 23000 atoms in a single system, as seen in 
Harvey et al. (2009); with more modern GPUs the performance is even higher. GPUs 
have many processing units each with their own cache and control units dedicated 
to their use as shown in (Gupta and Babu, 2011). By the use of each of these many 
processing units that work in parallel, a modern GPU can work with thousands of 
cores as stated in the specifications found in Nvidia (2015). This can be pictured as in 
figure 4.01, taken from Gupta and Babu (2011). ACEMD uses CHARMM, AMBER or 
OPLS force fields to perform its calculations as seen in Harvey et al. (2009). Due to 
this speed advantage there is more incentive to use an all‐atom system of explicit 
water molecules to generate more accurate data rather than using the potentially 
less accurate implicit solvent methods.  
 
 Figure 4.1. General architecture of
 
ACEMD’s advantage in speed comes with a price, namely that the code used must 
usually be in CUDA due to the use of NVIDIA GPUs
Moreover, CUDA is undergoing constant changes with new graphics ca
updated versions of the NVIDIA drivers are also required
further development time for the methods when upgrades are needed compared to 
higher order code written for a CPU which usually requires no major alterations 
from version to version, as seen for C++ in
recent years the Khronos group has published papers that demonstrate the use of 
OpenCL instead of CUDA for MD codes 
advantage this could present is that OpenCL is open source and not propriety of 
NVIDIA. OpenCL can be used across any form of GPU, and the language
similarities to traditional CPU programming as it doesn’t require many alterations to 
use as versions of the CUDA language are upgraded 
For consistency with the GROMACs work, we used 
MD simulations on the proteins described in the SeraPhic paper
Control 
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 a GPU 
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(2011). However we took the QM/MM polarized ligand charges and integrated them 
into the ligand. This is similar to the tests carried out using GROMACs. However they 
were performed at a much more rapid rate due to the aforementioned power of 
GPUs, as installed in a set of newly acquired workstations specifically designed to 
run ACEMD. These workstations featured a quad core i7 processor and 1 or 4 GT780 
Nvidia commodity GPUs that were heavily tested to ensure that they were of an 
appropriate quality for running MD simulations. 
 
4.2 Force fields 
As stated earlier, ACEMD is optimised to use two different force fields; CHARMM 
and AMBER. As described in section 3.2 these are MM force fields and they utilise 
similar equations to implement the energy and derivative calculations. Below 
(Equations 4.1, 4.2) is a comparison of the equations of these classical force fields as 
shown in Case et al. (2015). Due to their similarities, ACEMD can use them 
interchangeably with some re‐parameterization if the user chooses to convert from 
one force field to the other. 
   
Both force field equations share the same sum of energy terms over the bonds, 
angles and dihedrals. The non
(2015), but the major difference between the two force fields is that CHARMM uses 
3 additional bonded terms. The t
that extends to all 1‐3 interactions and the four body qua
MacKerell et al. (2000). Lastly, there is a cross term (CMAP), which is a function of 
two sequential backbone dihedrals 
improve the accuracy of the force field for treat
 
4.2.1 CHARMM 
The Chemistry at HARvard Macromolecular Mechanics (CHARMM) force fields are 
specific force fields developed for use with biological Macromolecules, unlike force 
fields such as MMF94 (Halgren, 1996)
program is currently able to support both serial 
‐bonded forms have different scaling Case et al. 
wo body Urey‐Bradley term (MacKerell et al., 2004)
dratic improper term from 
(Crowley et al., 2009) which was introduced to 
ing alpha helices.   
 that are more general purpose. The CHARMM 
and parallel architectures for MD
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Brooks et al. (2009) and functions well in hybrid models similar to the QM/MM 
methods described previously in section 2.3   
In the CHARMM force field, an atom is considered to be a charged point with no 
directional properties and without internal degrees of freedom Karplus (1983). In 
the earlier AMBER and CHARMM force fields, non‐polar hydrogens were simplified 
and combined with neighbouring heavy atoms to which they are bonded with in an 
extended atom model. They can also be set apart in an all atom model as shown in 
Zimrnermann (2003). The main advantage of the extended atom model is that i the 
force field describes fewer atoms and therefore has fewer terms; it is  thus easier to 
calculate Since there are large numbers of non‐polar hydrogen atoms in biological 
macromolecules, this results in fewer internal degrees of freedom that need to be 
taken into consideration. However, this is a crude approximation (Karplus, 1983). 
As shown in equation 4.3, the CHARMM energy function is based on separable 
internal coordinate and pairwise interaction terms. Expressed as: 
  =    +    +    +    +      +     +     +     +       (4.3) 
where the individual energy terms in equation 4.3 are Bond potentials (  ), Bond 
angle potentials (  ), Dihedral angle potential (  ), Improper torsions (  ), Van der 
Waal interactions (    ), electrostatic interactions (   ), Hydrogen bonding (   ), 
constraints for atom harmonics (   ) and dihedrals (   ). When expanded it forms 
the equation 4.3 shown earlier in equation 4.2. These terms are described further in 
reference Karplus (1983). 
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There are two ways to generate CHARMM parameters for a given system.  The first 
is to use an in‐house version of the CHARMM program, it is a proprietary software 
so if it is used this requires a purchase of a licence (Brooks et al., 2009) and the 
second is to utilise the CHARMM‐GUI (Jo et al., 2008). The CHARMM‐GUI is useful 
for generating force fields based on PDB files from either saved files or from the 
RSCB PDB database (H.M. Berman et al., 2000). However, the database does not 
contain the force field parameters for ligands and can require more preparation 
than is necessary. In contrast, AMBER is more appropriate for simulations involving 
protein‐ligand complexes due to facilities for generating ligand parameters, as will 
be discussed in section 4.2.2. 
 
4.2.2 AMBER 
The Assisted Model Building with Energy Refinement (AMBER) software was 
developed originally for biological macromolecules (as was CHARMM). MD 
simulations involving ligands use the GAFF or General Amber Force Field for their 
calculations as seen in Wang et al. (2004). The philosophy is to simplify the 
parameterisation process by having a general force field for common molecular 
fragments such as amino acid groups. It uses a small number of atom types, namely 
those found in bio‐macromolecules and ions, though GAFF incorporates both 
empirical and heuristic models to estimate force constants and partial atomic 
charges as seen in Case et al. (2005). 
One of GAFFs advantages is the ability to parameterise organic molecules that do 
not follow normal protein structure, such as ligands. GAFF has sets of basic atoms 
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types with different hybridsations that can be used to assign force fields to atoms 
(Wang et al., 2004). Amber can use a program called antechamber (Wang et al., 
2006) that can automatically assign the GAFF parameters to an unknown molecule 
such as a ligand. It also requires only the atomic numbers and bond connectivity of 
the basic molecule in order to use its algorithms.  
Due to this advantage, we used the AMBER force field since all of the validation 
proteins had by definition a ligand in their binding site. We also used the ff14SB 
protein force field, which is the most recent version of the AMBER force field for 
proteins (Maier et al., 2015). CHARMM was also considered but due to the ease of 
working with unknown molecules AMBER was a better fit to our purposes. 
 
4.3 Methods for simulating protein-ligand complexes 
While GROMACs and ACEMD share similar protocols, there are distinct differences 
between the two programs. The major operation change was to convert from the 
OPLS force field, used by maestro and GROMACs , to the AMBER force field.  
 
4.3.1 Protein-ligand complex Preparation 
AMBER version 14 has the capability to automatically process a protein to generate 
the AMBER force field through LEAP. However, as described earlier the ligand needs 
to be assigned its force fields separately. Consequently, the initial step was to 
separate the protein and the ligand into separate files. 
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The ligand was prepared using antechamber. However, instead of letting 
antechamber assign new charges, bespoke charges were assigned using a specific 
charge file. This specific charge file was taken from previous work on the ligand so 
that antechamber would obtain the polarised charges and assign them to the ligand. 
Antechamber would then assign GAFF force field parameters based on atom type 
before creating a prepi file, an input file containing the ligand topology, input co‐
ordinates and charges that could be read by LEAP. It also creates an frcmod file 
which lists the missing force field parameters taken from the GAFF force field. After 
the ligand was parameterized it was recombined with the parameterized protein to 
be read through LEAP. During this stage minor edits were made to some of the 
nomenclature in the protein files as the names used for capped amino acids is 
different between the two force fields.  
We prepared the complex in an explicit water bath. The basic script that converts 
the protein to use the AMBER force field is given in Appendix 4.1.  
Also at this stage, a constraint file was generated. This is for the next stage of 
minimisation where the waters and non‐backbone molecules are minimised. The 
constraint file is a simple pdb file where the beta column is filled with a 1 for each 
carbon of the back bone. This tells ACEMD that these are the constrained atoms; the 
size of the number is proportional to the harmonic potential that constrains the 
atoms – a value of 1 was found to be suitable.  
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4.3.2 Minimisation and MD 
The refinement of the protein prior to an unconstrained production simulation was 
performed in 4 stages. Firstly, a simple energy minimisation for 5000 steps was 
performed before equilibrating the molecule with NVT for 1 ns with constraints, and 
then changing the ensemble to NPT with constraints for 10 ns followed by keeping 
the ensemble as NPT without constraints for 10 ns. The time step was set to 4 fs, this 
large step was made possible by increasing the mass of the hydrogen atoms to 4 da 
as shown in  Pomès and McCammon (1990). The temperature was set to 300 K. 
Pressure was set to the default of 1.01325 bar. The production run for each protein 
was 200 ns. A typical script for carrying out these operations is given in Appendix 
4.2. 
 
4.3.3 Constraint Scaling Methods 
According to the work of Ryckaert et al. (1977), polyatomic molecules in MD have 
fast internal vibrations that are usually decoupled from rotational and translational 
motion. These vibrations are bond vibrations as seen in Hess et al. (1997). The time 
step becomes limited due to these bond vibrations. By adding constraints, the time 
scale can be increased by a factor of four according to Hess et al. (1997). These can 
be frozen by placing rigid bonds on the skeleton of the molecule; this is a form of 
constraint. In classical models this is treated by Lagrange‐Hamilton formalism; 
however, in modern systems with large macromolecules the number of degrees of 
freedom is very large so different constraints need to be used.  
Page | 119  
 
It is possible to use holonomic constraints as shown in Ryckaert et al. (1977). The 
most wildly used constraint algorithms are SHAKE and LINCS for large molecules, as 
seen in Kräutler et al. (2001) and Hess et al. (1997). These propose to solve the non‐
linear problem on resetting coupled constraints of bonds after an unconstrained 
update.  SHAKE is an iterative method which first sequentially sets all the bonds to 
the correct length. To attain the desired accuracy SHAKE will repeat this iteration 
since bonds are coupled. However due to the iterative nature of SHAKE it is hard to 
parallelize the process. LINCS on the other hand resets the constraints on each step 
of the calculation instead of using the derivatives of each of the iterations. LINCS 
uses a leap‐frog algorithm to calculate the constraints. However this has a drawback 
in that it does not set the real bond lengths but instead projects it using the leap‐
frog calculation. This causes the bond lengths to increase slightly but there are 
corrective algorithms to help alleviate this, as shown in Hess et al. (1997). LINCS is 
also designed to be used by modern computers and uses parallelization in its 
calculations. 
Constraining the molecule as stated before, will semi‐freeze the structure so that 
during equilibration it can find the energy minima. Water is also free to move while 
the macromolecule is equilibrating; in this process the water can move to reduce 
steric strain on the macromolecule, simply by reducing the repulsive forces. 
However in production runs there should be no constraints as in nature the 
molecules are not locked to a set position in Cartesian space.   
In addition, in the NPT and NVT ensembles, sometimes the protein had some 
trapped water molecules nestled within its structure. Removing the constraints all in 
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one go would result in a spike of energy as these waters attempted to escape, thus 
crashing the run. Thus we utilised a scaling method where the constraints were 
slowly eased off at a slow rate. A typical TCL script to implement this method is 
shown in appendix 4.3. This script also gives the default simulation parameters such 
as non‐bonded cut‐off etc. 
 
4.3.4 Correct usage of water bath sizes in ACEMD simulations 
As shown in sections 4.3.1 and 4.3.2 water baths needed to be generated for each of 
the MD simulations. In the case of ACEMD, if this was prepared incorrectly the 
periodic boundary would not be kept well. When preparing a water bath, ACEMD 
would randomly generate water in a pre‐determined box for each protein. The exact 
size of this box was not carried over to the simulation.  
ACEMD could guess where the edge of a water bath. However, if it was off by a 
fraction of an Å then water molecules would form large pockets of empty space at 
the corners of the water bath. The water would conglomerate nearer the centre and 
begin to stretch out. Sometimes, this behaviour could cause the protein in the 
middle of the water bath to reach the pocket of empty space; this caused the 
protein chain to move differently to how we would expect it to move. This problem 
was easy to encounter if measurements of the box were slightly off. When preparing 
each water bath extra precaution was taken so that the size of simulation was the 
exact size of the water bath or slightly smaller. 
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In membrane simulations in chapter 5, if this problem was encountered the entire 
membrane would unravel. The membrane would deform and attempt to form lipid 
micelles. This would cause the protein to lose some structural stability as the protein 
needed the lipid bilayer to maintain its shape. 
 
4.3.5 Swan: OpenCL errors 
A common error that can arise from ACEMD simulation is a swan error. This is 
referring to the Swan conversion program (Harvey and De Fabritiis, 2011) which 
ports CUDA programs into OpenCL. ACEMD was written in the CUDA language 
however Swan can be used to change it into OpenCL so the program can be read on 
most any card architecture and not just NVIDIA.  
The errors were caused for a variety of reasons. The most common cause was the 
equilibration was performed incorrectly, either by placing a box too small which 
would increase the energy of the system to an incorrectly high threshold or the 
constraints weren’t eased off slowly enough. If the constraints weren’t eased off 
slowly enough this would cause a water to be trapped and build up a lot of energy, 
usually to an incalculable number that Swan wouldn’t recognize and subsequently 
would not convert that part of the simulation into OpenCL which would cause the 
program to crash. 
Swan errors could also occur if ACEMD did not recognize a portion of the input 
file(s). Thus the front end of the program that would attempt to recognize this 
anomaly would put nonsense into the conversion algorithm so it would be nonsense 
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when it was converted to OpenCL to be read by the card, this would also result in a 
crash. This issue could be caused by numerous issues such as formatting one of the 
input files incorrectly or having a bad initial structure of a ligand or protein. These 
errors are remedied by carefully inspecting each file before taking it to the next 
stage of the process avoiding the potential crashes to the program.  
 
 
 
 
 
 
 
 
Page | 123  
 
4.4 Results – ACEMD simulation of SeraPhic validation set
 
Figure 4.2.  RMSD (in Å) for 1F5F, 1F8E and 1M2X ‐ against the initial docked pose and against the 
crystal structure. The total length of the simulation is 200 ns. 
 
With the longer simulation times in ACEMD when compared to our GROMACs MD 
simulations (Chapter 3) we can see more concrete patterns for ligand movement. 
Fig. 4.2 shows a side by side comparison of each ligand’s RMSD from their initial 
docked position (frame zero) on the left and the RMSD against the ligand as it is 
bound in the crystal structure on the right. The ligands do present varying results in 
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terms of the variation of RMSD with time but the majority have found a similar 
position to the crystal structure within the binding pocket and remain with the 
pocket. This is shown when the RMSD is low for both the frame zero and for the 
comparison against the crystal structure. A good example of this is 1F5F. However as 
we compare all of them side by side we can see some interesting behaviours come 
to light. 
Figure 4.3. RMSD (in Å) for 1M3U, 1MLW and 1OFZ against the initial docked pose and against the 
crystal structure. The total length of the simulation is 200 ns. 
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In figure 4.2, 1M2X has a very high RMSD, both against the crystal and first frame of 
the simulation. The ligand of 1M2X quickly leaves the binding pocket and moves 
around the outside of the protein. In figure 4.3 we can see that 1M3U when 
compared to its docked pose slowly leaves that position and moves to a different 
part of the binding pocket. As shown in figure 4.4 it moves from adjacent to PHE 216 
of the pocket over towards LYS 109. When we compare this movement to the 
position in the crystal structure it is correcting itself and repositioning itself closer to 
the crystal structure over time. The red ligand in figure 4.4 is the crystal structure 
position for reference.  
 
Figure 4.4. A graphical representation of the binding site of 1M3U. The red ligand is the crystal pose, 
the blue ligand is the average simulation pose. 
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Again, in Figure 4.3 we can see that both 1MLW and 1OFZ have found good ‘docking’ 
positions, defined similarly in section 3.10 as RMSD less than 4 Å, against the first 
step of trajectory as they do not fluctuate much. As by comparison to their initial 
dock (which is usually similar to frame zero of the simulation, if equilibration has a 
small effect) they do not leave the pocket they docked to; they have a low RMSD of 
around 0.8 and 1.5 Å respectively during the majority of the run.  
1MLW however docked incorrectly according to the initial docking results of the 
GLIDE docking. Further, the idea that the ligand in 1MLW is incorrectly docked is 
corroborated by the comparison to the crystal structure where their RMSDs are 
particularly high to start with but it gradually improves. The initial pose used for the 
simulation was however the best pose according to their GLIDE score despite not 
being the best RMSD pose. There is no binding information for 1MLW. This means 
that the glide docking has found a better pose for it and the polarisation has not 
changed that. This could mean that the binding pocket in the crystal structure is not 
a particularly good target or that when the ligand is binding to the structure it binds 
to other alternative sites as seen similarly in section 3.10. 1OFZ according to the 
SERAphic paper (Favia et al., 2011) also has a good experimental binding affinity of 
24.1 µM , which gives it a consistently good RMSD as seen in figure 4.3. 
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Figure 4.5. RMSD (in Å) for 1PWM, 1TKU and 1UWC against the initial docked pose and against the 
crystal structure. The total length of the simulation is 200 ns. 
 
 
In figure 4.5 we again see some interesting behaviour due to the simulation 
with 1PWM. According to the RMSD results against frame zero, the ligand begins to 
leave its docked pose and continues to go further away from the docked position. 
Although when we compare it to the RMSD results against the crystal structure, 
shown in figure 4.5, we see that 1PWM is initially docked nearby, partly in the 
correct position, it then leaves the binding pocket and attempts to correct itself by 
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returning close to the crystal structures position. So, despite the good GLIDE score, 
the ligand leaves the binding site but then the simulation attempts to return it to the 
correct position.  
The ligand in 1TKU starts off bound in the right position according to the 
crystal structure and is ejected from the binding pocket. This is caused by oscillation 
of the ligand within the binding site. The ligand appears to be bound weakly and 
builds up enough energy to leave the binding site. There is no binding data on the 
ligand. To some extent the ligand attempts returns to the binding site, but is finally 
fully ejected. 1UWC shows an interesting motion of the ligand in both graphs. When 
looking at the graphics of the simulation, we see that there is actually a breathing 
movement to the protein. The ligand does leave the binding pocket for small bursts 
of time but due to the motion of the protein and how it binds to the sides of protein, 
it is pushed back into the pocket by intermolecular forces. This protein also had a 
problem in simulation that we were not able to correct. As 1UWC breathed it 
pushed the ligand to the edge of the periodic boundary however during this 
simulation ACEMD was set to wrap the boundary box before trajectory completion 
in error. This means the ligand appears to be on the opposite side of the system 
despite periodic boundary conditions being in effect. Thus it has given erroneous 
spikes where the RMSD appears to be 50 Å; a similar effect is also seen for 1M2X (Fig 
4.2) and 1TKU (Fig 4.5). In this case the lower RMSDs are more indicative of the true 
value.  
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Figure 4.6. RMSD (in Å) for 1W1A, 1WOG and 1Y2K against the initial docked pose and RMSD based 
on the crystal structure. The total length of the simulation is 200 ns. 
 
Figure 4.6 shows that 1W1A has found a slightly different pocket to that in the 
crystal structure. Starting at 4.0 Å for 1W1A, the ligand begins to leave the docked 
position. This is the position it found with the highest glidescore but in this case it is 
not well suited to binding this ligand in place. The oscillations observed are similar to 
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those observed for 1TKU and 1UWC, as such the ligand returns for small periods of 
time. There isn’t any binding data for 1W1A. 
1WOG starts as a quite well‐bound structure and then fluctuates within its binding 
site, the RMSD fluctuates between 1 Å and 3 Å. However this is still within the 
pocket. This is one of the simple cases of a correct dock.  
1Y2K is another ligand that exhibits some interesting behaviour. When compared to 
frame zero, it flips over according to the graphics and then fluctuates in that state. 
However, upon examining what it does compared to the crystal structure it is 
docked in a different pose then continues to move away and comes back in a 
constant motion. Looking at the graphics of the simulation in figure 4.7, this is due to 
part of the ligand anchoring itself to the binding pocket while the rest of the ligand 
then moves around in the binding site, shifting and rotating around this anchor. So, 
despite this high RMSD fluctuation the ligand is still bound well enough for a 
fragment. The benzene ring on the top part of the ligand is the fluctuating portion. 
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 Figure. 4.7 The ligand (orange) of 1Y2K (ribbons). Receptor ‐ ligand interactions  are 
shown as green dotted lines. 
 
Figure 4.8. RMSD (in Å) for 2AIE, 2BRT and 2CIX against the initial docked pose and RMSD based on 
the crystal structure.  The total length of the simulation is 200 ns. 2CIX redock was used in simulation. 
 
In Figure 4.8 we see for 2AIE that in both the crystal structure‐based RMSD and the 
frame zero‐based RMSD, there is a fluctuation of about 2 Å. This is similar to 1Y2K, 
where part of the ligand has bound well whereas the rest of it is oscillating within 
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the place it is bound in, as shown in figure 4.9. This again is similar to 1Y2K where 
since the ligand is a fragment and only part of the ligand is bound instead of the 
whole molecule like a drug. This could be useful knowledge when building linkers or 
seeking to identify a decent point to grow such a fragment into a lead compound.  
 
Figure 4.9. A graphical representation of the 2AIE binding site. The residues around the ligand are 
shown as a molecular surface. 
  
 
2BRT is one of the ligands showing some more promise. According to frame zero it 
leaves where it’s bound and moves further and further away. However when 
compared to the crystal structure it actually begins to get closer towards the crystal 
binding site. It doesn’t quite get there in over 200 ns of MD simulation but looking at 
the graphics in the simulation we see that it attempts to get closer than its initial 
position.  
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2CIX exhibits some very sharp fluctuations within its simulation and appears to be 
leaving the binding site continuously. Due to its small size we can’t say that only part 
of the ligand is fluctuating as the ligand is only a small fructose ring. Looking at the 
simulation, what is happening is that protein is showing a breathing moment around 
the binding site. The site is actually very small and a tight fit even for this small 
ligand. The ligand appears to bind to a fold in the protein where it binds to Val182 
and Glu183. The ligand is then pushed in when the protein ‘breathes in’ then is 
ejected again when the protein ‘breathes out’. This motion happens quite 
consistently and the ligand continually returns to its low RMSD. This motion is 
shown in the PCA figure 4.10, the arrows show which parts of the ligand are moving 
significantly. We can see to the right of the ligand the breathing portion which opens 
up to let the ligand out. The constant leaving and returning the ligand exhibits shows 
that it can consistently bind to the site with a high affinity and in nature would likely 
begin a reaction to bind fully instead of being ejected out again. 
 
Figure 4.10. A graphical representation of a PCA for 2CIX.   
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Figure. 4.11. RMSD (in Å) for 2FF2, 2GVV and 2Q6M against the initial docked pose and RMSD based 
on the crystal structure.  The total length of the simulation is 200 ns. 
 
In Figure 4.11, 2FF2 in both frame zero and against the crystal structure fluctuates 
around 2 Å within the binding site, thus it is bound but relatively weakly.  
2GVV has very sharp spikes, similar to what was seen in 2CIX but exhibits behaviour 
similar to 1Y2K. When looking at the graphics of the simulation in figure 4.12, the 
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ligand in 2GVV has an anchor point then fluctuates between 2 poses with the chain 
on one side then on the opposite side. It is doing so quite suddenly which explains 
the spikes.  
The ligand in 2Q6M begins in its binding site and begins to leave, rising to an RMSD 
of ~ 6 Å and then returns, with an RMSD of ~ 2 Å. It had been bound close to the 
crystal structure in its initial pose, which is why there is barely any difference 
between the two plots for 2Q6M in figure 4.10. For 2Q6M Kd = 510 nM as seen in 
table 2.1 which could explain why it is bound in a small area.  
 
 
Fig. 4.12. A graphical representation of the binding site of 2GVV. The ligand is in 
purple, with a transparent molecular surface; neighbouring protein residues are 
denoted by a coloured molecular surface. 
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Figure 4.13. RMSD (in Å) for 2RDR, 2ZVJ and 3DSX against the initial docked pose and RMSD based on 
the crystal structure.  The total length of the simulation is 200 ns. 
 
Figure 4.13 shows more examples of the ligands oscillating into and out of their 
crystal structure poses, despite the high glidescore they were given in the original 
docking and polarized re‐docking, Table 2.1. 2RDR appears to be leaving the binding 
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site according to the RMSD relative to frame zero but it is moving away from the site 
to get closer towards its crystal structure binding site. 
2ZVJ is similar in that regard where it attempts to leave the initial (top glide pose / 
step 0) binding site, it is oscillating quickly to build up momentum to leave, as 
reflected in the many dips and troughs in RMSD. It then finally leaves. What is 
happening better shown against the crystal structure in figure 4.13: is it is leaving a 
binding site that is very far away from the crystal structure pose. The ligand breaks 
away from its top glide pose position then moves towards its experimental binding 
site in the crystal structure. It hasn’t made it to a low RMSD of 2 Å. However, it is 
attempting to rearrange itself in the binding site at the end of the simulation.  
3DSX is leaves the binding site only to return to the same one in a slightly different 
part of the pocket. The ligand for 3DSX has a Kd of 1.4 mM.  It leaves the binding site 
and moves around on the outside of the protein before being pushed back in and 
rebinding to the pocket.     
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4.5 Discussion 
As in chapter 3 (GROMACS simulations), there were several ligands that continued 
to show expected behaviour by binding strongly and staying with relatively low 
RMSD (<4 Å) such as 1F5F, 1F8E, 2RDR and 1WOG, continuing the trend that tightly 
bound fragments will stay bound tightly. However, whereas in Table 2.1 the RMSDs 
are generally below 2 Å, the RMSDs obtained from the simulations are higher, partly 
because these are dynamic systems and so it is inevitable that the breaking and 
reforming of hydrogen bonds will yield a higher RMSD. Fragments showing this type 
of behaviour under MD may be the best candidates for experimental testing, or if 
the experimental screening is positive, for optimization into a lead compound. 
Some ligands went through a rapid oscillating motion showing one of two things. 
Either the ligand is moving around rapidly it its binding site or part of the ligand is 
anchored down while part of the ligand is oscillating freely causing a higher RMSD 
such as 2GVV (Figure 4.11).   
Other ligands were docked with a low RMSD were then ejected from the binding 
site, then returning to the binding site later in the simulation. Examples include 
2RDR and 3DSX (Figure 4.13). This potentially in part shows the ligand kinetics as the 
dissociation constant is an equilibrium constant that measures the propensity of the 
products (protein complex) to dissociate reversibly into its reactants (ligand and 
protein). This can be shown in MD as the ligand moving to infinity, or at least moving 
a reasonable distance away where the attractive forces are low or insignificant. . 
Some of the ligands become trapped in their pocket by the conformation of the 
protein as seen in 1M3U (Fig 4.4). The flap that is keeping the ligand inside the 
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binding pocket feeds into the ligand kinetics as this mechanism shows how it 
increases the on rate. Thus the MD simulations have the potential to show specific 
mechanisms of ligand binding in proteins.  
Some ligands eventually built up enough energy to move to a new binding site and 
fluctuate in that region such as 2CIX which ejects part way through the simulation to 
find a new site. So it’s possible that we can use the MD methods to find other 
positions for the ligands to bind as the ligand was fluctuating mostly in this new 
area.  
The longer simulations made possible by the more powerful GPUs has allowed a 
better look at the behaviours of several of the ligands. 2CIX for example moved out 
of its binding site and then returned as the protein breathed. This return could not 
be seen in the very short 10 ns MD runs which we performed with GROMACs 
(Chapter 3, Figure 3.5). However, the oscillations in Figure 4.8 suggest that even with 
a reasonably low RMSD after the redock, because of its poor binding and the 
breathing nature of the protein it will probably continue to leave that binding site.  
1MLW, as shown before (Figure 4.3), seems content in its new binding site, 
fluctuating little and not leaving it, suggesting further that it was correctly docked 
(into an allosteric binding site) despite the higher RMSD at the initial phase of 
docking.  
With this set we also have another poorly docked ligand in 1M3U.  The ligand in 
1M3U has found a different conformation in the binding pocket in which to bind 
after simulation. After equilibration it moved closer to its crystal structure position, 
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giving an RMSD of 3 Å instead of an RMSD of 6 Å, as in the initial docking. However, 
during the simulation it continued to move to where it was originally docked without 
polarization (Table 2.1, ‘before’ column, RMSD ~ 2 Å).  
Ligands in proteins such as 1PWM, despite the low RMSDs from docking (Chapter 2 / 
Table 2.1), could be ejected and slowly leave the binding site during the MD. 1TKU 
exhibits similar behaviour but it was not docked that well, with the RMSD of initial 
and polarized docking both at around 3 Å. The similar behaviour between these two 
show that both ligands can be ejected despite obtaining a good conformation in the 
binding site, showing possibly that strong binding affinity is also needed to serve as a 
good anchor (KD for 1TKU is unknown). The polarization results could suggest that 
1PWM, despite being able to get a good conformation (low RMSD), actually doesn’t 
have a good charge complementarity in that binding area, possibly because the KD is 
low; IC50 = 935 nM (Table 2.1). 
However, sometimes the RMSDs can be misleading and extra care should be taken 
to look at the trajectory in motion, for example with 2AIE and 2GVV. In the shorter 
simulations, both were found to have tighter binding and did not fluctuate much. 
However when looking at their RMSDs, it appears as the ligands act poorly by not 
staying bound. Part of the ligand is still bound to the correct binding site but due to 
the length of the ligand in both of these cases, only part of the fragment finds a 
strong anchor point and the rest continues to fluctuate in the binding site. This is 
interesting information though and can be used when growing the ligand out in an 
FBDD programme. If we examine the ligand with the MD and find that one side of a 
ligand has a clear anchor point and the other does not, we can grow the ligand out 
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from the section that is fluctuating a lot. We could also possibly try to find a 
different part of the pocket that we could grow the ligand out into and perform 
docking experiments to find a new fragment that has a good conformation in that 
site, and then combine the two. In either FBDD approach, be it growing or 
combining, we can then do a retest of the fragment in the binding area to see if the 
fluctuations are far less. If the new end is bound tightly then the new ligand should 
have fewer fluctuations.  
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Chapter 5 
Membrane simulations for wildtype thermostabilized β1-
adrenergic receptor 
5.1 Introduction 
In a seminal paper Serrano‐Vega et al. (2008) described conformational 
thermostabilization of a G‐protein coupled receptor. This facilitated crystallization of 
a β1‐adrenergic receptor (βAR), the structure of which was found by Warne et al. 
(2008). Serrano‐Vega et al. (2008) indicated that thermostabilization may greatly 
increase the ease with which X‐ray crystallographic structures of integral membrane 
drug targets such as G‐protein coupled receptors (GPCRs) can be obtained. Such 
structures are highly desirable in a FBDD programme. Despite much success since as 
described by Congreve et al. (2011), the process of obtaining structures of these 
important medicinal chemistry targets is not necessarily straightforward. For 
example, the mutations identified by thermostabilization experiments shown in 
Shibata et al. (2009) were not the ones that yielded an X‐ray crystal structure; the 
resultant structure did not therefore have the motifs or activity that was originally 
expected, as seen in White et al. (2012). 
A serious limitation to rational drug design for GPCR targets is the lack of 3D 
structural information. The crystallographic determination of GPCR structures 
remains difficult because of low expression levels as shown in Chelikani et al. (2006), 
non‐homogeneous modifications (such as glycosylation) as seen in Reeves et al. 
(2002), folding problems in bacteria demonstrated by the work of Baneres et al. 
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(2003), instability in detergents and multiple conformational states shown in 
Schwartz et al. (2006). Thus, Serrano‐Vega et al. (2008) devised a generic strategy for 
producing detergent‐stable eukaryotic integral membrane proteins. Their 
comprehensive mutagenesis study involved over 300 mutations, including residues 
in all seven transmembrane domains, yielding 18 mutants with increased stability. 
Promising mutations were combined to generate βAR‐m23 in which the Tm (the 
temperature at which a reference ligand can bind to 50% of receptors) had risen to 
53C from 32C for the β1‐AR wild‐type (βAR‐wt). The X‐ray structure of this 
stabilized form of the receptor in complex with the inverse agonist cyanopindolol 
was subsequently determined as seen in the results of the paper in Warne et al. 
(2008). However, neither the resultant βAR‐m23 crystal structure nor the analysis of 
the equivalent mutated positions in the rhodopsin structure gave any indication as to 
the origin of the enhanced stability as seen in Warne et al. (2008) and Serrano‐Vega 
et al. (2008). Moreover, since similar stabilizing mutations in the adenosine, 
chemokine and neurotensin receptors as seen in the papers by Shibata et al. (2009), 
Lebon et al. (2011a), Lebon et al. (2011b) and Wu et al. (2010) did not occur at 
equivalent positions, it seems that in its current form, conformational 
thermostabilization is difficult to apply in a rational way. 
Other researchers such as Balaraman et al. (2010) and Chen et al. (2012) have 
studied packing effects in GPCR stability, RMSF and connectivity analysis as seen in 
Simpson (2011). Here we consider RMSD and root mean square fluctuation (RMSF) 
analysis as a measure of thermostabilization.  
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This study is to investigate whether computational methods can be used to 
understand and model the stability of mutant receptors. The hypothesis is that by 
using these computational methods, if the results are as expected, it should be 
possible to gain understanding and prioritize and study proposed mutants prior to 
experimental assessment. 
 
5.2 Methods 
The mutant of a 1‐adrenergic receptor, pdb code 2VT4, found by Serrano‐Vega et 
al. (2008), was shown to be thermodynamically stabilized. The topology for the wild 
type was found in Yarden et al. (1986). According to Serrano‐Vega et al. (2008), this 
thermostability is attained by the following mutations: R681.59S, M902.53V, Y2275.58A, 
A2826.27L, F3277.37A and F3387.48M. Where 68 is the beta(1)‐AR residue number and 
1.59 is the Weinstein and Ballasteros universal number (Ballesteros and Weinstein, 
1995)  in which 1 refers to the helix number, and position 59 is the most conserved 
residue in the helix. Here, we investigated these findings with molecular dynamics. 
The aim was to observe whether during an MD simulation the mutant was more 
stable than the wildtype. We measured the RMSD (as a measure of stability) over 
the course of 200 ns and we also measured the RMSF across both proteins.  
Afterwards, we performed tests to ascertain if temperature had any effect on the 
RMSF of each protein and if there was any temperature where one protein was 
more stable than the other.  In addition, we investigated the stability with and 
without the ligand. The hypothesis is that the RMSD and RMSF data should correlate 
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with Serrano‐Vega et al. (2008) where the mutant should be more stable than the 
wildtype – provided that RMSD and RMSF are related to thermostability. 
 
5.2.1 Preparation of the membrane around the proteins 
The two proteins were prepared separately, namely the wildtype and the mutant. 
The mutant was taken from the RSCB; The wildtype was developed by comparative 
modelling using Modeller 9.12 as the best structure from 100 alternative models 
(Eswar et al., 2007). Each protein was prepared in the identical process shown in 
section 4.3.  
After the basic preparation and minimisation, we used the desmond membrane 
package from maestro to generate a POPC lipid bilayer. The proteins were 
duplicated and the ligand DHA was docked to the protein. At this point, there were 4 
prepared proteins with membranes; wildtype with and without ligand, mutant with 
and without ligand. Each of these proteins were exported from maestro and 
converted into the amber format.  A water bath and constraint file was generated in 
the same manner as in section 4.3. A set of typical input files is found in appendix 
5.1. 
 
5.2.2 MD simulation 
Full details of the input files that specify the details of the MD simulations can be 
found in Appendix 5.2. The typical parameters are summarized below. 
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There were 6 production runs which are as follows: Wildtype, Wildtype with ligand, 
Wildtype at various temperatures, Mutant, Mutant with ligand, Mutant at various 
temperatures. 
All proteins were minimised for 5000 steps each. They were then equilibrated using 
NVT for 2 ns and NPT with constraints for 20 ns followed by 20 ns without 
constraints. The time step was set to 4 fs; this large step was made possible by 
increasing the mass of the hydrogen atoms to 4 da. The temperature was set to 300 
K. Pressure was set to the default of 1.01325 bar. The production run for each 
protein was 200 ns. 
For the temperature production runs on each protein a tcl script was appended to 
the input file. The tcl script increased the temperature every 40 ns. The temperature 
started at 300 K and at every 40 ns was increased by 8 K.      
 
5.2.3 Converting membranes for use in ACEMD 
As discussed in section 5.2.1, ACEMD has no native program that can generate a 
membrane. Options were available for generating a membrane through the 
CHARMM‐GUI or by using Maestro. The CHARMM‐GUI seemed the simpler option as 
CHARMM and amber shared similar formats. However, the mutated 2VT4 protein 
was generated through modelling and was not completely standardized. Due to this, 
the CHARMM‐GUI did not recognize any of our files correctly and would generate 
membranes without a protein present. Maestro however could read the protein and 
generate a membrane for each protein, so this option was chosen. Maestro again 
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has its own format and had to be converted to be recognized by amber. The 
membrane had to be converted using old conversion scripts found in the appendix, 
the scripts were made by Ian Gould (Imperial College London) and Ross Walker 
(UCSD). 
 
5.3 Results 
The βAR‐m23 and βAR‐wt receptor structure is shown in Fig. 5.1 
 
Figure 5.1. The β1‐AR model; the mutated amino acids are shown as sticks. 
 
Page | 150  
 
The RMSDs of βAR‐m23 and βAR‐wt over the course of a 200 ns simulation and at 
different temperatures are shown in Figure 5.2. Each protein appears to be 
reasonably stable with just modest fluctuation in RMSD. βAR‐m23 (blue) however 
across the different runs has a consistently lower RMSD than βAR‐wt, which is  in 
line with expectations, showing more thermostability with the 2VT4 mutant than 
with WT. One of the reported effects of thermostabilization is to freeze the protein 
in a particular state, which may be an inactive form, if an inverse agonist was used as 
the ligand in the stabilization process, or it may be an active form if an agonist was 
used as shown in Serrano‐Vega et al. (2008). In this case, the ligand was an inverse 
agonist, so while βAR‐wt may sample active and inactive conformations, βAR‐m23 
should only sample inactive conformations and so should have a lower RMSD. The 
expected result in Figure 5.2a‐e suggests that average RMSD is a good indicator of 
receptor stability. Consequently, we have also analysed the RMSF over all atoms of 
the receptors in the absence of ligand; these results are given in Figure 5.3.  
 
Figures 5.2a‐e shows that the RMSD of the average structure for the βAR‐m23 
mutant at each temperature is lower, with the exception of 324 K. At 324 K the 
wildtype has a lower RMSD for ~20 ns before 2VT4 once again has the lower RMSD. 
This lower RMSD for the βAR‐m23 suggests that it is more thermodynamically 
stable, which matches the findings of the experimental data.  
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Figure 5.2a the RMSD (in Å) against the average structure of βAR‐m23 (red) and 
βAR‐wt (wildtype) over the full 200 ns of the production run. The RMSD is for the 
backbone of the protein excluding any hydrogens; this figure is for 300k. Each frame 
is 200 ps. A 6th order polynomial was fitted to the RMSD data, denoted Poly.(WT‐300 
and 2VT4‐300). 
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Figure 5.2b(top) and 5.2c(bottom) the RMSD (in Å) against the average structure of 
βAR‐m23 (red) and βAR‐wt (wildtype) over the full 200 ns of the production run. The 
RMSD is for the backbone of the protein excluding any hydrogens; figure 5.2b is for 
308k and figure 5.2c is for 316K. Each frame is 200 ps. A 6th order polynomial was 
fitted to the RMSD data, denoted Poly.(WT‐308 or 316 and 2VT4‐308 or 316). 
Page | 153  
 
 
Figure 5.2d(top) and 5.2e (bottom) the RMSD (in Å) against the average structure of 
βAR‐m23 (red) and βAR‐wt (wildtype) over the full 200 ns of the production run. The 
RMSD is for the backbone of the protein excluding any hydrogens;figure 5.2d is for 
324k and figure 5.2c is for 332K . Each frame is 200 ps. A 6th order polynomial was 
fitted to the RMSD data, denoted Poly.(WT‐324 or 332 and 2VT4‐324 or 332). 
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Figure 5.3 shows that the RMSF is largely negative, suggesting that the βAR‐m23 
fluctuates more than βAR‐wt. The point where the βAR‐m23 appears to be more 
stable is at the ends of each helix. This is seen in spikes of positive values along the 
figure. For the other regions, the wildtype is more stable. So the central part of the 
bundle appears to be more stable in the wildtype, while the ends of the helix are 
more stable in the thermostabilized receptor. Since during activation, it is the ends 
of the helices that move most, the lower RMSF in this region may be an indicator of 
increased thermostability. 
 
Figure 5.3 The difference of RMSF across the all atoms between the βAR‐m23 
mutant and the βAR‐wt wildtype. A positive value indicates that the RMSF is higher 
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in the wildtype. (The tail end of the structure is different between the two receptors 
which is why there is a spike of RMSF at the very end.)  
 
The wildtype was used as the base and the RMSF of the mutant was subtracted from 
it at each point. This means that a positive value would show that the conformation 
of the mutant was fluctuating less as its RMSF was lower than that for the wildtype, 
meaning the mutant was more stable,  whereas a negative value would show that 
the wildtype has a lower RMSF at those values showing that it was fluctuating less. .  
The results shown in Figure 5.3 were obtained in the absence of ligand, and so the 
corresponding results in the presence (and absence) of ligand are shown in Figure 
5.4, over the C atoms. On the right of Figure 5.4 we can see that the RMSF concurs 
with the previous data in 5.3 with βAR‐m23 (in blue) as it has a higher RMSF, 
continuing the trend of being less stable in simulation. With the inclusion of the 
ligand, both proteins exhibit more stability. Despite their stability being very close, 
Figure 5.4 shows that the mutant is still slightly less stable as it exhibits a higher 
RMSF.  
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Figure 5.4. The effects of the presence (left) and absence (right) of ligand on the 
RMSF of the alpha carbons of βAR‐m23 (blue) and βAR‐wt (black).  
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Figure 5.5. The effect of temperature on RMSF for the wild‐type and mutant 
receptor. The temperatures are, 300 K (blue), 308 K (green), 316 K (black), 324 K 
(orange), 332 K (red).  
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The effect of temperature on RMSF is shown in Figure 5.5. This shows some 
interesting results.  There is a lot more of an effect of temperature on the mutant 
than there is on the wildtype. The RMSF drops to the most stable at 308 K for both 
proteins, which is relatively close to body temperature; this is likely to be close to 
the optimal temperature for this receptor. As the temperature increases for the 
wildtype it stays relatively stable, fluctuating around 2.5 Å RMSF with spikes for the 
intracellular and extracellular loops that join the transmembrane helices.  The βAR‐
m23 mutant (2VT4) is least stable at 324 K but drops back to a 2.5 Å RMSF, with 
exception to the non‐transmembrane regions at 332 K. The result for the mutant 
appears to be erratic but again, is consistently less stable than the Wildtype. 
  
Figure 5.6: Ligand RMSD (in Å) for the receptor:ligand complex over the full 200 ns 
of the production run. βAR‐m23 is shown in blue and βAR‐wt is shown in black. The 
RMSD is for the bound ligand; the reference point is the average structure. Each 
frame is equivalent to 200 ps. 
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The RMSD of the ligands for βAR‐m23 and βAR‐wt over the full 200 ns of the 
production run is shown in figure 5.6. The RMSD for the ligand in the βAR‐m23 
mutant is lower than that of the wildtype, fluctuating at about 0.8 Å, compared to 
the wildtype’s 1‐1.2 Å. This shows that the ligand in the βAR‐wt is not bound as 
tightly as in the mutant.  
This is further corroborated by figures 5.7a‐e which shows how many hydrogen 
bond interactions there are between an important interaction between Arg135 and 
Glu285 in helices 3 and 6 over the course of the simulation. This bond helps the 
overall stability between helices 3 and 6. Each trough shows that there are no 
hydrogen bonds between the two amino acids. In figure 5.7a the βAR‐m23 is 
forming more hydrogen bonds at 300 K and has fewer disconnects than the 
wildtype. This pattern stays the same for figures 5.7b‐5.7d at 308, 316 and 324 K. In 
figure 5.7e at 332 K something interesting happens. The wildtype is unable to keep 
the Arg‐Glu salt bridge for 10 ns whilst the βAR‐m23 structure manages to maintain 
the interaction. This further supports the idea that 2VT4 is more thermodynamically 
stable. As seen in figure 5.8, the RMSF of the ligand for βAR‐m23 mutant (2VT4) is 
lower. This shows that the structure of the ligand is more stable in the binding site 
but is a little less tightly bound the ligand in the wildtype which continues the trend 
shown in figure 5.6. A principal component analysis (PCA) was also performed for 
the each of the biomacromolecules shown in figure 5.9a‐b. The green arrows 
attached to the helices show which parts are fluctuating greater than 1 Å. It is 
difficult to see from the figure but the central helices for 2VT4 are fluctuating slightly 
more than the wildtype.  
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Figure 5.7a. Hydrogen bonds between Arg135 and Glu285in helices 3 and 6 at 300 K. 5.7.a1 
(Top) is βAR‐wt, 5.7.a2 (bottom) is βAR‐m23. Each frame is 200 ps. 
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Figure 5.7b. Hydrogen bonds between Arg135 and Glu285 in helices 3 and 6 at 308 K. 5.7.b1 
(Top) is βAR‐wt, 5.7.b2 (bottom) is the βAR‐m23. Each frame is 200 ps. 
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Figure 5.7c. Hydrogen bonds between Arg135 and Glu285 in helices 3 and 6 at 316 K. 5.7.c1 
(Top) is βAR‐wt, 5.7.c2 (bottom) is βAR‐m23. Each frame is 200 ps. 
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Figure 5.7d. Hydrogen bonds between Arg135 and Glu285 in helices 3 and 6 at 324 K. 5.7.d1 
(Top) is βAR‐wt, 5.7.d2 (bottom) is βAR‐m23. Each frame is 200 ps. 
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Figure 5.7e. Hydrogen bonds between Arg135 and Glu285 in helices 3 and 6 at 332 K. 5.7.e1 
(Top) is βAR‐wt, 5.7.e2 (bottom) is βAR‐m23. Each frame is 200 ps. 
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Figure 5.8. Ligand RMSF over the 200 ns simulation of the ligands in complex with (A) 
βAR‐m23 (2VT4) and (B) βAR‐wt (Wildtype).  
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Figure 5.9a-b:  Graphical representations of PCA for (a) βAR‐m23 (2VT4) on the left and (b) βAR‐wt on the right. The green arrows represent the movement 
for that portion of the protein.
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5.4 Discussion  
The results complement data from the study shown in Serrano‐Vega et al. (2008). In 
the study, Serrano‐Vega et al. measured DHA binding at different temperatures and 
with different detergents. Their results showed that the mutant had more DHA 
bound throughout most temperatures between 6 oC and 40oC (279‐313 K). Whilst 
our data does not show how much is bound, the RMSD and RMSF of the ligand in 
figures 5.6 and 5.8 show that the βAR‐m23 structure fluctuates less and maintains 
its conformation more than the wildtype. This means that our data is showing that 
the ligand binds more tightly in βAR‐m23 in than the wildtype which is consistent 
with the literature.  
The paper also inferred that due to this stronger binding, βAR‐m23 is more 
thermostable for use in crystallography, since X‐ray crystallography ideally requires 
binding of ligands to stabilize the receptor structure and hence to create good 
crystals that will diffract. Serrano‐Vega et al. (2008) go onto say that this stability is 
used to prevent conformational change, making it easier to crystallize. Our data 
corroborates this, showing that the average RMSD of the βAR‐m23 is consistently 
less than the wildtype. RMSF data and PCA in figures 5.5 and 5.9 show however that 
the βAR‐m23 mutant fluctuates more as a whole, but differently. This is due to the 
greater movements of the extra‐membranous regions of the protein that fluctuate 
more in the mutant than the wildtype, shown in the PCA as longer arrows in those 
regions. This therefore will increase the RMSF as a whole for the βAR‐m23. The 
mutations might have had an effect on the stability on these extra‐membranous 
regions of the structure as two of the mutations are in this region, as shown in figure 
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5.2. This however, has a lesser effect on the binding region as the data shows the 
intra‐membranous region is more stable in the βAR‐m23 mutant.   
The ligand results also appear to be consistent what with Serrano‐Vega et al. (2008) 
have found. As stated previously, there is more bound ligand in the mutant than the 
wildtype. However in the results in figures 5.7a‐e and 5.8 the helices (3 & 6) around 
the binding site open up more readily in the wildtype than in the βAR‐m23 mutant 
shown in the results on hydrogen bonds. The ligand is bound more tightly in βAR‐
m23 according to the RMSD studies as well.  
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Chapter 6 
Concluding remarks 
6.1. Soluble proteins 
As shown in the results presented here, inclusion of polarization has an effect on 
improving the docking results of ligands to the protein, as signified by the RMSD 
values of the molecules in the validation sets; this effect can range from minor to 
major. Thus when polarization was included, 13 out of 38 tested proteins had better 
RMSD values.  The docking process was optimised to generate polarized charges 
that could replace the standard charges found on the ligands in the validation set; 
this process involved polarizing the ligand according to the top pose generated by 
docking the ligand with standard unpolarised charges. Inevitably, because of the 
nature of the docking process, 6 of the ligands docked into the wrong positions, with 
errors up to ~ 10 Å in the RMSD. Nevertheless, during MD simulations of incorrectly 
docked ligands, each of these ligands showed signs of moving closer to their correct 
binding sites, sometimes returning to a binding position with an RMSD of  less than 1 
Å (9/21 returned to within 3 Å, while 2/21 returned to within 1 Å). Polarization can 
therefore impact some results while leaving some unchanged; In only 1 case did 
polarization make the results worse. 
Thus, we have shown that inclusion of polarization has a clear positive effect on 
these calculations. However, it is important to discuss the key question as to 
whether polarization can be routinely included in docking and simulation to improve 
docking and simulation studies relevant to drug design. 
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The question comes down to opportunity, ease of implementation and cost. So it 
seems that inclusion of polarization is a positive step forwards. The time added to 
the preparation of each ligand was minimal even with the use of in‐house scripts 
that weren’t part of the docking programs. If the process was fully incorporated into 
the docking program very little additional time would be required to improve the 
results. This is probably the most significant next step for carrying this polarized 
docking work forward. Ideally, this would be carried forward in GLIDE but could also 
be carried forward into other docking programs such as Autodock (Morris et al., 
2009). 
 
Blind docking and cross-docking in drug design: Including molecular dynamics as an 
extra stage does add a lot more computational time to the process and at the 
current time this might not be the most useful additional step to a screening 
protocol. There is therefore scope for discussion on the best way to use MD in this 
situation. Firstly, it could be used to assess whether a ligand is docked correctly – if it 
drifts away from its binding site then perhaps it was not docked correctly. 
Alternatively, for a set of fragments in a FBDD programme where it is not necessarily 
known how the fragment binds, it could be included in a two stage process similar to 
that used in current methods of HTS. First, attempt to dock a ligand library to a 
targeted protein through use of programs such as GLIDE.  Find a small subset of 
ligands that have high binding affinity. Secondly, for this subset of ligands, new 
charges based upon polarization could be generated. Then having generated these 
new polarized ligand/protein charges, MD simulations could be performed on the 
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complexes. The ligands should be able to converge near to the correct binding site. 
This process would allow comparison of the location of all the ligands as they should 
be converge towards the binding site. This could help pinpoint alternative or 
allosteric binding sites by observing the region in where the ligands are attempting 
to bind. Finally, the MD simulations give insight into the dynamic nature of fragment 
binding, which cannot necessarily be obtained from docking alone or from X‐ray 
crystallography. Some ligands bind as expected, forming well‐defined interactions, 
while other ligands are more dynamic and oscillate between alternative binding sites 
in a process where interactions are made and broken. This in particular may be 
useful for indicating how fragment interactions could be improved. 
For our MD simulations the charges stayed static through the entire simulation. 
Future research should be into how we could improve the charges to update for 
each frame of a simulation. If these charges were based on the QM/MM induced 
charge method we used, the QM methods would be updating at each step of the 
simulation or updating every time the geometry of the system changed by a set 
amount. This would become very resource intensive as it stands for current 
programs and systems. We could wait until the systems improve to a point we could 
do this but it could take decades if we are to use CPUs as they have hit a clock speed 
cliff in this past decade. The solution to that problem is adding more cores.  
However, that is a crude solution, with the current advancements in the field of 
FBDD with regards to GPU use it is possible that the complexity allowance in systems 
will continue to rise.  
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With QM/MM hybridization methods the problem will always be the resource 
intensive QM portion. New methods are emerging where the protein is divided into 
different regions that are modelled using different water models. Within 5 Å of the 
point of interest in the protein, the water is explicit, between 5‐10 Å the water is 
coarse‐grained and beyond 10 Å the water is modelled implicitly. This is an efficient 
compromise for calculating the energy and the positions of molecules in the system 
because the calculations take into account fewer terms the further one goes from 
the point of interest. Using the ideas from these studies we could propose a system 
that changes the model of the protein based on distance from the point of interest, 
e.g. the ligand. Currently in the QM/MM method, the protein is treated by MM and 
explicitly using all atom models. However over the years in the literature there have 
been coarse‐grained models for proteins as well (Tozzini, 2005). For coarse grain if 
the protein in a system was treated as a Gō‐like model it depicts each amino acid as 
a separate bead. This was originally used for models to research folding. However it 
could equally be used in MD. By following this model for amino acids say 5 ‐ 10 Å 
away from the ligand, it could become far simpler and easier to calculate the 
dynamics of the system. However the region closest to the ligand will still be explicit. 
Therefore at this point it could be possible to calculate the QM more easily. This will 
cut down on the computational time needed to calculate the QM at each step. There 
however is one additional problem to this. That is the water in the system. When 
these ligands were polarized they were not in the presence of water and in the 
presence of a static protein so the computational power that was needed is small. 
Since water is a polar molecule, when it is added into the system it will affect the 
polarization of each step. Due to how ubiquitous water is in a system there will be 
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many interactions with the ligand in that system. As was done it chapter 2 we could 
change the water to an implicit model to improve the computational time. However 
during a simulation this means that we are losing the polarization that would 
happen due to the explicit waters’ presence. There are many challenges ahead but 
we believe that there will eventually be a programming solution for determining the 
charges of a dynamic system. 
 
6.2. Membrane simulations: In chapter 5, the MD simulations for the 
transmembrane protein β1‐AR were largely successful and corroborated with 
experimental data in the literature. The methods we use to ascertain this are similar 
to the RMSD‐based methods used to assess binding in Chapters 2‐4. By showing MD 
simulation data (Figures 5.2 – 5.6) that matches the experimental data on the 
protein stability in the paper by Serrano‐Vega et al. (2008)we have provided further 
evidence to help validate our findings.  
However, to further improve on these simulations we could continue to increase the 
sampling time to 200 ns for each temperature. This should allow for any possible 
errors in sampling to be greatly reduced. 
These simulations also did not include our polarization terms as the aim was mostly 
to ascertain the stability of the mutant protein and the wildtype. However we could 
also include the polarization of the DHA ligand. As seen in figure 5.4, the RMSF of 
the protein is far lower when it the ligand is bound. This is due to the breathing 
motion of the helices 3 and 6; with no ligand bound helixes 3 and 6 fluctuate more 
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freely. Thus, the interaction between ligand and protein is used to improve its 
stability. By including polarization we should be able to further improve the 
computational method for assessing protein stability. We would follow the same 
procedure described  in Chapter 2 to generate atomic charges based on our induced 
charge method. Then redock the ligand to the binding site and importing the new 
atomic charges into the MD before performing a production run. 
Serrano‐Vega et al. (2008)described assays at high temperatures. The highest 
temperature we used is 332 K.. However, we could also perform extreme 
temperature simulations in ACEMD. We could then also ascertain if the 
thermostability present at the lower temperatures for βAR‐m23 mutant stays 
consistent into the higher temperatures such as 360 K which is where the 
experimental data tests the half‐life of the stable mutant.  
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Appendix 
2.1 Script to take into account atoms of equivalent value in RMSD calculations 
#!/usr/bin/perl 
$symetry="symetry"; 
open(AGR,">agree"); 
$arg=@ARGV; 
if($arg<2){ 
 die "Need residuum names for QM and list file containing names 
of mae files \n"; 
}; 
if(-s "$symetry"){ 
 $sym=1; 
 print STDERR "Symetry file will be aplied\n"; 
}else{ 
 $sym=0; 
 print STDERR "No symetry file will be aplied\n"; 
}; 
 
#Read template name 
for($i=0;$i<$arg-1;$i++){ 
 if(($lig[$i],$lnum[$i])=$ARGV[$i]=~/^(.+)%(.*)/){ 
  unless($lnum[$i]=~/^[-]?\d+$/){ 
   print STDERR "Warning: $lnum[$i] is not a number. 
Using all $lig[$i]\n"; 
   $lnum[$i]=""; 
  }; 
 }else{ 
  $lig[$i]=$ARGV[$i]; 
  $lnum[$i]=""; 
 }; 
}; 
#Read the list of mae files 
open(LST,"$ARGV[$arg-1]") or die "File  $ARGV[$arg-1] does noi 
eixts\n"; 
$i=0; 
while($line=<LST>){ 
 chomp($line); 
 if(-e $line){ 
  $filename[$i]=$line; 
  $i++; 
 }else{ 
  print STDERR "Filename $line does not exsists, it will be 
ignored\n"; 
 }; 
};  
$nposes=$i; 
for($prvni=0;$prvni<$nposes-1;$prvni++){ 
open(MAE1,"$filename[$prvni]") or die "File $filename[$prvni] does 
not exist\n"; 
#Read input file 
$i=$hi=$mi=0; 
while($line=<MAE1>){ 
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if(($indx1[$i],$x,$y,$z,$rn,$ch,$r,$a,$el)=$line=~/^\s*(\d+)\s+\d+\s
+([-+]?\d+\.\d+)\s+([-+]?\d+\.\d+)\s+([-+]?\d+\.\d+)\s+([-
+]?\d+)\s+\"[^"]*\"\s+\w+\s+(?:(?:\"[^"]*\")|\w+)\s+\d+\s+([-
+]?\d+\.\d+)\s+[-
+]?\d+\.\d+\s+\"\s*(\w+)\s*\"\s+\"\s*([\w']+)\s*\"\s+\"[^"]*\"\s+(\d
+)\s+/){ 
  $flag=0; 
  for($ii=0;$ii<$arg-1;$ii++){ 
   if($r eq $lig[$ii]) { 
    if($lnum[$ii] eq "" or $lnum[$ii]==$rn){ 
     $flag=1; 
                                 $last; 
    }; 
   }; 
  }; 
                if($flag==1) { 
                        $nm1[$i]=$a; 
                        $xx1[$i]=$x; 
                        $yy1[$i]=$y; 
                        $zz1[$i]=$z; 
          print "$a $x $y $z\n"; 
   unless($el==1){ 
    $nm1h[$hi]=$a; 
    $xx1h[$hi]=$x; 
    $yy1h[$hi]=$y; 
    $zz1h[$hi]=$z; 
    $hi++; 
   }; 
  $i++; 
               }else{ 
   unless($el==1){ 
    $xxm1[$mi]=$x;; 
    $yym1[$mi]=$y;; 
    $zzm1[$mi]=$z;; 
    $mi++; 
   }; 
  }; 
 }; 
}; 
$cpa1=$i; 
$cpa1h=$hi; 
if($cpa1h==0){ 
 die "There is zero QM havy atoms\n"; 
};  
$cpm1=$mi; 
for($druhy=$prvni+1;$druhy<$nposes;$druhy++){ 
open(MAE2,"$filename[$druhy]") or die "File $filename[$druhy] does 
not exist\n"; 
$i=$hi=$mi=0; 
while($line=<MAE2>){ 
        
if(($indx2[$i],$x,$y,$z,$rn,$ch,$r,$a,$el)=$line=~/^\s*(\d+)\s+\d+\s
+([-+]?\d+\.\d+)\s+([-+]?\d+\.\d+)\s+([-+]?\d+\.\d+)\s+([-
+]?\d+)\s+\"[^"]*\"\s+\w+\s+(?:(?:\"[^"]*\")|\w+)\s+\d+\s+([-
+]?\d+\.\d+)\s+[-
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+]?\d+\.\d+\s+\"\s*(\w+)\s*\"\s+\"\s*([\w']+)\s*\"\s+\"[^"]*\"\s+(\d
+)\s+/){ 
  $flag=0; 
  for($ii=0;$ii<$arg-1;$ii++){ 
   if($r eq $lig[$ii]) { 
    if($lnum[$ii] eq "" or $lnum[$ii]==$rn){ 
     $flag=1; 
                                 $last; 
    }; 
   }; 
  }; 
                if($flag==1) { 
                        $nm2[$i]=$a; 
                        $xx2[$i]=$x; 
                        $yy2[$i]=$y; 
                        $zz2[$i]=$z; 
          print "$a $x $y $z\n"; 
   unless($el==1){ 
    $nm2h[$hi]=$a; 
    $xx2h[$hi]=$x; 
    $yy2h[$hi]=$y; 
    $zz2h[$hi]=$z; 
    $hi++; 
   }; 
  $i++; 
               }else{ 
   unless($el==1){ 
    $xxm2[$mi]=$x;; 
    $yym2[$mi]=$y;; 
    $zzm2[$mi]=$z;; 
    $mi++; 
   }; 
  }; 
 }; 
}; 
$cpa2=$i; 
$cpa2h=$hi; 
$cpm2=$mi; 
if($cpa1 != $cpa2){ 
  die "Number of QM atoms file $ARGV[$arg-2] is $cpa1 and 
in file $ARGV[$arg-1] is $cpa2 disagreement!!!!\n"; 
}; 
if($cpa1h != $cpa2h){ 
  die "Number of the heavy QM atoms in file $ARGV[$arg-2] 
is $cpa1h and in file $ARGV[$arg-1] is $cpa2h disagreement!!!!\n"; 
}; 
if($cpm1 != $cpm2){ 
  die "Number of the heavy MM atoms in file $ARGV[$arg-2] 
is $cpm1 and in file $ARGV[$arg-1] is $cpm2 disagreement!!!!\n"; 
}; 
print STDERR "There are $cpa1 atoms including $cpa1h heavy atoms\n"; 
   
 
if($sym==0){ 
 for($i=0;$i<$cpa1h;$i++){ 
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  $rms=$rms+($xx2h[$i]-$xx1h[$i])**2+($yy2h[$i]-
$yy1h[$i])**2+($zz2h[$i]-$zz1h[$i])**2; 
 }; 
  $rmsd=sqrt($rms/$cpa1h); 
 $bestrmsd=$rmsd; 
 print STDERR "$cpa1h QM heavy atoms with RMSD=$rmsd\n"; 
}else{ 
#symetry operations 
open (SYM,"$symetry") or die "File $symetry does not exist\n";  
$i=0;  
while($line=<SYM>){ 
        $line=~s/^\s*//; 
        @tmp=split(/\s+/,$line); 
        $tmpn=@tmp; 
        $nsyat[$i]=int($tmpn/2); 
        for($k=0;$k<$nsyat[$i];$k++){ 
   $flag1=$flag2=0;  
          for($l=0;$l<$cpa1h;$l++){ 
             if($nm1h[$l] eq $tmp[2*$k]){ 
  if($flag1==1){ 
   die "Duplicit marking of heavy atom $nm1h[$l] \n"; 
  }; 
  $flag1=1; 
  $syat1[$i][$k]=$l; 
      }; 
             if($nm1h[$l] eq $tmp[2*$k+1]){ 
  if($flag2==1){ 
   die "Duplicit marking of heavy atom $nm1h[$l] \n"; 
  }; 
  $flag2=1; 
  $syat2[$i][$k]=$l; 
             };               
          };    
        }; 
 $#tmp=-1; 
        $i++; 
};  
$cpso=$i; 
for($i=0;$i<2**$cpso;$i++){ 
 for($l=0;$l<$cpa1h;$l++){ 
  $tpx[$l]=$xx1h[$l]; 
  $tpy[$l]=$yy1h[$l]; 
  $tpz[$l]=$zz1h[$l]; 
 }; 
 $b=dec2bin($i); 
 $symper[$i]=substr($b,-$cpso); 
        for($sm=0;$sm<$cpso;$sm++){ 
          if(substr($symper[$i],$sm,1) eq "1"){ 
  for($k=0;$k<$nsyat[$sm];$k++){ 
  
 ($tpx[$syat1[$sm][$k]],$tpx[$syat2[$sm][$k]])=($tpx[$syat2[$sm
][$k]],$tpx[$syat1[$sm][$k]]); 
  
 ($tpy[$syat1[$sm][$k]],$tpy[$syat2[$sm][$k]])=($tpy[$syat2[$sm
][$k]],$tpy[$syat1[$sm][$k]]); 
Page | A5  
 
  
 ($tpz[$syat1[$sm][$k]],$tpz[$syat2[$sm][$k]])=($tpz[$syat2[$sm
][$k]],$tpz[$syat1[$sm][$k]]); 
  }; 
   };  
        }; 
 $rms=0; 
       for($l=0;$l<$cpa1h;$l++){ 
  $rms=$rms+($xx2h[$l]-$tpx[$l])**2+($yy2h[$l]-
$tpy[$l])**2+($zz2h[$l]-$tpz[$l])**2; 
 }; 
 $rmss[$i]=sqrt($rms/$cpa1h); 
        print STDERR "RMS for symetrical operation $symper[$i] is 
$rmss[$i]\n"; 
  
}; 
$bestrms=0; 
for($i=1;$i<2**$cpso;$i++){ 
 if($rmss[$i] < $rmss[$bestrms]){ 
  $bestrms=$i; 
 }; 
}; 
$bestrmsd=$rmss[$bestrms]; 
print STDERR "The best rms of all symetrical operations is 
$rmss[$bestrms] of symetrical operation $symper[$bestrms]\n"; 
}; 
printf AGR "%s %s 
%8.4f\n",$filename[$prvni],$filename[$druhy],$bestrmsd; 
close(MAE2); 
}; 
close(MAE1); 
}; 
 
         
#-------------------------------------------------------------------
-------------------------------- 
sub dec2bin{ 
 my $str=unpack("B32", pack("N",shift)); 
 return $str; 
}; 
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2.2 In house polarization script for polarization of docked pose 
#!/usr/bin/perl 
$dir="/software_repository/polarization_reha/ian_script"; 
$covergence=0.1; 
$arg=@ARGV; 
$schrod=$ENV{'SCHRODINGER'}; 
if($arg<2){ 
 die "Need residuum names for QM and mae file\n"; 
}; 
$xyz=$ARGV[$arg-1]; 
$VYB=""; 
for($i=0;$i<$arg-1;$i++){ 
 $VYB=sprintf("%s %s",$VYB,$ARGV[$i]); 
};  
unless(($infile)=$xyz=~/^([\w\.]+).mae$/){ 
 die "Improper name for mae file($xyz)\n"; 
}; 
unless(-e "$infile.in") { 
 die "$infile.in does not exist\n"; 
}; 
$infilep=$infile; 
$infile=sprintf("%s_%02d",$infilep,0); 
$infilej=sprintf("%sJ%02d",$infilep,0); 
print "$infilep $infile\n"; 
mkdir "00"; 
chdir "00"; 
`cp ../$infilep.in $infile.fin.in`; 
`cp ../$xyz $infile.fin.mae`; 
if(-f "atomsPP"){ 
 `cp ../atomsPP atomsPF`; 
}else{ 
 `touch atomsPF`; 
}; 
print "Copied\n"; 
$opst=1; 
for($z=0;$z<5;$z++){ 
 $opstf=sprintf("%02d",$opst); 
 $opstpf=sprintf("%02d",$opst-1); 
 print "Cycle $opst\n"; 
 mkdir "../$opstf"; 
 chdir "../$opstf"; 
 print "Created changes\n"; 
 system "pwd"; 
 open(IFL,"../$opstpf/$infile.fin.in") or die "cannot open the 
file ../$opstpf/$infile.fin.in\n"; 
 open(IFLO,">$infilej.in"); 
 print IFLO "GPTSFILE: $infile.pts\n";  
 print "Read init\n"; 
 while($line=<IFL>){ 
  if($line=~/GPTSFILE:/){ 
   next; 
  }; 
  if($line=~/MAEFILE:/){ 
   next; 
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  }; 
  print IFLO "$line";  
  if($line=~/\&gen/){ 
   last; 
  }; 
 }; 
 print IFLO "gcharge=-6\nip172=2\n"; 
 $igeopt=0; 
 while($line=<IFL>){ 
  if($line=~/gcharge=-6/ or $line=~/ip172=2/){ 
   next; 
  }; 
  if($line=~/mmqm=1/){ 
   next; 
  }; 
  if($line=~/igeopt/){ 
   unless($line=~/igeopt=0/){ 
    $igopt=$line; 
    $igeopt=1; 
    print IFLO "igeopt=0\n"; 
   }else{ 
    print IFLO  $line; 
   }; 
  }else{ 
   print IFLO $line; 
  }; 
  if($line=~/\&$/){ 
   last; 
  }; 
    
 }; 
 close(IFLO); 
 close(IFL); 
 `cp ../$opstpf/$infile.fin.mae $infile.mae`; 
 `cp ../$opstpf/atomsPF atomsPP`; 
 `$dir/extractMM_filed_mae2pts $VYB $infile.mae >$infile.pts`; 
 `$dir/extractQMmae2jag $VYB $infile.mae >>$infilej.in`; 
 `$dir/extractMMmae2jag $VYB atomsPP $infile.mae 
>>$infilej.in`; 
 `$dir/extractGUESSjag ../$opstpf/$infile.fin.in 
>>$infilej.in`; 
 print "$schrod/jaguar run -WAIT $infilej.in\n"; 
# exit; 
 `$schrod/jaguar run -WAIT $infilej.in`; 
 print "After schrod\n"; 
 `$dir/readESP_J $infilej.resp >field0`; 
 print "$dir/polasignMMmae_def $VYB $infile.mae >XYZS\n"; 
 `$dir/polasignMMmae_def $VYB $infile.mae >XYZS`; 
 $fiel=`wc -l field0`; 
 $ccc=`wc -l XYZS`; 
 unless($fiel==$ccc){ 
  die "Disagreement between field0 and XYZS"; 
 }; 
 `paste -d ' ' field0 XYZS >FCS`; 
 `$dir/calc_indpolF FCS`; 
 `cp ene2 ene2P0`; 
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 $enex=`cat ene2`; 
 ($enep)=$enex=~/^\s*([-+]?\d+\.\d+)/; 
 print "Energy $enep\n"; 
 `cp atoms2 atomsP00`; 
 `cp com comP00`; 
 `cp centr centrP00`; 
 unless(-e "$infilej.01.in"){ 
  die "File $infilej.01.in does not exist, probably qsite 
run crushed\n"; 
 }; 
 $bstd=1; 
 $num=1; 
 while ( $bstd > $covergence){ 
  $numa=$num-1; 
  $numf=sprintf("%02d",$num); 
  $numaf=sprintf("%02d",$num-1); 
  $numff=sprintf("%02d",$num+1); 
  `cp $infilej.$numf.in $infilej.$numf.in.tmp`; 
  open(IFA,"$infilej.$numf.in.tmp"); 
  open(IFAO,">$infilej.$numf.in"); 
  while($line=<IFA>){ 
   if($line=~/&pointch/){ 
    last; 
   }; 
   print IFAO $line; 
  }; 
  close(IFAO); 
  `$dir/extractMMmae2jag $VYB atomsP$numaf $infile.mae 
>>$infilej.$numf.in`; 
  open(IFAO,">>$infilej.$numf.in"); 
  while($line=<IFA>){ 
   if($line=~/&\s*$/){ 
    last; 
   }; 
  }; 
  while($line=<IFA>){ 
   print IFAO $line; 
  }; 
  close(IFAO); 
  close(IFA); 
  print "$schrod/jaguar run -WAIT $infilej.$numf.in\n"; 
  `$schrod/jaguar run -WAIT $infilej.$numf.in`; 
  `$dir/readESP_J $infilej.$numf.resp >field$numf`; 
  $fiel=`wc -l field$numf`; 
  $ccc=`wc -l centrP$numaf`; 
  unless($fiel==$ccc){ 
   die "Disagreement between field$numf and 
centrP$numaf"; 
  }; 
  `paste -d ' ' field$numf centrP$numaf >FCS$numf`; 
  `$dir/calc_indpolF FCS$numf`; 
  `cp ene2 ene2P$numf`; 
  $enex=`cat ene2`; 
  ($ene)=$enex=~/^\s*([-+]?\d+\.\d+)/; 
  `cp atoms2 atomsP$numf`; 
  `cp com comP$numf`; 
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  `cp centr centrP$numf`; 
  unless(-e "$infilej.$numff.in"){ 
   die "File $infilej.$numff.in does not exist, 
probably qsite run crushed\n"; 
  }; 
  $bstd=abs(($ene-$enep))/$ene; 
  print "Energy $ene\n"; 
  print  "Difference $bstd\n";  
  $enep=$ene; 
  $num++; 
 }; 
 `cp atomsP$numf atomsPF`; 
 `$dir/readinmae_indchg $VYB atomsP$numf 
../$opstpf/$infile.fin.mae >$infile.mae`; 
 open(IFL,"../$opstpf/$infile.fin.in") or die "cannot open the 
file ../$opstpf/$infile.in\n"; 
 open(IFLO,">$infile.in"); 
 while($line=<IFL>){ 
  if($line=~/MAEFILE/){ 
   print IFLO "MAEFILE: $infile.mae\n"; 
   next; 
  }; 
  print IFLO $line; 
  if($line=~/\&mmkey/){ 
   last; 
  }; 
 }; 
        print IFLO "use_mae_charges=YES\n"; 
 while($line=<IFL>){ 
  if($line=~/&guess/){ 
   last; 
  }; 
  unless($line=~/use_mae_charges/){ 
   print IFLO $line; 
  }; 
 }; 
 close(IFL); 
 close(IFLO);  
 `$dir/extractGUESSjag $infilej.$numff.in >>$infile.in`; 
 print "$dir/extractGUESSjag $infilej.$numff.in 
>>$infile.in\n"; 
 `$schrod/qsite -WAIT $infile.in`; 
 print "$igeopt\n"; 
 if($igeopt!=0){ 
  print "Optimization\n"; 
  unless(-e "$infile.01.in"){ 
   die "File $infile.01.in does not exist, probably 
qsite run crushed\n"; 
  }; 
  $infilef=sprintf("%s_%02d",$infilep,$opst); 
  `cp $infile.01.in $infilef.fin.in`; 
  `$dir/readoutmae_indchg $VYB atomsPF $infile.01.mae 
>$infilef.fin.mae`; 
 }else{ 
  last; 
 }; 
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 $infile=$infilef; 
 $infilej=sprintf("%sJ%02d",$infilep,$opst); 
 $opst++; 
}; 
   
 
 
3.1 Gromacs input file 
title  = mini 
cpp  = /lib/cpp 
define  = -DFLEX_TIP4P 
constraints = none 
integrator = steep 
dt  = 0.002 
nsteps  = 50000 
nstlist  = 10 
ns_type  = grid 
rlist  = 0.9 
coulombtype = PME 
rcoulomb = 0.9 
rvdw  = 1.0 
fourierspacing = 0.12 
fourier_nx = 0 
fourier_ny = 0 
fourier_nz = 0 
pme_order = 4 
ewald_rtol = 1e-5 
optimize_fft = yes 
 
emtol  = 1000.0 
emstep  = 0.01 
 
4.1 Script to generate AMBER force field 
source leaprc.gaff 
source leaprc.ff14SB 
 
# Load special FF files for phoshpotyrosine 
loadamberparams 16D.frcmod 
#loadoff par_files/Y2P.off 
 
# Note: .off and .lib files are the same 
 
#set default disulfide auto 
 
loadamberprep 16D.prepi 
mol1 = loadpdb 1WOG.pdb 
mol2 = loadpdb NEWPDB.PDB 
fullmol = combine{mol1, mol2} 
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solvatebox fullmol TIP3PBOX 12.0 
#addions fullmol Na+ 0 
#addions fullmol Cl- 0 
saveamberparm fullmol 1WOG_solvated.prmtop 1WOG_solvated.inpcrd 
savepdb fullmol 1WOG_solvate.pdb 
 
quit 
 
4.2 ACEMD input file 
# Configure time variables 
set steps_min   500     ; # Number of steps to minimize 
set steps_nvt   25   ; # Number of steps for NVT 
set steps_npt1  250   ; # Number of steps for NPT with constraints 
set steps_npt2  250 ; # Number of steps for NPT without constraints  
set numSteps    [expr $steps_nvt + $steps_npt1 + $steps_npt2]    ; # 
Total number of steps for the simulation. 
 
# Set reusable variables 
set inputname   input 
set outputname  nve 
set structure   1F8E_solvated 
set parameters  parameters 
set temperature 300 
set logfreq     1000 
 
# Set inputs 
#structure       $structure.psf 
#coordinates     $structure.pdb 
#bincoordinates  $structure.coor 
#binvelocities   $structure.vel 
#parameters      $parameters 
 
# Set outputs 
energyfreq      $logfreq 
restart         on 
restartfreq     5000 
restartname     $outputname.restart  
outputname      $outputname 
dcdfreq         25000 
dcdfile         $outputname.dcd 
 
# Set box dimensions, manually or via extendedsystem 
celldimension 82 90 91   
#extendedsystem  $inputname.xsc 
 
# Configure holonomic restraints 
rigidbonds      all  
 
# Configure integration 
timestep        4 
hydrogenscale   4 
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# Configure electrostatics 
pme             on 
pmegridspacing  1.0 
#pmefreq         2 
cutoff          9 
switching       on 
switchdist      7.5 
exclude         scaled1-4 
1-4scaling      1.0 
fullelectfrequency 2 
 
# Configure positional restraints, if any 
constraints     on 
consref         $structure.restrain.pdb 
constraintscaling   1.0 
 
# Configure thermostat 
langevin        on 
langevintemp    $temperature 
langevindamping 1 
 
# Configure barostat 
berendsenpressure   on 
berendsenpressuretarget 1.01325 
berendsenpressurerelaxationtime  800  
#useconstantratio on ; # For use with membrane systems 
 
# Amber settings 
amber on 
coordinates $structure.pdb 
parmfile    $structure.prmtop 
1-4scaling      0.833333333333 
 
# Run minimization 
minimize $steps_min  
# Run simulation 
run $numSteps 
 
4.3 TCL script to ease off constraints 
tclforces on 
tclforcesfreq   1 
 
# Relaxation variables 
set scaling_original 1.0 
set scalefreq 25 ; # Must be a factor of $steps_npt1 
set downscale 0.8 
 
set t [getstep] 
set scalefactor [expr floor($t/$scalefreq)] 
set scalemax [expr ceil($steps_npt1/$scalefreq)] 
set scaling [expr $scaling_original*pow($downscale, $scalefactor)] 
constraintscaling $scaling 
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proc calcforces_init {} { 
  global steps_nvt steps_min 
  global steps_nvt steps_npt1 steps_npt2 
  global scaling_original scaling scalefactor scalefreq scalemax 
downscale 
 
  set t [ getstep ] 
  if { $t == 0 } { 
    puts "Running $steps_min steps of energy minimization" 
  } else { 
    puts "Restarting" 
    if { $t < $steps_nvt } { 
      puts "Running $steps_nvt steps of NVT with constraints" 
      berendsenpressure off 
      tclforcesfreq [expr $steps_nvt ] 
    } elseif { $t < [expr $steps_nvt + $steps_npt1 ] } { 
      if { $steps_npt1 % $scalefreq == 0 } { 
        tclforcesfreq $scalefreq 
        set scalefactor [expr floor(($t-$steps_nvt)/$scalefreq)] 
        set scaling [expr $scaling_original*pow($downscale, 
$scalefactor)] 
        constraintscaling $scaling 
        puts "STEP:     $t" 
        puts "SCALING:  $scaling" 
        puts "SCALEFACTOR: $scalefactor" 
      } else { 
        # Dont do force scaling if $steps_npt1 not a multiple of 
$scalefreq 
        set scalefactor $scalemax 
        tclforcesfreq [expr $steps_nvt + $steps_npt1 ] 
        puts "Force scaling will not be performed because 
\$scalefreq not a factor of \$steps_npt1" 
      } 
    } else { 
      puts "Running $steps_npt2 steps of NPT without constraints" 
      constraintsclaing 0. 
    } 
  } 
} 
 
proc calcforces {} { 
  global steps_nvt steps_npt1 steps_npt2 
  global scaling_original scaling scalefactor scalefreq scalemax 
downscale 
  set t [ getstep ] 
 
  if { $t == 1 } { 
    puts "Running $steps_nvt steps of NVT with constraints" 
    berendsenpressure off 
    tclforcesfreq $steps_nvt 
  } 
  if { $t == $steps_nvt } { 
    # turn barostat on 
    puts "Running $steps_npt1 steps of NPT with constraints" 
    berendsenpressure on 
Page | A14  
 
    if { $steps_npt1 % $scalefreq == 0 } { 
      tclforcesfreq $scalefreq 
      set scalefactor [expr floor(($t-$steps_nvt)/$scalefreq)] 
      set scaling [expr $scaling_original*pow($downscale, 
$scalefactor)] 
      constraintscaling $scaling 
      puts "STEP:     $t" 
      puts "SCALING:  $scaling" 
      puts "SCALEFACTOR: $scalefactor" 
    } else { 
      # Dont do force scaling if $steps_npt1 not a multiple of 
$scalefreq 
      set scalefactor $scalemax 
      tclforcesfreq [expr $steps_nvt + $steps_npt1 ] 
      puts "Force scaling will not be performed because \$scalefreq 
not a factor of \$steps_npt1" 
    } 
  } 
  #if { $t > $steps_nvt && [expr $steps_nvt + 
$scalefreq*$scalefactor] < [expr $steps_nvt + $steps_npt1] } {} 
  if { $t > $steps_nvt && [expr $scalefreq*$scalefactor] < [expr 
$steps_npt1] } { 
    # Gradually reduce constraint scaling 
    set scalefactor [expr floor(($t-$steps_nvt)/$scalefreq)] 
    set scaling [expr $scaling_original*pow($downscale, 
$scalefactor)] 
    constraintscaling $scaling 
    puts "STEP:     $t" 
    puts "SCALING:  $scaling" 
    puts "SCALEFACTOR: $scalefactor" 
  } 
  if { $t == [expr $steps_nvt + $steps_npt1] } { 
    # turn constraints off 
    constraintscaling  0. 
    puts "Running $steps_npt2 steps of NPT without constraints" 
  } 
 
} 
 
proc calcforces_endstep { } { } 
 
 
 
5.1 ACMED input file for membrane simulations 
 
# Configure time variables 
set steps_min   500     ; # Number of steps to minimize 
set steps_nvt   250000  ; # Number of steps for NVT 
set steps_npt1  2500000 ; # Number of steps for NPT with constraints 
set steps_npt2  2500000 ; # Number of steps for NPT without 
constraints  
set run1  5000000 ; # temp1 
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set run2        5000000 ; # temp2 
set run3        5000000 ; # temp3 
set run4        5000000 ; # temp4 
set run5        5000000 ; # temp5 
#set run6        2500000 ; # temp6 
#set run7        2500000 ; # temp7 
#set run8        2500000 ; # temp8 
#set run9        2500000 ; # temp9 
#set run10       2500000 ; # temp10 
set numSteps    [expr $steps_nvt + $steps_npt1 + $steps_npt2 + $run1 
+ $run2 + $run3 + $run4 + $run5 ]  ; # Total number of steps for the 
simulation. 
 
# Set reusable variables 
set inputname   input 
set outputname  2VT4_x2_temp_output 
set structure   2VT4+ligand_solvated 
set parameters  parameters 
set temperature 289 
set logfreq     15000 
 
# Set inputs 
#structure       $structure.psf 
coordinates     $structure.pdb 
#bincoordinates  $structure.coor 
#binvelocities   $structure.vel 
parameters      $parameters 
 
# Set outputs 
energyfreq      $logfreq 
restart         on 
restartfreq     30000 
restartname     $outputname.restart  
outputname      $outputname 
dcdfreq         15000 
dcdfile         $outputname.dcd 
 
# Set box dimensions, manually or via extendedsystem 
#celldimension    
extendedsystem  input.xsc 
 
# Configure holonomic restraints 
rigidbonds      all  
 
# Configure integration 
timestep        4 
hydrogenscale   4 
 
# Configure electrostatics 
pme             on 
pmegridspacing  0.16 
#pmefreq         2 
cutoff          11 
switching       on 
switchdist      7.5 
exclude         scaled1-4 
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1-4scaling      1.0 
fullelectfrequency 2 
pmegridsizex    100 
pmegridsizey    100 
pmegridsizez    100 
 
# Configure positional restraints, if any 
constraints     on 
consref         $structure.restrained.pdb 
constraintscaling   1.0 
 
# Configure thermostat 
langevin        on 
langevintemp    $temperature 
langevindamping 1 
 
# Configure barostat 
berendsenpressure   on 
berendsenpressuretarget 1.01325 
berendsenpressurerelaxationtime  800  
useconstantratio on ; # For use with membrane systems 
 
# Amber settings 
amber on 
coordinates $structure.pdb 
parmfile    $structure.prmtop 
1-4scaling      0.833333333333 
 
# Run minimization 
minimize $steps_min  
# Run simulation 
run $numSteps 
 
5.2 TCL script to change temperature during simulation 
 
tclforces on 
tclforcesfreq   1 
 
# Relaxation variables 
set scaling_original 1.0 
set scalefreq 25000 ; # Must be a factor of $steps_npt1 
set downscale 0.8 
 
set t [getstep] 
set scalefactor [expr floor($t/$scalefreq)] 
set scalemax [expr ceil($steps_npt1/$scalefreq)] 
set scaling [expr $scaling_original*pow($downscale, $scalefactor)] 
constraintscaling $scaling 
 
proc calcforces_init {} { 
  global steps_nvt steps_min 
  global steps_nvt steps_npt1 steps_npt2 
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  global scaling_original scaling scalefactor scalefreq scalemax 
downscale 
 
  set t [ getstep ] 
  if { $t == 0 } { 
    puts "Running $steps_min steps of energy minimization" 
  } else { 
    puts "Restarting" 
    if { $t < $steps_nvt } { 
      puts "Running $steps_nvt steps of NVT with constraints" 
      berendsenpressure off 
      tclforcesfreq [expr $steps_nvt ] 
    } elseif { $t < [expr $steps_nvt + $steps_npt1 ] } { 
      if { $steps_npt1 % $scalefreq == 0 } { 
        tclforcesfreq $scalefreq 
        set scalefactor [expr floor(($t-$steps_nvt)/$scalefreq)] 
        set scaling [expr $scaling_original*pow($downscale, 
$scalefactor)] 
        constraintscaling $scaling 
        puts "STEP:     $t" 
        puts "SCALING:  $scaling" 
        puts "SCALEFACTOR: $scalefactor" 
      } else { 
        # Dont do force scaling if $steps_npt1 not a multiple of 
$scalefreq 
        set scalefactor $scalemax 
        tclforcesfreq [expr $steps_nvt + $steps_npt1 ] 
        puts "Force scaling will not be performed because 
\$scalefreq not a factor of \$steps_npt1" 
      } 
    } else { 
      puts "Running $steps_npt2 steps of NPT without constraints" 
      constraintscaling 0. 
    } 
  } 
} 
 
proc calcforces {} { 
  global steps_nvt steps_npt1 steps_npt2 run1 run2 run3 run4 run5 
run6 run7 run8 run9 
  global scaling_original scaling scalefactor scalefreq scalemax 
downscale 
  set t [ getstep ] 
  set outputname 2VT4_step 
 
  if { $t == 1 } { 
    puts "Running $steps_nvt steps of NVT with constraints" 
    berendsenpressure off 
    tclforcesfreq $steps_nvt 
  } 
  if { $t == $steps_nvt } { 
    # turn barostat on 
    puts "Running $steps_npt1 steps of NPT with constraints" 
    berendsenpressure on 
    if { $steps_npt1 % $scalefreq == 0 } { 
      tclforcesfreq $scalefreq 
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      set scalefactor [expr floor(($t-$steps_nvt)/$scalefreq)] 
      set scaling [expr $scaling_original*pow($downscale, 
$scalefactor)] 
      constraintscaling $scaling 
      puts "STEP:     $t" 
      puts "SCALING:  $scaling" 
      puts "SCALEFACTOR: $scalefactor" 
    } else { 
      # Dont do force scaling if $steps_npt1 not a multiple of 
$scalefreq 
      set scalefactor $scalemax 
      tclforcesfreq [expr $steps_nvt + $steps_npt1 ] 
      puts "Force scaling will not be performed because \$scalefreq 
not a factor of \$steps_npt1" 
    } 
  } 
  #if { $t > $steps_nvt && [expr $steps_nvt + 
$scalefreq*$scalefactor] < [expr $steps_nvt + $steps_npt1] } {} 
  if { $t > $steps_nvt && [expr $scalefreq*$scalefactor] < [expr 
$steps_npt1] } { 
    # Gradually reduce constraint scaling 
    set scalefactor [expr floor(($t-$steps_nvt)/$scalefreq)] 
    set scaling [expr $scaling_original*pow($downscale, 
$scalefactor)] 
    constraintscaling $scaling 
    puts "STEP:     $t" 
    puts "SCALING:  $scaling" 
    puts "SCALEFACTOR: $scalefactor" 
  } 
  if { $t == [expr $steps_nvt + $steps_npt1] } { 
    # turn constraints off 
    constraintscaling  0. 
    puts "Running $steps_npt2 steps of NPT without constraints" 
  } 
 
if { $t == $steps_nvt + $steps_npt1 + $steps_npt2 } { 
   puts "Production run @300 for 40ns" 
   berendsenpressure off 
   langevintemp 300 
   langevindamping 0.1 
   constraintscaling 0. 
   restartname     $outputname.300.restart 
  } 
 
if { $t == $steps_nvt + $steps_npt1 + $steps_npt2 + $run1 } { 
   puts "Production run @308 for 40ns" 
   berendsenpressure off 
   langevintemp 308 
   langevindamping 0.1 
   constraintscaling 0. 
   restartname     $outputname.308.restart 
  } 
 
if { $t == $steps_nvt + $steps_npt1 + $steps_npt2 + $run1 + $run2 } 
{ 
   puts "Production run @316 for 40ns" 
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   berendsenpressure off 
   langevintemp 316 
   langevindamping 0.1 
   constraintscaling 0. 
   restartname     $outputname.316.restart 
  } 
 
if { $t == $steps_nvt + $steps_npt1 + $steps_npt2 + $run1 + $run2 + 
$run3 } { 
   puts "Production run @324 for 40ns" 
   berendsenpressure off 
   langevintemp 324 
   langevindamping 0.1 
   constraintscaling 0. 
   restartname     $outputname.324.restart 
  } 
if { $t == $steps_nvt + $steps_npt1 + $steps_npt2 + $run1 + $run2 + 
$run3 + $run4 } { 
   puts "Production run @332 for 40ns" 
   berendsenpressure off 
   langevintemp 332 
   langevindamping 0.1 
   constraintscaling 0. 
   restartname     $outputname.332.restart 
  } 
 
if { $t == $steps_nvt + $steps_npt1 + $steps_npt2 + $run1 + $run2 + 
$run3 + $run4 + $run5 } { 
   puts "Production run @340 for 40ns" 
   berendsenpressure off 
   langevintemp 340 
   langevindamping 0.1 
   constraintscaling 0. 
   restartname     $outputname.340.restart 
  } 
} 
 
proc calcforces_endstep { } { } 
 
